S U S TA I NA B I L I T Y R E P O R T 2 0 1 1
Preserving the Future
Contents
I.
A message from the President of the Board of Trustees..............................5
A message from the President of the Executive Directors of the
Antônio Prudente Foundation.........................................................................7
A message from the CEO..................................................................................9
A message from the Sustainability Committee..........................................13
II. The Hospital......................................................................................................15
2.1.The History of the Institution.....................................................................17
2.2.Recognition and Certification.....................................................................21
2.3. Corporate governance.................................................................................25
2.4.Mission, vision and values..........................................................................29
2.5.Operational Structure.................................................................................31
2.6. Code of conduct and ethics........................................................................33
III. Performance indicators...................................................................................35
3.1.Treatment ..................................................................................................39
3.2.Research.....................................................................................................47
3.3.Support and participation..........................................................................53
3.4.Teaching ....................................................................................................57
3.5.Relationship with suppliers........................................................................61
3.6.Relationship with clients............................................................................65
3.7. Voluntary work...........................................................................................69
3.8.Philanthropy...............................................................................................71
3.9.AVS.............................................................................................................79
3.10. Financial Health Indicators........................................................................81
3.11. Communication with society......................................................................83
3.12.Donations ..................................................................................................89
3.13.Internal Public Relations Indicators...........................................................91
3.14. Environmental Performance.......................................................................99
3.15.Targets......................................................................................................103
IV. Scientific Production 2011............................................................................105
V. Medical Staff...................................................................................................125
VI. GRI Table of Contents....................................................................................133
VII. Independent Auditors’ Report on Limited Assurance..............................137
2

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
A m e s s ag e f r o m t h e P r e s i d e n t
o f t he B oa r d o f T ru s t ee s
S
ince its creation, in 1953, the A.C.Camargo Hospital has taken important steps to permanently improve the widely acknowledged quality
of its teaching and the success rates of the treatments it offers pa-
tients, These results rival those of other world renown institutions. (GRI 2.1)
Together with the excellence of its health care professionals, teachers
and scientists, the financial health of the institution has paved the way for
numerous achievements throughout the last decade. The Hospital’s desire
to balance economic, social and environmental concerns has allowed it to
sustain a long history of important victories in the health care field.
Even so, from time to time, the hospital has had to overcome unexpected
obstacles. At the end of 2011, we received the sad news of the passing away
of the head of the hospital, professor Ricardo Brentani; the bedrock of this
institution and the unifying force in the areas of teaching, research and patient care at the highest levels. His death at the age of 74 in November of
2011 affirmed to all of us at the Antônio Prudente Foundation the certainty
that his legacy would live on, most importantly in his plans for the future
which are being implemented on a daily basis.
José E rmírio
de M oraes Neto
As he used to say, with pride and full of hope, “2011 was a great year, and
2012 will be equally wonderful”. It was the optimistic view of a leader who
seemed to reinvent himself year after year, surpassing obstacles and creating new challenges for himself. His work as head of research in the State of
São Paulo and his striking presence in other spheres of scientific production
in Brazil and internationally elevated his influence to an unprecedented
level. Because of Ricardo Brentani’s unyielding commitment to health care
we have all gained a great deal.
Obstacles are often difficult to surpass and the ability to deal with adversities is what makes us better every day. As head of the Antônio Prudente
4

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
5
Foundation, together with my colleagues who make us proud, it is no different. As was the wish of Professor Brentani, we are always lifting ourselves
up and moving on and always looking towards a more optimistic future.
Jo sé E r mír io d e M o r a e s Ne t o
A m e s s ag e f r o m t h e P r e s i d e n t
o f t he E x ec u t i ve D i r ec to r s o f
t he A n tô n i o P ru den t e F o u ndat i o n
A
s I said at a recent reception to international scientists, the A.C.
Camargo Hospital is an institution which has always looked to the
future. We have, due to good judgment and sound thinking, our
feet firmly planted in our long history. This hospital was founded with the
mission of saving lives, achieving positive results and providing our patients
with a better quality of life.
With an efficiency that might astonish many, every year we manage to
reach our goals. If we look only at the last decade, we have increased by a
multiple of 3 the number of SUS and private patients we treat. We saw a significant leap in scientific production that is without precedent in this country.
Currently, two out of every three scientific works of impact in oncology are
carried out at our institution. At the end of the year 2000 we actively participated in one of the most ambitious international projects of research in
this area – the Cancer Genome project, which resulted in the hospital being
second only to the United States, as the largest contributor of genetic sequences in the world. With regular financial contributions from the Fapesp
and the CNPq, we promote innovation and scientific research through pro-
José Hermílio Curado
grams such as the Cepid and the São Paulo School of Translational Science,
the second conference which took place in this institution in 2011.
In the area of teaching, we reached the mark of over one thousand oncologists, out of approximately two thousand working in the country today, who
have specialized in our institution. We were evaluated by the Capes/MEC as
the being the best institution for preparing Masters and Doctors in the field
of oncology. In 2010 we created the CIPE, the International Research Center,
located in a modern building with the most advanced equipment used in
the world today. There, we follow a number of research lines, the results of
which are applied daily in the medicine practiced in our consultations and
6

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
7
a m e s s ag e f r o m t h e c e o
D
ear Trustees of the Antônio Prudente Foundation, despite closely
observing the on going operations of the Hospital, the results the
staff bring us each day often come as a pleasant surprise. Only two
years ago we were celebrating being awarded the ONA II, the highest level of
accreditation for quality in health services in Brazil. I can now announce to
you, with enormous pride, the distinction of being presented with the international certification from the Canadian Council for Health Services Accredita-
tion. This achievement represents the profound transformation we have gone
through in the last five years, when we began adopting internal procedures
consistent with internationally recognized standards.
Throughout the 18 months of involvement from all the areas of the institution we spent a great deal of time and energy rethinking, reformulating
and reorganizing so as to achieve the highest quality of service. We are the
first oncology institution in the country to achieve such a distinction from
one of the most renowned international institutes.
In the center
A.C.Camargo’s CEO, Irlau
Machado and pathologist,
In the midst of this achievement, we also developed the methodology,
operating theaters. From the workstation to the doctor’s bag, we practice
planning and structural organization required to conclude the new instal-
science aimed at curing cancer.
Because of the success of these practices it is safe to say that today we
lation of the Tamandaré Tower. The new facility will be operational within
are able to cure 68% of our patients, defining cure as five years without the
the next few months and will significantly increase our institution’s capac-
illness reappearing, as recommended by the WHO. Theses results are con-
ity to care for patients. The building which was bought in 2010 and com-
are António Coutinho,
sistent with the best institutions in North America. On the financial side
pletely renovated in 2011, will house the new Pediatrics Unit and a kitchen
Martin Raff, Alan
our revenue grew by almost 600% in ten years and our institution is now
which will cater to the entire Hospital. In addition, it will add 120 new beds,
without any debt.
increasing our total number of beds to 441. Because of these acquisitions
Director of Research
and Teaching, Fernando
Soares. From left to right
Ashworth, Curtis Harris,
Harald zur Hausen and
and improvements our oncology center will be one of the three largest in
This is called sustainability. This is our present, looking to the future.
Kai Simons, members
of the International
Scientific Committee.
8
Irlau M achado Filho
Jo sé He r mílio C u r a do
the world in terms of patient population.
In a year when we were presented for the third time with the award – Guia
Você S/A Exame – As Melhores Empresas para Você Trabalhar (The Best Compa-

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
9
leader in the fight against an illness that grows every year. With improvement
in diagnostic resources and the increase in the population’s life expectancy
we will continue to see significant growth in decades to come.
With increasing effectiveness we have improved our procedures while
constantly observing the technological evolution taking place around us.
Today, we are on equal footing with the main international centers. Our
reputation attracts patients in search of the best cures and excellence in all
stages of integrated and multidisciplinary treatments.
Positive experiences by our patients are clearly seen in our customer satisfaction survey where 98% of the patients stated that they would recommend A.C.Camargo to those looking for quality oncology treatment.
In the financial sphere our ability to find creative solutions has allowed
us to achieve consistent and sustainable growth, with increasing profits and
significant amortization of debt.
Due to the implementation of cost saving measures in the administration of the hospital we have continued our investments in patient care, research and teaching, allowing us to provide premium quality health care
for all our clients.
These outstanding results have allowed us to fulfill our goal of providing the highest quality of health care to the patients of the Sistema Único
de Saúde and will be fundamental to the prominence of A.C.Camargo in the
years to come. Consistent with our vision of sustainability, these numbers
are the result of the teamwork that makes us proud of our history. The three
thousand collaborators and professionals of the Medical Staff are directly
responsible for these achievements. (GRI 1.1)
In the present context of Brazilian economic growth and despite the turbulence that has hit the so-called developed world, we are focused on the
present and always planning for the future. With new challenges presenting
themselves in a increasingly complex world, we understand the need to be
nies for You to Work for), it seems clear that the involvement of the different
teams which form this institution is wide ranging, and comprehensive. The
areas of teaching and research continue to thrive and are maintaining their
national leadership in scientific production in Oncology.
In 2011, the Oncology department had 175 students attending masters,
doctorates and post-doctorate courses, placing it in a position of promi-
agile and continue to pursue innovation. As an institution with the common
good in mind, our goal is to always seek what might seem unattainable and
strive to achieve it.
In the constant search for excellence in our services, above all, I would
like to thank the Board Members for their vision and support for our noble
mission of fighting cancer patient by patient.
nence amongst the most traditional schools of medicine and universities in
I r l a u M a c ha d o Fi l ho
Brazil. In a country with just over two thousand practicing oncologists, we
surpassed the mark of one thousand oncologists graduated and 400 Masters
and PhDs who today teach in medical schools across the country.
The excellent performance in this area has provided world class professionals not only for our institution but for all of Brazil as well, making it a
10

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
11
A m e s s ag e f r o m t h e
S u s ta i nab i l i t y C o m m i t t ee
T
(GRI 1.1)
he A.C.Camargo Hospital is a civil, private, non-profit entity maintained by the Antônio Prudente Foundation. We are, for the first time,
publishing an Annual Sustainability Report which complies with the
guidelines set forth in the Global Reporting Initiative (GRI). The report will
detail the hospital’s economic, social and environmental performance within
the precepts of corporate responsibility.
Created in 2011, the A.C.Camargo’s Sustainability Committee, was an important step in aligning and integrating the various services carried out in
the Hospital, particularly in the areas of oncology, patient care, teaching, research and those related to economic and environmental matters.
The Committee is responsible for assuring that management and accountability are carried out with sustainability in mind. The review includes
the definition of guidelines, the validation of strategies, the construction of
indicators and the systematization of targets. It is an important forum for
reflection and evaluation, where representatives discuss results and the benefits of actions already adopted or expected in the future, aligning them to
strategic planning and to the policies of sustainability.
The Committee’s help in producing this annual report is fundamental at
a moment when the institution is adopting the GRI (Global Reporting Initia-
tive) indicators, the set of guidelines and orientation most widely accepted
in the world today for elaborating sustainability reports.
In line with the third version of the GRI guidelines (GRI-G3), the information presented here is based on interviews with managers of each area
of the company and demonstrate, in a transparent and detailed form, the
commitment of the whole institution.

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
13
The Hospital
14

A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
15
Th e H i s to ry o f t h e I n s t i t u t i o n
Pioneering, tenacity, capacity to overcome
difficulties, efficiency
A pioneering spirit is a quality that is in the DNA of the A.C.Camargo
Hospital, be it caring for patients, teaching or in cancer research. The
capacity to venture through the unexplored, innovate what is already
known, always with balance and efficiency, projects the history of the
A.C.Camargo to a future under the perspective of sustainability. This is
what the trajectory of the institution confirms:
1934 Antônio Cândido de Camargo, teacher at the Medical Faculty of the
University of São Paulo, creates the Associação Paulista de Combate ao Câncer (APCC), with the aim of offering medical assistance to patients with malignant tumors, spread information and enhance medical knowledge about
the illness. At his side is a brilliant former student: Antônio Prudente. In the
30s, oncology was still an area practically unknown in Brazilian medicine.
1943 One of Antônio Prudente’s patients – Giuseppe Martinelli, “Commander Martinelli” – donates a considerable sum, 100 contos de réis, quickly
transformed into one thousand contos de réis through campaigns to build a
hospital. It is the beginning of the mobilization for the conquest of the first
Hospital in São Paulo built with money given by the people, and destined
to them, with no links to any official healthcare institution, nor financial
backing of any religious organization, or even sponsorship from colonies of
immigrants, as was common at the time.
16
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
17
1946 Journalist Carmen Prudente, wife of Antônio Prudente, creates the
Rede Feminina de Combate ao Câncer (Female Network for the Fight
against Cancer) to mobilize the population of São Paulo around building
the Hospital.
1953 The A.C.Camargo Hospital is founded on the 23rd April with a medical staff of 92 specialists, including doctors, surgeons, radiotherapists and
laboratory assistants, as well as 35 nurses from the German Red Cross. In
the same year the first program of Medical Residency in oncology in the
country is created, which is responsible for the graduation of one in every
three oncologists working in Brazil.
1954 In December, the Hospital registers a fourfold increase in the number of surgeries. The number of people looking for assistance had tripled
and the index of patients with the illness looking for assistance in a situation
that was so critical that any attempt at cure was impossible had fallen from
53% to 17%. Assistance and the campaigns to inform the public achieved
their aim.
1964 The Hospital creates the Pediatric Oncology, the first in the country.
The specialized treatment of the A.C.Camargo brings a new concept to Pediatric oncology and helps to expand the possibilities of cure.
1971 A new building is built which doubles the institutions constructed area.
1973 The Associação Paulista de Combate ao Câncer becomes the Antônio Prudente Foundation, today a private non-profitable entity and maintainer of the Center for Treatment, Teaching and Research in Cancer of the
A.C.Camargo Hospital.
tumors in the country, a resource which is fundamental for research.
1999 The project Genoma Humano do Câncer – GHC is launched by the
Foundation for the support of research of the State of São Paulo (Fapesp),
in partnership with the Ludwig Institute for Cancer Research, institution
1983 The Brazilian branch of the Ludwig Institute for Cancer Research is
installed in the A.C.Camargo Hospital.
which the A.C.Camargo housed for more than 20 years. The Hospital becomes the greatest supplier worldwide of samples for the GHC, supplying
30 research laboratories involved in the Project in the State of São Paulo.
1987 On the 15th October the specialized school Schwester Heine is inaugurated, the first in a hospital institution in the country.
2000 The A.C.Camargo receives the first PET-CT (Positron emission tomography) equipment dedicated to the treatment of cancer in the country.
1997 The Post-Graduation course stricto sensu is created, the first in the
country in a private hospital institution. The A.C.Camargo Hospital’s PostGraduation was recognized and evaluated with the maximum grade by the
Ministry of Education. Also in 1997 the A.C.Camargo Hospital’s nursing
18
school and the bio bank are founded, the oldest bank of frozen samples of
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
2001 The A.C.Camargo Hospital is chosen by the Fapesp as one of the ten
CEPIDs – Centro de Excelência em Pesquisa, Inovação e Difusão do Estado de
São Paulo, with the guarantee of regular financial support for 11 years, in activities aimed at research, innovation and promotion of scientific knowledge.
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
19
R e c o g n i t i o n a n d C e rt i f i cat i o n
Recognized trajectory
2006 The process of modernizing and expanding the Hospital installations
begins, increasing in 85% the Hospital’s capacity to attend patients.
2007 The A.C.Camargo Hospital creates the Instituto Nacional de Ciência
e Tecnologia em Oncogenômica (INCiTO), leading, for the first time in Brazil, a network of over 50 researchers in Brazil and abroad in the study of the
hereditary nature of breast, prostate, intestine and head and neck tumors.
This same year, the A.C.Camargo Hospital establishes its partnership with
the MD Anderson Cancer Center, linked to the University of Texas, USA, for
cooperation and exchange of research, teaching, technological innovation
and techniques for the treatment of cancer.
(GRI 2.10)
Throughout its history, the quality of the assistance and teaching at the
A.C.Camargo Hospital has received recognition from society and national
and international entities. The prizes and certificates obtained over the
last few years, above all in 2011, have come to confirm this trajectory and
stimulate the institution to follow the path of quality.
1961 The medical residency, created in 1953, is officially recognized by the
Ministry of Education.
1980 The A.C.Camargo Hospital is the only private hospital institution in
the country taken to Category CaCon 3 (Center of high Complexity in oncology) by the Ministry of Health.
2007 The A.C.Camargo is elected by the Guia Você S/A Exame as one of the
2009 The Advanced Oncology Nucleus of the A.C.Camargo Hospital in
the city of Santo André is inaugurated to attend the regional community.
2010 The CIPE – International Center for Research of the A.C.Camargo
Hospital is inaugurated with the presence of Scientist and Noble Prize Winner Harald Zur Hausen. Also this year, in partnership with the FAPESP, the
A.C.Camargo Global Meeting is launched, a course with international validation which brings together more than 150 masters and young scientists
“Best companies for You to work for”. The Hospital receives this recognition again in 2009 and 2011. Also in 2007, the Hospital is appointed by the
magazine IstoÉ Dinheiro as one of the “500 Best companies” in the healthcare sector, recognition that it receives again in 2008 and 2009. It is elected
by the magazine Valor 1000, as one of the one thousand greatest companies,
both in 2008 and 2009. Still in 2007, it is elected by the Anuário Valor Carreira
as one of the best companies in the Management of People, a title that it
receives again in 2008.
of 14 countries to study the frontiers of oncology knowledge.
20
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
21
2009 The Hospital enters the ranking of the greatest companies in Bra-
2010 The A.C.Camargo Hospital received the certification duns number
zil, in an evaluation carried out by the magazine Exame Melhores & Maiores,
(Data Universal Numbering System), given by Dun & Bradstreet international
receiving once again this recognition the following year. It also receives the
(D&B), a specialized consultancy that evaluates the balance sheets, billings,
highest level of excellence in attendance and management by the National
financial data and the company’s history. With this certification, the insti-
Organization of Accreditation (ONA), body that evaluates and certifies the
tution began to be part of a select group of companies located in more than
quality of health services delivered.
220 countries and inserted into a data bank consulted by thousands of companies throughout the world for the creation of safe relationships during a
negotiation.
2011 The A.C.Camargo receives the prize Gestão com Qualidade 20112012 from the COREN – SP, Regional Nursing Counsel, and received the prize
Prêmio SciVal Brasil. The initiative carried out by Publishing House Elsevier,
with the support of the Coordenação de Aperfeiçoamento de Pessoal de Nível
Superior (Capes), gave prizes to nine Brazilian institutions responsible for
the production of more than 73 thousand works and which stood out due to
their importance on the Brazilian scientific scenery. The A.C.Camargo won
a prize for its researches and publications in the category “Citações por
documento” (research institutes and others)”. The winning institutions were
selected based on nine indicators extracted from the computerized tool for
managing scientific production, SciVal, by Elsevier.
The year of 2011 ends with one more important achievement: after a process of evaluation which happened throughout 2011, the A.C.Camargo Hospital is certified by the Canadian Council for Health Services Accreditation
(CCH- SA), one of the most important quality management certificates in
health services throughout the world. The A.C.Camargo is the first oncology
institution in the country to receive this international recognition.
The Canadian accreditation strengthens A.C.Camargo’s position as a reference centre in quality assistance and the safety of the oncologic patient.
The announcement of the certification was made by the Institute Qualisa
de gestão – iQg, Brazilian body certified by the Canadian Council, which accompanied and guided all the process of certification of the A.C.Camargo
over a period of 18 months. During this time, the processes geared at the
patient’s safety were evaluated, processes these that follow methodological
criteria previously established, the so called ROPs (Required Organizational
Practices). The methodology of evaluation adopted observes the control of
medication (chemotherapeutic, opioids and antibiotics), organization in the
process of transferring the patient from one sector to the other, safety practices in surgical procedures, hygiene of the hands in all sectors, amongst
others. (GRI PR1))
22
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
23
C o r p o r at e g ov e r n a n c e
(GRI 4.1)
A Non-Profit-Making Private Entity
The Board of Trustees elects the Executive Directors and along with
them defines and supervises the operational administrative staff
of the institution.
T
he A.C.Camargo Hospital is an institution maintained by the Antônio Prudente Foundation, a private non-profit entity, considered
a federal, state and municipal public utility. It is the Board of Trust-
ees of the Antônio Prudente Foundation that periodically elects the Hospital’s Executive Directors, defines the administrative staff and supervises
the management. (GRI 2.6)
Governance at the A.C.Camargo is organized by values, principles, policies
and governance bodies that ensure transparency for the various stakeholders, and its executive base is structured in such a way as to guarantee that
the long term strategic vision of the A.C.Camargo Hospital becomes a reality.
Governance and Sustainability
The Sustainability Committee has as its main objectives the promotion and
formulation of guidelines and the answering to the various strategic actions
of corporate social responsibility in the management of the business, the
identification of themes for sustainability and the evaluation of risks and
opportunities. It is also active in receiving and requesting topics related to
the various committees which exist within the theme of Social Responsibility and Environment.
24
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
25
The following committees and commissions are in place at the Antônio
Prudente Foundation:
Medical Ethics
Commission
Discusses the very serious incidents in Medical
processes (Error/Public Accusation), and evaluates
and communicates with the CRM (Regional Medical
Council), or not, depending on the seriousness and
develops a plan of action to solve the problems.
Doctors
Pharmacy and Therapy
Commission
Evaluates all the requests in order to standardize
buying and the new medication used in the Hospital.
Doctors
Pharmacists
Risk Management
Commission
Discusses the risks that are involved in caring for
patients: falls, errors in medication, flaws in procedures,
phlebitis, and evaluates what were the damages that
month and what plan of action is necessary.
Doctors
Managers
Pharmacists
Lawyers
Committees
Attributions
Members
Committee for
Internal Auditing
of Management of
Corporative Risks – FAP
Verification of compliance with Institutional Policies,
internal, administrative, accounting, financial and fiscal
controls.
Superintendents
Building Committee
Approval of building projects and verification of the
bidding processes.
Directors
Presidents
Superintendents
Budgeting Committee
Definition of the prerequisites for quantities, prices and
costs for budget planning to be sent to the Financial
Superintendents
Managers
Intra-Hospital
Transplant
Commission
Identify potential donors within the Hospital (patients)
and activate the respective bodies in the donation
process.
Doctors
Nurses
Multi-professional
Commission for
Antineoplastic Therapy
Defined by law RDC-220 that gives the guidelines for
Antineoplastic Therapy. Brings together professionals
involved in the application of chemotherapy where it
analyzes the flows, processes and protocols adapting
them according to the needs.
Doctors
Nurses
Pharmacists
Multi-professional
Commission for
Antineoplastic
Therapy of the Núcleo
Oncológico Avançado
ABC branch
Defined by law RDC-220 which gives the guidelines for
Antineoplastic Therapy. Brings together professionals
involved in the application of chemotherapy where it
analyzes the flows, processes and protocols adapting
them according to the needs.
Doctors
Nurses
Pharmacists
Commission for the
Analysis of Deaths
Evaluates deaths to check if there was any flaw in the
assistance given.
Doctors
Managers
Commission for the
Analysis of Medical
Records
Evaluates the logistics, the filing and analyses the
documents necessary for compiling a medical record
and suggests a plan of action for possible problems
encountered.
Doctors
Managers
Coordinators
Lawyers
Nutritional Therapy
Commission
Provides assistance and nutritional therapy for patients
at risk and improves and/or maintains their nutritional
situation minimizing the effect of oncologic treatment.
Doctors
Nutritionists
Pharmacists
Nurses
Multi-disciplinary
Transfusion
Commission
Evaluates all the process of blood derivatives and
consent terms, defines the actions which should be
carried out if there are problems and reactions with
blood transfusions and defines the process flow for the
entire hospital.
Doctors
Committee for analysis
HR Committee
Supports the HR Superintendent with regards to
elaborating studies for Policies for Incentive schemes
and Organizational Climate Management.
Superintendents
Property Security
Committee
Monitoring of controls and outlining the policies for
property security in the Institution.
Superintendents
Hospital Infection
Control Commission
Discusses the Hospital’s infection numbers and
promotes a plan of action to prevent them.
Managers
Nurses
Doctors
Pharmacists
Waste Management
Commission
Proposes corrective measures, orientates, supervises
and controls all the actions related, directly or
indirectly, to the collection process, binning, transport
and final destination of the waste generated by
the various units of the institution, through the
Gerenciamento de Resíduos dos Serviços de Saúde
(PGRSS) (Health Services Waste Management) plan.
Doctors
Nurses
Pharmacists
Coordinators
Engineers
Nutritionists
Evaluates if the research project can be carried out from
a statistical and results point of view, if the period of
time established is viable and checks if the requested
project has previously been carried out by other
researchers.
Doctors
Discusses the very serious incidents in nursing
cases (Error/Public Accusation), and evaluates and
communicates with the COREN (Regional Nursing
Council), or not, depending on the seriousness, and
develops a plan of action to solve the problems.
Nurses
Research Commission
Nursing Ethics
Commission
26
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
27
Committee for Ethics
during Research
Evaluates all the research projects which are requested.
The subjects for Research are ethically protected
as regulated by the Comissão Nacional de Ética em
Pesquisa – CONEP
Doctors
Nurses
Managers
Nutritionists
Researchers
Social Assistants
Radiology Protection
Committee
Evaluates where there is emission of radiation in the
hospital in materials, equipment and recommended
safety practices for the patient and professional.
Verification of occurrences in the processes that can
generate damages or risks.
Doctors
Nurses
Biosecurity Committee
Regulates the norms for the levels of safety in
Laboratories that deal with genetically modified
organisms.
Doctors
Researchers
Quality Committee
Establishment, implementation and maintenance of the
system of Quality Management; Accompaniment and
guidance of internal audits of the Quality Management
System; Negotiations and accompaniment of noncompliance, as well as preventative and corrective
actions and opportunities to improve.
Superintendents
Managers
Supervisors
Analysts
Occupational
Physicians
Pharmacists
Commission for
Standardizing
Materials
Evaluates all the supplies of non-standardized
material to the Hospital. Analysis of the quality, Anvisa
registration, Cost x Benefit, logistics and use. Prevents
problems with materials.
Doctors
Nurses
Pharmacists
Committee for
Evaluation and
Revision of Protocols
Defines and implements multi-professional and
assistance protocols focusing on the patient’s safety.
Superintendents
Clinical Director
Managers
Supervisors
Officers
Analysts
Contributing towards a better Corporate Governance, the entity’s administration management also has the support of an Internal Audit of Corporate
Risk Management and of an External Audit of the Accounting Statements to
monitor the institution’s internal controls.
28
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
M ISSION, VISION AN D VALUES
(GRI 4.8)
Shared objectives
The values and targets that guide the path of the A.C.Camargo were created
in a participative manner. Born from group dynamics, they were submitted
to the Administration Council for approval and are periodically evaluated
and shared with the collaborators. They are not, therefore, only words, but
agreements that, made by all, permeate the organizational culture.
Mission
Defeat cancer patient by patient.
Vision
Be recognized as a world center of excellence in oncological treatment,
teaching and research, excelling in quality, auto-sustainability and human
development.
Values
»» Ethical practice;
»» Therapeutic effectiveness based on science;
»» Development and spread of knowledge about cancer;
»» Humanized care;
»» Defeat cancer patient by patient;
»» Value human resources;
»» Social-Environmental responsibility;
»» Economic-Financial Sustainability.
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
29
OPERATIONAL STRU C TURE
(GRI 2.3)
On the path to growth
The construction of the new Tamandaré Building is one of the
achievements of 2011
W
ith the ability to act in the prevention, diagnosis and outpatient and surgical treatment of the more than 800 types of cancer identified by Medicine, the A.C.Camargo hospital receives
around 15 thousand new patients every year. Since it was founded, it has already diagnosed and treated over 700 thousand patients, with results which
are increasingly encouraging: the Hospital’s most recent data indicate that
the cure rates are currently at an average of 68% amongst adults.
The hospital’s good results are due to an experienced multidisciplinary
team working in a structure comparable to the best international centers
for cancer treatment. The A.C.Camargo Hospital’s multidisciplinary clinical
staff includes around 500 specialists, of which approximately 120 are oncologists, the majority with Masters or Doctorate degrees, and the support
of more than 2.000 healthcare professionals. They have at their disposal a
complete center for oncological treatment with over 60 thousand m² and 321
beds, to which will be added another 120 beds with the inauguration of the
Miriam Palladino
Management Superintendent
of the São Paulo network of
Bradesco Seguro Saúde
30
“Established in 1991, the partnership between the A.C.Camargo Hospital
and Bradesco Seguro Saúde presents a solidity that increases year by year.
We respect and highly appreciate the A.C.Camargo Hospital, which is truly
differentiated and has received deserved international recognition. With a
history of more than five decades, it stands out as a center for the diagnosis
and treatment of cancer – with an interdisciplinary team –, and also for
its great scientific production. Apart from this, it is the main trainer of
oncologists in the country and has an excellent post-graduation course. As
we are two big companies, our partnership brings many fruit and we are very
happy to know that the quality care provided at the A.C.Camargo is available
to those insured by us.”
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Tamandaré building. It is a configuration comparable to the MD Anderson
Cancer Center, in the USA, the largest oncology center in the world and one
of A.C.Camargo’s partners.
The Hospital’s various sectors – Outpatient Care, Imaging and Laboratory
Diagnosis, Nuclear Medicine, ICU, Surgical Center, Pathological Anatomy, Molecular Biology, Genetic Sequencing, Chemotherapy and Radiotherapy – are
equipped with modern instruments applied to the diagnosis, prognosis and
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
31
Code of conduct and ethics
In 2011 3.313 high
precision exams
were carried out,
all using the latest
equipment
help forecast the response to specific treatment, which leads to a personalized and more efficient treatment.
Pioneers in the use of PET-CT in oncology, in 2011 the Hospital carried out
3.313 of these high precision exams, surpassing the previous year, when 3.042
PET-CTs were carried out. It is the Reference Center for the training of professionals in the use of new technologies. In 2011, it established a partnership
with Cardinal Health, a company that is world leader in healthcare services,
for the installation of a cyclotron and the production of short half-life (FDG),
used in the exams. Currently, for imaging exams, the Hospital has two PETCTs, two SPECT CTs, four tomography units, two magnetic resonances and
five mammography units, as well as other equipment.
For Radiotherapy treatments the A.C.Camargo Hospital has four state-ofthe-art linear accelerators. The Outpatient Chemotherapy area has 41 rooms
of individual chemotherapy and an additional two children’s rooms that can
attend two children apart from six armchairs for applying the medication
Ethics practiced day by day
(GRI EC8)
Values that helped mold the institution, today guide its actions with the
support of all the collaborators
T
he A.C.Camargo Hospital believes that its reputation, founded on
ethical and humanitarian principles, is as important as the services
offered to the people. And this reputation is built every day, in the
smallest details that direct our treatment, teaching and research, reflected
in our Code of Conduct and Ethics.
The Code of Conduct and Ethics guides actions such as the management
of information and records, donations and the offering of presents, hiring of
staff, business deals, the rational use of environmental resources, safety at
work and relationships with suppliers, as well as various other aspects present in the day to day of a healthcare sector company.
and two beds (totaling eight application points) at the ABC branch. And with
the inauguration of the Tamandaré building in 2012 we will have another
nine chemotherapy application points available to Hospital patients. For surgical treatment, there are 14 operating theaters, and one for intraoperative
radiotherapy and three for outpatient surgeries.
Expansion – For 2012 new investments are already planned, the highlights
of which are:
»» an increase in the number of beds destined to bone marrow transplants;
»» hiring around 200 new collaborators.
32
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
33
Pe r f o r m a n c e
Indicators
34
The Hospital
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
35
TREATMENT, TEACHING AND RESEARCH
(GRI 2.2)
Integration in favor of life
The A.C.Camargo Hospital confirms its commitment to be a
pioneering quality institution with continued improvement in the
services offered. In the day to day this statement materializes in
the Hospital’s three areas– treatment, teaching and research –,
expressing itself in cure rates which are only comparable to
the main international centers, medical conquests, scientific
advances and patient satisfaction surveys. (GRI 2.7)
Jefferson Luiz Gross
Surgeon and oncologist,
Clinical Director of the
Nucleus of Lung and
Thoracic Cancer at the
A.C.Camargo
36
“It was here at the A.C.Camargo that I did all my academic studying in
Oncology, a place where I learnt a great deal and where I still learn every day.
My main feeling is one of gratitude for all that I can do here for the wellbeing
of patients and their families. If my life weren’t linked to the A.C.Camargo,
where there is an extraordinary integration between research and practice,
maybe I wouldn’t feel so fulfilled, for I would not be able to make use of
what we have the best of here, which is the possibility of making decisions
together with an incredible interdisciplinary team”.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
37
T r e at m e n t
A national reference center
Quick attendance, the acquisition of new equipment, care with safety,
humanization: the assistance data for 2011.
T
here was a time when the word cancer was forbidden. People feared
the illness so much that one used to avoid saying the word out
loud, talking instead about “that illness” or “bad thing”. Today, with
cure rates that surpass 90% for some types of tumor diagnosed in their
initial stages, cancer is no longer a death sentence. And the A.C.Camargo
Hospital is one of the institutions that has most collaborated with this
change in prospects, attending 15 thousand new patients a year. In 2011,
1.109.823 procedures were carried out, 63,1% of them on SUS (Sistema Único de Saúde) patients, attended in an identical way to patients coming from
private medical plans.
38
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
39
nologies. The transfer and expansion of the Endoscopy service, for example,
went from two to three examination rooms and also received new equipment.
For the treatment of prostate cancer, a new technology was acquired: the
Ablatherm Robotic HIFU equipment, a robotic ultrasound devised to attack
small targets and destroy them under a temperature of 90 degrees.
Fully automatic, the equipment allows for led invasive equipment, elimi-
Investments in
new technologies,
of approximately
R$ 9,6 million,
were one of the
highlights of 2011
nating tumors with the least damage to nearby tissues and organs and, in
this manner, diminish the risks of impotence and urinary incontinence. The
urologist programs the machine and an automatic probe is responsible for
emitting the ultrasound. If the patient moves or the ultrasound beams come
close to non-programmed areas, the robotic HIFU automatically turns itself
off, guaranteeing safety in the procedure. The only one in Brazil, the equipment is indicated for prostate cancer reoccurrences, even after radiotherapy.
Speed in attendance – In the outpatient care, various initiatives are in place
to speed up attendance. In this manner, for example, patients with strong
indications of cancer attended in the Breast Cancer Department can carryout immediate Breast Ultrasound and Mammography, and be attended by a
Number of surgeries
doctor the following day. The data show that the number of patients oper-
Number of surgeries in 11 of the 23 Hospital departments.
Departments
ated on in up to 40 days from the first attendance has increased after the
implementation of the project, an index that brings direct benefits to the
2010
2011
510
508
1.294
1.542
Safety and health – Throughout 2011, the Hospital expanded even more the
Gynecology
914
1.028
safety margins of the services offered. The restructuring of the Risk Manage-
Breast Cancer
965
962
ment area was of great importance, which began to centralize, analyze and
Neurosurgery
177
173
manage all the occurrences that could bring risks to the Hospital, in such a
48
33
651
694
1.931
2.320
Reparatory
424
531
Thoracic
362
439
active observatories for the performance and safety of regularly used health-
Liver Transplant
102
112
care products, such as medications, blood and its components, kits for labo-
7.378
8.342
ratory examinations, prostheses, equipment and medical-hospital materials.
Abdomen
Head and Neck
Ophthalmology
Skin Cancer
Pelvic (+ orthopedic)
Total (added)
prognosis of the illness.
way as to guarantee that each one of these occurrences had a plan of action
to constantly improve the process.
In 2011, the A.C.Camargo Hospital was again accredited by the Agência
Nacional de Vigilância Sanitária, the Anvisa, to take part in the “Rede Brasileira de Hospitais Sentinela”. These are high complexity hospitals, which act as
The A.C.Camargo Hospital also participates of the Programa Brasileiro de
Surgical hours: In 2011 in the Surgical Center 31.550,81 hours of surgery
Segurança do Paciente, created by the Instituto Qualisa de Gestão (IQG) with
were carried out.
international partnership. The A.C.Camargo acts as one of the “multiplying
hospitals” of the program: hospitals which, recognized for their good practice
40
In the constant search for excellence in attendance, in the year of 2011
and safety culture, were invited to carryout the role of spreading information,
the A.C.Camargo Hospital invested approximately R$ 9,6 million in new tech-
contributing to speed up the process of implementing improvement strate-
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
41
In order to offer
patients and
their families
more comfort and
convenience the
services center
was developed
gies, focusing on patient safety. Each multiplying hospital stands as a param-
ular teaching (for children and middle school education), as well as unique
eter for another two institutions that participate of the program. (GRI PR1)
opportunities of social interaction and leisure activities.
There is also the “Yoga na Praça” (Yoga at the square), which offers patients
Cure estimate – The Hospital Cancer Register (Registro Hospitalar de Cânc-
of any age moments of physical and mental well-being and the “Oficina de
er) keeps a record of all the cases of cancer diagnosed or treated at the Hospi-
Culinária” (Cooking Workshop), an initiative carried out by the Department
tal and accompanies the cases annually, for up to 15 years. In the table below,
of Oncologic Nutrition which offers free classes on healthy eating, available
the cases diagnosed and treated at the institution as of year 2000 show the
not only to patients and caretakers, but to the community in general.
number of people alive five years after the diagnosis (period after which a
In 2011, one other initiative was added to these: the program “Sua Voz”
patient is considered free from the illness). With this, the Hospital reached
(Your voice) was created by the A.C.Camargo Hospital’s Speech Therapy Ser-
2009 with an average index of 68% of people alive 5 years after diagnosis, for
vice. It is an interdisciplinary group which cares for Laryngectomized pa-
all types of cancer, considering the base year as 2004-2009.
tients with the aim of rehabilitating their voices. Time has shown that all
participants manage to evolve in comparison to their initial stage and that
the majority obtain great results. The program is not restricted to patients
Rate of people alive 5 years after discovering the illness
from the A.C.Camargo: so that people who were submitted to a laryngectomy,
being or not in treatment in another institution, as well as caretakers and
2000
2001
2002
2003
2004
family members can participate. After all, A.C.Camargo’s fight against cancer
goes beyond the hospital’s doors. The Hospital team knows that cancer pa-
*Only cases diagnosed and
treated at the Hospital and with
patients over the age of 18.
63%
66%
68%
68%
68%
tients are, above all, citizens searching for their right to life, a life with quality and dignity. This is why the Hospital also elaborated a Handout entitled
“The rights of cancer patients”. In it one can find the laws that talk about
Humanization of care – The hospitality area of the A.C.Camargo works to
provide comfort to patients and their families during their stay at the Hos-
the rights of people who have cancer and/or serious illnesses, being that the
aim is to increase understanding and help in the process of requesting the
pital. With this purpose, in 2011 it developed a project called Services Center, to answer requests related to comfort during internment. In 2012 it will
remodel the International Attendance Center, providing personalized care
for foreign patients.
In 2011, the A.C.Camargo created two new job positions with the aim of
providing more comfort and well being during internment: the position of
chambermaid and of “captain-porter”. Professionals who are prepared to
welcome patients and their families in a differentiated way, the “captainporters” help with the arrival and departure of patients and guide them until
they reach the Hospital’s reception.
But the initiatives in favor of the oncology patient’s quality of life are not
limited to the care during their time of internment. Support groups such as
the “Amor à Vida” and the “Grupo Afeto”, provide patients, caretakers and
family members with emotional support throughout any stage of treatment.
The group Amor à Vida promotes monthly meetings with patients, in a pleasant and carefree environment, allowing for the exchange of information and
the demystification of the illness. For children and teenagers between the
ages of 0 and 21, the Specialized School Schwester Heine offers not only reg-
42
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
43
benefits granted by law, which can ease the financial and social impacts of
oncology patients. In 2011 there were 23.214 accesses with free downloads
of this Handout on the Hospital’s website.
Targets of qualit y a ssita n c e
One of A.C.Camargo’s strategic guidelines is quality. It permeates all
its policies, norms, governance, management model, processes and
technology and makes itself viable, above all, in the attendance area.
Having quality as a parameter, in 2011, some of the targets for assistance
were reached and others for 2012 were established:
Targets reached in 2011:
Obtainment of Canadian Certification
Target set for 2012:
Obtainment of the ONA recertification.
44
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
45
R e s e a r ch
A Leader in Scientific Production
The A.C.Camargo reached 2010 being responsible for 87% of all the
country’s scientific production in oncology
T
he A.C.Camargo Hospital’s contribution to oncologic science, above
all in the fields of cellular and molecular biology, and the genetics
and genomics of cancer, consolidate the relevance of the institution
on the Brazilian and international scientific scene. According to the website
SCImago Journal & Country Rank (www.scimagojr.com), between 2001 and
2010, Brazil produced 1.459 articles. In 2010, 216 works were published in
magazines with international indexes, being the A.C.Camargo responsible for
the production of 188 high impact articles, representing 87% of scientific production in oncology in the country. According to the Institute for Scientific Information (ISI), amongst the 48 main medical specialties, Oncology is the one
of most impact in scientific production in Brazil (2005 – 2009 five-year period).
With the Hospital’s incentive, most of its medical staff is involved in the
development of scientific projects.
On the front line – Since 2007, the A.C.Camargo coordinates the Instituto Nacional de Ciência e Tecnologia em Oncogenômica (INCiTO), financed
by the Conselho Nacional de Desenvolvimento Científico e Tecnológico do
Ministério da Ciência e Tecnologia (CNPq/MCT) and, in the state of São Paulo,
Bárbara Pereira
de Melo
Biologist and Doctor in
Sciences, an A.C.Camargo
Hospital graduate.
46
“The A.C.Camargo Hospital offers the researcher all the necessary
instruments for competent work. Not having yet reached the age of 30
I can say that I am a very lucky researcher, for here professionalism
is what most stands out. Here, research is truly done and it is the best
place to work. All those working in the laboratories can make use of an
incredible structure which includes a tumor bank, a RNA bank and first
world equipment”.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
carried out together with the Fundação de Amparo à Pesquisa de São Paulo
(Fapesp). Covering the areas of epidemiology and tumor biology, clinical trials, recruitment and the monitoring of patients, the INCiTO forms a network
of national and international institutions.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
47
Bio-bank – The oldest storage bank for cancer samples in Brazil, created in
1997, the A.C.Camargo Hospital’s biobank is responsible for the collection,
storage and management of samples of different types of human materials: tissues, blood, RNA and DNA, amongst others, according to norms and
national and international standards.
The structure of the A.C.Camargo Hospital’s biobank consists of the Tumor Bank and the Macromolecule Bank (samples of DNA and RNA). It is the
The A.C.Camargo
provides the
Biobank software
for use in tumor
banks of a number
of institutions in
Brazil and abroad
largest collection of tumor tissues for research in cancer in Latin America,
with approximately 19500 samples of frozen tissue stored (approximately
8,500 from tumors and 11,000 non-neoplastic).
The A.C.Camargo also supplies the Biobanks software and provides training for its use at other tumor banks at institutions in Mexico, Uruguay, Argentina and as well as at 50 Brazilian hospitals.
Medical information technology – Apart from the samples of material, the
A.C.Camargo stores in total confidentiality and safety, clinical information
about the more than 700 thousand patients that have already been attended,
diagnosed and treated since the Hospital’s foundation. This data bank has
an incalculable value for the development of science and requires specific
tools for its control. For this reason, Medical Information Technology created
specific computer tools for managing all aspects of cancer scientific research
– right from submission and ethical approval of the developed projects up
All investment involved in the INCiTO project aims to translate research
results into clinical practice, in a way that new knowledge can be quickly
and efficiently transferred to the Brazilian healthcare system.
to the use of samples and patient data.
The “Biobank” software manages the frozen and paraffin-impregnated tissues, leucocyte, plasma, DNA and RNA, as well as the requests for use of these
samples by researchers (which go through a series of evaluations, in which
New investments – Research teams linked to the A.C.Camargo have at their
they can be approved or not). It is integrated to the system that manages sci-
disposal an area of nearly four thousand meters with spacious laboratories
entific projects, therefore, only ongoing projects with the necessary approval
containing infrastructure comparable to that of the best international cen-
from the Ethics Committee can request and use samples from the Biobank.
ters. Inaugurated in August 2010 during an event at which Nobel Prize winner
The program is published with the “GNU-GPL v3” license, a license for free
Harald zur Hausen was present, the new home of the Centro Internacional de
software, which allows it to be downloaded and modified by institutions with
Pesquisa do Hospital A.C.Camargo (CIPE) received new investments in 2011.
no cost, as long as the results from this research are also made public. As
A new resource was bought to be added to the large scale-sequencing
there is public access, the program developed by A.C.Camargo’s researchers
platform SOLiD 4, a technology that allows the sequencing of complete hu-
avoids problems resulting from commercialization, such as costs, difficulty
man genomes in less than one week. The A.C.Camargo Hospital bought the
in implementing improvements and in copying the data to other formats,
SOLiD 5.500, a smaller and more potent equipment than the previous model,
providing an unmatchable autonomy to its users and contributing to the
capable of reading a larger number of sequences per runs – whilst the SOLiD
dissemination of science.
4 reads 500 million sequences per run, the 5.500 model reads one billion –
48
which results in a lower cost per sequence. For this it was necessary to buy a
From the laboratory to the clinic: basic and clinical research – Basic
number of computers exclusively for processing the analysis resulting from
cancer research has undergone a real revolution in the last decades, with
the Foundation’s sequencing platforms.
the discovery of the structure of DNA, in the 50s, and the development of
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
49
techniques for molecular diagnosis. The Projeto Genoma do Câncer no Bra-
The A.C.Camargo also works on the field of clinical research, a fundamen-
sil, under the leadership of researcher Ricardo Brentani, in 2000, was also a
tal tool in the fight against cancer, through which it is possible to obtain more
historic step: the opening of a new and promising field of research. Today,
effective and safe medications. And to ensure that research is carried out ac-
at the A.C.Camargo, the basic research structure in Oncology is formed by
cording to strict scientific and ethical standards, it is supervised by three com-
five laboratories: Cancer Genomics and Molecular Biology, Cytogenetics and
mittees: the Committee for Ethics in Research, the Internal Commission for
Molecular Genetics, Investigative Pathology, Medical Genomics and Bioinfor-
Biosecurity and the Research Commission, which also carry out basic research.
matics and Molecular Oncogenetics.
Genetic studies allow for the identification of high-risk individuals for
»» Comitê de Ética em Pesquisa (Committee for Ethics in Research) – CEP – Re-
the development of cancer and the definition of strategies in tracking and
sponsible for analyzing researches that involve human beings in order
an early detection of the illness, which reduces death rates and treatment
to guarantee and protect their integrity and the rights of the volunteers
costs. The A.C.Camargo Hospital has one of the main Genetic Oncology clin-
involved in the researches.
ics in the world, attending patients with 16 different hereditary syndromes.
»» Comissão Interna de Biossegurança (Internal Commission for Biosecurity) –
In 2011 alone, the Oncogenetics clinic carried out 1.322 attendances, 680 of
CIBio – Responsible for monitoring projects and researches that involve
which were first time attendances.
manipulation, production and transport of Genetically Modified Organ-
Amongst the Oncogenetics projects that stand out internationally is the
study of Li-Fraumeni syndrome. The A.C.Camargo Hospital possesses one
of the greatest casuistics in Li-Fraumeni in the world and works on tracking
and accompanying patients with a clinical and molecular diagnosis of this
illness through partnerships and collaboration with renowned national and
international institutions.
115 research
projects, in stages
ii to iv, are being
carried out
with the use of
medications in
test phase
isms (GMOs).
»» Comissão de Pesquisa (Research Commission) – COPE – Responsible for evaluating the effectiveness and importance of research projects, linked or
not to post-graduation, orientating the planning and stimulating multidisciplinary collaboration and integration. Also evaluates if the availability of financial resources and the deadline for the studies are adequate.
Presently, 115 projects are being undertaken, between phases II and IV
with the use of test medications.
With the aim of stimulating the link between scientific investigation and
clinical application, so called “translational medicine” the A.C.Camargo Hospital was the stage of an important event in 2011: the 2nd Escola São Paulo
de Ciência Translacional (São Paulo School of Translational Science), with
the theme Molecular medicine: from bench to bedside, from the 19th to the
24th of June 2011.
Due to its partnership with the Instituto Nacional de Neurociência Translacional, the A.C.Camargo Hospital received one hundred and twenty young
scientists from Brazil and abroad. They were able to share their knowledge
with 33 scientists from renowned institutes such as the Memorial SloanKettering, Robarts Research Institute, SicKids, Sanford-Burnham and Ludwig
Institute for Cancer Research, apart from scientists from universities in the
United States, Canada and Brazil. Those who took part in the meeting discussed the lines of research that are at the forefront of molecular medicine,
focusing above all on molecular and cellular alterations linked to cancer and
neurodegenerative illnesses. In its first edition, carried out in April 2012, the
A.C.Camargo Global Meeting brought together scientists who discussed the
latest in Genomics, Oncology, Immunology and Neuroscience.
50
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
51
SUPPORT AN D PARTI C IPATION
National and international partnerships
T
he production and dissemination of high level scientific information, aspects which are intrinsically linked to excellence in the care
provided, are not possible without a qualified network of exchanges
and agreements. The A.C.Camargo Hospital established a number of partnerships through the National Institute of Science and Technology in Oncogenetics (INCiTO), for which it is responsible since 2007. The INCiTO includes
the following participants:
National
»» Faculdade de Saúde Pública, USP, SP
»» Instituto de Pesquisas Energéticas Nucleares, IPEN, SP
»» Hospital de Câncer de Barretos, Barretos, SP
»» Hospital Amaral Carvalho, Jaú, SP
»» Faculdade de Medicina de Botucatu, UNESP, Botucatu, SP
»» Hospital do Câncer – Instituto do Câncer de Ceará, Fortaleza, CE
»» Universidade Estadual de Londrina, Londrina, PR
»» Universidade Federal de Mato Gross do Sul, Mato Grosso do Sul, MS
International
»» MD Anderson Cancer Center, Houston, USA
»» International Agency for Research on Cancer, Lyon, France
52
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
53
»» McGill University, Montreal, Canada
»» University of Heindelberg, Heindelberg, Germany
»» Memorial Sloan- Kettering Cancer Center, NY, USA
»» Virginia Bioinformatics Institute, Virginia, USA
»» Grupo colaborativo Uruguayo, Investigacion de Afecciones Oncologicas
Hereditárias, Montevideo, Uruguay
»» Hospital Italiano, Buenos Aires, Argentina
»» Instituto Nacional de Enfermedades Neoplásicas, Peru
Partnership in the production of inputs
In 2011 the A.C.Camargo Hospital and the Cardinal Health Group, the world’s
largest producer of short half-life radiopharmaceuticals (FDG) became partners. The initial investment will be of R$ 10 million and involves the setting up of a cyclotron, equipment that produces radiopharmaceuticals, used
above all in imaging exams (such as PET-CT) and treatments (radioisotope
therapies). Apart from the production of inputs for PET-CT exams, this partnership provides an opening for lines of research.
54
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
55
TEAC H IN G
Storehouse of specialists
It is estimated that one third of all Brazil’s oncologists are graduates from
the A.C.Camargo Hospital’s Medical Residency program.
P
rior to the foundation of the A.C.Camargo Hospital, in 1953, anyone
who wanted to specialize in Oncology had to leave the country. In the
same year in which the hospital was created, the first Medical Resi-
dency in Oncology program was set up in Brazil, with the creation of the Escola de Cancerologia Celestino Bourroul, linked to the Hospital.
Each year the Hospital receives around 40 new residents. In 2011, 42 new
residents started the program, 8 of which received a grant from the Antônio
Prudente Foudation, 10 of which received a grant from the Ministry of Health
and 22 of which received a grant from the Secretary of Health. The Hospital
also offers help in accommodation for students coming from other states.
With the graduation of 37 new specialists in 2011, the A.C.Camargo has
now graduated a total of 1009 oncologists from its Medical Residency. It is
estimated that the A.C.Camargo is responsible for the graduation of one in
very three oncologists practicing in Brazil today.
Fernando S. Perrota
Resident Doctor at the
A.C.Camargo Hospital
56
“I have admired the A.C.Camargo since I graduated in Medicine. I already knew
the hospital through my father who concluded his residency in the institution
in 1975. I began to like oncology when I was at university and whilst I was still
studying I carried out an optional internship at A.C.Camargo’s Department
of Pelvic Surgery with Doctor Ademar Lopes. I had the opportunity to meet
him personally, not only at the hospital but also on a personal level. This
was when I decided once and for all that I would carryout my studies in
Surgical Oncology at this Hospital. It has a history of five decades and this
is not common. Through its history, the old Cancer Hospital, today the
A.C.Camargo, acquired experience to offer the best oncology to patients. And I
have no doubt that this history is the Hospital’s identity and should always be
remembered and celebrated”.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
At present, teaching is divided in five big areas:
»» Escola de Cancerologia (Cancerology School) – Medical Residency program, Continued Learning, Improvement, Observation Internship
»» Post-Graduation Stricto Sensu – Masters and Doctorates
»» Post-Graduation Lato Sensu – Specialization and Improvement in regular
and long-distance learning courses
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
57
»» Program of Scientific Initiation – aimed at preparing graduate students
The A.C.Camargo
confirms, up
until today, the
graduation of 1009
oncologists in its
Medical Residency
Program
who are interested in beginning research activities, and, in the future
post-graduation
»» Technical Teaching in Nursing
By the end of 2011, the institution had 23 students of Scientific Initiation,
85 Masters students, 73 Doctorate students and 17 Post-graduation students.
Its post-graduation was the best evaluated in Oncology in the country in the
last decade.
flow of titles per level – 1999 to 2011
45
42
30
25
25
21
18
17
14
14
2000
2002
2003
2005
2006
2008
2009
D Titles
D Titles
2010
M Titles
M Titles
D Titles
M Titles
D Titles
D Titles
2007
M Titles
M Titles
D Titles
M Titles
D Titles
D Titles
2004
M Titles
M Titles
D Titles
M Titles
D Titles
D Titles
2001
4
3
M Titles
D Titles
M Titles
D Titles
M Titles
1999
3
M Titles
3
9
7
6
0
15
13
7
8
3
18
17
2011
study center 2010/2011
Courses
Total number of
students – 2010
Total number of
grants – 2010
Total number of
students – 2011
Total number of
grants – 2011
Post-Graduation
Lato Sensu
182
44
242
64
Extension Courses
473
49
224
24
Technical Courses
76
32
21
1
239
44
305
55
1.634
531
1.552
547
Long-distance learning
Events
58
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
59
R e l at i o n s h i p w i t h s u p p l i e r s
(GRI 4.14)
Buying policy guarantees transparency
Suppliers are continually evaluated in a multidisciplinary process that
guarantees the quality of the products acquired and the legal fulfillment of
criteria by the companies
T
he A.C.Camargo Hospital has as a premise that its relationship with
suppliers, with respect to competitive bids, must occur in a transparent form, guaranteeing that, apart from the commercial aspects,
legal, fiscal and employment related aspects are fulfilled.
For this to happen, a Buying Policy, approved by the Hospital’s directors,
regulates all the institution’s acquisition process.
The approval of new suppliers and their periodical evaluation are also
supported by a Suppliers Approval and Continued Evaluation Policy, which
seeks to establish technical and commercial criteria which guarantee safety
in acquisition processes.
The approval of suppliers is carried out in a multidisciplinary way, involving both the Supplies Department and the two commissions below:
»» Pharmacy and Therapeutics Commission (CFT), responsible for the evaluation of suppliers and products from the pharmacy industry which will
be used by the institution.
»» Commission for the Standardization of Materials, responsible for the evalDécio José Carreiro
Founding-partner of the
Focus Group
security and services
60
“We have been working with the A.C.Camargo Hospital since 2005 and we
are very proud of this partnership. To be responsible for Security at the
A.C.Camargo is a differential for our company, for it is an international
reference center in Oncology. When we first started working here, our main
focus was to adequate our daily activity to the A.C.Camargo Hospital’s
mission to offer special care to patients and their families.”
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
uation of materials and their suppliers, identifying which ones can be
used in the institution.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
61
To enhance the process of approval of suppliers of medications and materials, the institution’s pharmacy sector participates as an effective member of the Grupo de Avaliação de Fornecedores (GAFO), made up of hospital
pharmacists from Brazil’s main hospitals. This group has as its aim the evaluation and qualification of suppliers of medications and healthcare products,
looking to contribute to the improvement of matters relating to the quality
and fulfillment of legal requirements by the companies. (GRI PR1)
62
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
63
RELATIONS H IP W IT H C LIENTS
(GRI 4.14)
The Satisfaction Survey Results (GRI PR5)
Confirmation of reliability: 98% of the patients interviewed stated that
they would indicate the Hospital to whoever was in need.
D
ialogue and transparency permeate the relations based on the commitment to fight cancer patient by patient, in an individual and
humanized way. The A.C.Camargo team know that their mission
is not only to treat the illness but also to treat the person who is suffering
from it. In 2011, in the search for excellence in the care provided, the Hospital noted the need to carry out a systematic evaluation of the patient’s and
their family member’s opinions about the services provided and promoted
a wide-ranging Client Satisfaction survey.
The Hospital opted to carry out a quantitative survey, for which a specialized institute was contracted. The questionnaire was applied by specialized
staff trained for the project.
Interviews were carried out with 813 patients and 372 family members
or friends, randomly selected, following the procedures established in the
Ethical Code of the ABEP, Associação Brasileira de Pesquisa, and ESOMAR,
European Society for Opinion and Market Research.
Recognition – The numbers confirmed what was expected: 92% of patients
and 92,5% of those accompanying them stated that they were “completely
Beatriz Nunes
Schiavon
Ex-patient, biomedical
scientist and masters
student at the
A.C.Camargo Hospital
64
“In 2003, when I was still very young, aged 14, I arrived at the
A.C.Camargo Hospital to receive cancer treatment. Being treated here
made all the difference to my life, being a decisive factor in directing
my career in the Healthcare sector. Today I am cured, I am a biomedical
scientist and I am completing a masters here at the A.C.Camargo. To be
able to carry out research on cancer is to be able to repay the care which
I received and try, somehow, to help other patients”.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
satisfied” with the A.C.Camargo Hospital; 97,5% of patients and 98,9% of
those accompanying them had “total trust” in the institution. And almost all
the patients and those accompanying them – 98% and 98,4%, respectively
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
65
– “would definitely indicate the A.C.Camargo” to someone who was in need.
The positive aspects which most reappeared in the open-ended questions
directed at patients related to the good attendance at reception, emergency,
nursing, medical staff, support areas and the attention they received.
Attribute
Scale of Agreement %
Rates %
P1 – I am totally satisfied with the
I totally
I disagree
I don’t agree and
I slightly
I totally
A.C.Camargo Hospital
disagree
slightly
I don’t disagree
agree
agree
Disagree*
Do not
disagree**
Agree**
patients
0.7%
5.3%
2.0%
19.9%
72.1%
6.0%
94.0%
92.0%
those accompanying patients
0.5%
2.7%
4.3%
22.6%
69.8%
3.2%
96.8%
92.5%
Attribute
P4 – I would definitely recommend
Scale of Agreement %
Rates %
I totally
I disagree
I don’t agree and
I slightly
I totally
disagree
slightly
I don’t disagree
agree
agree
patients
0.6%
0.5%
0.9%
5.7%
92.4%
1.1%
98.9%
98.0%
those accompanying patients
0.3%
0.3%
1.1%
9.4%
89.0%
0.5%
99.5%
98.4%
the A.C.Camargo Hospital to
someone in need
Disagree*
Do not
disagree**
Agree***
The satisfaction survey revealed that the A.C.Camargo Hospital accomplished its 2011 target of being recognized due to the excellence in its care.
The Hospital also presented excellent results in the satisfaction survey
answered by SUS patients, (patients from the government health service –
Sistema Único de Saúde), published by the Secretaria de Saúde do Estado de
São Paulo in 2011. 574 hospitals of the SUS/SP were evaluated and the average grade obtained was 8,86. The grades obtained by the A.C.Camargo were
significantly superior to the average:
»» Procedures – Final result: 9, 466
»» Internment – Final result: 9,427
Qualitative evaluation of professionals
»» Medical team– Final result: 9,694
»» Nursing Team– Final result: 9,612
It is worth noting that the survey was answered by 100% of those interviewed.
66
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
67
VOLUNTARY WOR K
(GRI 4.14)
The strength of the a.c.camargo’s voluntary
network
A
direct inheritance of Carmem Prudente’s entrepreneurial spirit and idealism, the Voluntary Network, which, literally, made the
A.C.Camargo Hospital what it was in the 1950s, today has the im-
portant role of supporting patients and those accompanying them. The volunteers also work in making removable breast prostheses and colostomy bag
holders. At present the Voluntary Network includes around 250 volunteers,
47% of which have been at the Hospital for over 10 years, which demonstrates
these people’s commitment with the institution and its cause.
Magda Egleé
Anderlini Joyce
Volunteer at the
A.C.Camargo Hospital
since 1980
68
“Today I see that being a volunteer at the Hospital was one of the
happiest decisions I took in my life. You can’t imagine how special
every Wednesday is for me… I never arrange any other commitment
on this day: it is reserved for the creation of breast prostheses, which
me and my colleague do with a great deal of love and care. It is very
rewarding to see the patient’s happiness when they receive and begin
using the prosthesis!”
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
69
P H ILANT H ROPY
Social commitment: the reason for our work
Social responsibility is the reason for our existence at the A.C.Camargo
Hospital. It was this consciousness which created in the hearts of the
Hospital’s founders the desire to create the hospital and which was
made true thanks to a network of volunteers that worked hard to raise
the necessary resources. Today, the Hospital repays society with true
obstinacy: its philanthropic actions are spread throughout its work in
assistance, where the attendance of patients from the Sistema Único
de Saúde, the SUS, stand out, and in teaching and research, with the
sponsorship of projects and the granting of scholarships. (GRI SO1)
T
he institution maintains an agreement with the SUS local Municipal
Manager for oncologic assistance. The main institutional characteristic for the evaluation of compliance of assistential production for
evaluation by the CEBAS (Certificado de Entidade Beneficente de Assistência
Lourdes Massae
Sonohara Furugen
Prefeitura da Cidade de
São Paulo / Secretary
of Health
70
“The Antônio Prudente Foundation / A.C.Camargo Hospital and the São Paulo
Municipal Secretary of Health celebrated their first agreement in August
2003 and since then the partnership has progressively evolved, always with
the aim of offering, through the Sistema Único de Saúde (SUS), quality
oncology assistance to the people of São Paulo and patients coming from
other municipalities. As it is certified as a Teaching Hospital by the Ministries
of Health and Education, we are currently establishing some physical and
qualitative targets in the areas of assistance, research and teaching, to
strengthen our partnership. The A.C.Camargo is nationally and internationally
registered as an institution that offers quality healthcare assistance in
oncology with state-of-the-art technology and the agreement with the
Municipality of São Paulo, therefore, is necessary, appropriate, and important
for the city’s SUS network.”
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Social) is established by the Article 4, section II, of law nr 12.101, of the 27th
November 2009, regulated by the Decree 7.237 of the 20th July 2010, altered
in part by the Decree 7.300 of the 14th September 2010, and also by the Order
nr. 1.970 of the 16th August 2011.
In 2011, the institution’s total attendances of patients coming from the SUS
represented a significant increase compared to the previous year.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
71
2010
2011
Total Attendances
944.501
1.109.823
SUS attendances
584.994
700.020
61,9%
63,1%
% of SUS attendances
The final percentage obtained for SUS – Sistema Único de Saúde – attendances in 2011 was 63.1% (61.9% in 2010), which was above the minimum
percentage established of 60% by legislation.
The de-hospitalization in oncology, through the application of protocols in
referenced world treatment, is a reality practiced in this specialization, which
concentrates its efforts in outpatient procedures (the great majority of interventions are outpatient interventions, reaching over 90%). In this context, in
2011, the A.C.Camargo Hospital carried out 695.554 outpatient procedures
on patients coming from the SUS, corresponding to 63.7% of the total number of outpatient attendances, and 396,980 procedures on non-SUS patients.
These outpatient attendances, summed to the admittance of SUS pa-
a complete diagnosis center, doctors from all specialties, high technology
equipment, a complete human resources structure and materials in only
one place, allowing for greater speed and comfort for the patients, who do
not need to go to other institutions to complete their treatment.
Main social actions and costs
»» 63,1% of procedures carried out on SUS patients;
»» Oncogenetic attendances on SUS patients;
»» Approximately 127 PET-CT exams carried out for the Secretaria de Estado da Saúde (patients from the Santa Marcelina Hospital, USP Ribeirão,
Servidor Público Estadual, IAMSP, Heliópolis Hospital, Mandaqui Hospital
and the HC, amongst others);
»» Carrying out of IMRT (Intensity Modulated Radiation Therapy) sessions,
Stereotactic Radiotherapy and Radiosurgeries (agreement with the SES);
tients, generated credits re-passed by the manager of approximately R$22.090
»» Radiotherapy and Brachytherapy (176 SUS patients) through cooperation
million, being that these same attendances and admittances generated an
with the Pérola Byington Hospital, Vila Nova Cachoeirinha Hospital and
estimated cost of approximately R$67.775 million, that is, approximately
the Radiotherapy Institute of the Vale do Paraíba, Heliópolis Hospital,
R$45.685 million were subsidized, which correspond to a value greater than
amongst others;
the entire exemption and immunity of social contributions received due to
its legal characteristics.
The A.C.Camargo Hospital also made treatments such as radiosurgery,
IMRT, PET-CT diagnosis and other types of diagnosis available to SUS patients, as well as Oncogenetic procedures that are not covered by the SUS
list. In the same period, it carried out procedures for the Redes de Atenção
(Attention Networks) in High Complexity Cardiovascular procedure, High
Complexity Neurology and High Complexity Traumato-orthopedics, as aids
»» The distribution of 16.746 geriatric and infant nappies to patients;
»» Provision to patients of special medications and materials not covered by
donations from people and companies;
»» Education, Prevention and Early Diagnosis of cancer in Public Schools,
APAE, Hotel workers Trade Union, CFAP – Centro de Formação e Aperfeiçoamento de Praças, AMA- Associação Amigos do Autista; Mothers Day
and Fathers Day campaigns, having attended 8.458 people in 2011;
in oncologic treatment, which are not covered (not accredited by the Ministry
»» Management of the donation of 1.239 temporary removable prostheses
of Health). Throughout this period, 110 liver and bone marrow transplants
for patients with breast cancer, including patients from other institutions;
were also carried out on SUS patients.
The cure and survival rates obtained by the treatments carried out at the
A.C.Camargo Hospital represent a significant economy in resources in the
695,554 outpatient
procedures were
carried out on
patients coming
from the sus, this
corresponds to 63.1%
of these attendances
in 2011
»» Free distribution of 2.590 drip supports to patients;
»» Free distribution of 550 tracheostomy protectors to patients.
area of public health and social security. Such rates are not found in other
general hospitals. Well-treated patients do not require new surgeries or to
be submitted to a number of protocols and can, with greater frequency,
be re-integrated into their professional, family and social activities after a
short length of time. At the institution, treatment is planned and discussed
in a multi-professional way. In its hospital complex, the institution houses
72
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
73
Philanthropy in education
791 scholarships were given, of which:
»» 12 Doctorate scholarships (CAPES);
»» 25 Masters scholarships (CNPq);
»» 34 for Residents in Oncology;
»» 23 PIBIC scholarships (Scientific Initiation);
»» 10 for Post-Graduation in Oncologic Hospital Pharmacy;
»» 7 for Post-Graduation in Hospital and Oncologic Physiotherapy;
»» 5 for Post-Graduation in Dysphagia;
»» 3 for Post-Graduation in Orofacial Motricity;
»» 32 for the 14th Class of Specialization in Oncology Nursing;
»» 7 for the 15th Class of Specialization in Oncology Nursing;
»» 6 for the Course of Psycho-Oncology;
»» 4 for the Extension Course in Hospital Teaching;
»» 4 for the Extension Course in Oral Oncology;
»» 6 for the Extension Course in Nutrition;
»» 7 for Improvement courses (Nutrition, Medical Physics, Physiotherapy
and Mouth Cancer);
»» 45 for EAD – Oncogenetics;
»» 7 for EAD – Antineoplastic;
»» 547 free entrances to Events in 2011;
»» 4 for course in improvement in Imaging;
»» 3 for EAD – Oral Nutritional Therapy, Enteral and Parental for the Oncologic Patient.
»» Availability of 290 places in Support Houses for the accommodation of
patients and their families, with food and transport included, making the
treatment of people coming from other cities and states possible;
»» 680 Classes and 11.340 presences of 1.480 student-patients including interned and oupatients (Schwester Heine School);
»» 23.214 accesses with free download of the Cartilha de Direitos dos Pacientes
– Patients’ Rights Handout between January and December 2011 (withdrawal of the FGTS, PIS, Payment of debts from Home Ownership, exemption from the IPVA, exemption from the Rodízio de Automóveis, exemption
from Income Tax, free public transport, amongst other benefits which the
patient and his family have the right to);
»» Donation of Animal Ventilation MCA FLEX-VENT to the Medical Faculty
of the USP;
»» Donation of an Electrocardiogram equipment to the State Hospital Dr. Car-
Social responsibility
»» Approximately R$ 250.000 was invested in improvements to the Cessão
building headquarters of the Dona Carolina Tamandaré Foundation; in support of the development of the project involving more than 60 poor children
from the Glicério district, as well as the donation of food, toys and books
for the children of the Carolina Tamandaré Foundation;
»» 45.538 consultations for support in Social Services, providing patients and
family members with a great deal of help and clarification;
74
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
los da Silva Lacaz;
»» Approximately 200 items and pieces of furniture donated to the Casas
André Luiz;
»» Approximately 950 items and pieces of furniture donated to the Casa da
Criança Excepcional Maria Maia;
»» Contribution to the maintenance of the Casa de Apoio à Criança Carente
com Câncer, (granting the free use of the building in which the institution
operates);
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
75
More than 8
thousand patients
were attended
in prevention
campaigns, where
179 cases of cancer
were identified
and treated at the
institution during
the initial stages
of the illness
summarizing table – cost of social activities in 2011
(gri la8)
Early diagnosis – Every year, the A.C.Camargo Hospital offers to the general public the possibility of carrying out cancer prevention and early di-
2011 Gratuities
Value in thousand R$
Cost of SUS procedures
45.685
Subsidies in Research Area
7.977
Stricto Sensu (*) Courses (masters, doctorates, Postdoctorates and scientific initiation)
5.382
Improvement Courses (*)
4.756
Costs with Medical Residency
3.579
SUS Gratuity (extra values above ceiling)
686
Gratuity – Lato Sensu scholarships
302
Voluntary Network Donations (donated toys, nappies,
food, and exams carried out not covered by the SUS)
238
Total
68.605
(*) Estimate based on researches carried out with similar institutions.
agnosis exams through campaigns. In 2011 more than 8 thousand patients
were attended in prevention campaigns, during which 179 cases of cancer
were identified and treated at the institution in the illnesses’ initial stages.
Without actions such as this one, these patients would only diagnose cancer
much later, when the chances of cure are lower.
Numbers from the campaign (GRI LA8)
Patients Attended during the Campaign
% Cancer without attendance
Tumors Diagnosed at an early stage in Campaigns
Cancer of the Bladder
2
Head and Neck Cancer
10
Cervical Cancer
0
Cancer of the colon
0
Stomach Cancer
3
Cancer of the Larynx
3
Tongue Cancer
1
Breast Cancer
30
Cancer of the Palate
2
Cancer of the Pancreas
1
2
Skin Cancer
19
Prostate Cancer
59
Lung Cancer
6
Thyroid Cancer
0
17
Hepatic Cancer
3
Cancer of the rectum
9
Liver Cancer
3
Sigmoid Cancer
1
Cancer of the Testicles
3
Cancer of the Biliary ducts
1
Lymphomas
2
Soft tissues sarcomas
1
Total
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
2011
1
Gynecological Cancer
Performance Indicators
2,10%
Cancer of the Tonsils
Parotid Cancer
76
8458
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
179
77
AVS
Added Value Statement
The distribution of the aggregated wealth of the Antônio Prudente
Foundation (GRI 2.8) (EC1)
periods ending on the 31st december 2011 and 2010
(In thousands of Reais)
2011
2010
1. Revenue
505.020
403.920
Sale of products and services
494.176
396.080
Allowance for Loan Losses
(7.399)
(5.271)
Other operations
18.243
13.111
2. Inputs acquired from Third Parties
239.712
193.901
Costs of products and services
177.295
140.507
62.417
53.394
265.308
210.019
4. Withholdings
9.100
8.222
Depreciation, amortization and depletion
9.100
8.222
Materials, electricity, services by third parties and others
3. Gross Value Added (1-2)
78
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
79
2011
2010
256.208
201.797
6. Value Added Received in Transfer
15.243
9.906
Financial revenue
15.243
9.906
7. Total Value Added to be Distributed (5+6)
271.451
211.703
8. Distribution of Value Added
271.451
211.703
Personnel and Tax Expenditures
107.993
86.501
Direct Payment
81.318
67.191
Benefits
18.791
12.557
5. Net Value Added produced by the Institution (3-4)
Tax expenditures
Taxes and contributions
Funding of SUS procedures
Third Party Capital Remuneration
Interests
Rent
Return on own Capital
Surplus retained in the period
7.884
6.753
939
2.294
45.685
42.322
3.448
3.547
281
720
3.167
2.827
113.386
77.039
113.386
77.039
F i n a n c i a l H e a lt h I n d i cato r s
net revenue from services
ebtida
(R$ million)
(R$ million)
494,0
500
120
106,8
100
396,0
400
344,0
77,6
80
293,0
63,4
300
231,0
60
53,1
189,0
200
148,0
88,0
100,9
37,7
40
117,9
27,8
100
15,6
20
1,3
0
2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
0
–20
operational surplus after
depreciation and financial result
(6,9)
1,5
2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
net surplus
(R$ million)
(R$ million)
112,7
120
113,4
120
100
100
78,5
80
60
49,9
66,0
60
32,5
40
77,0
80
61,9
47,8
40
22,8
20,8
20
20
5,2
0
–20
80
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
11,9
1,8
(6,5) (14,3) (6,8)
2002 2003 2004 2005 2006 2007 2008 2009 2010
52,1
0
2011
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
–20
(6,5)
0,8
2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
81
debt (debt/cash)
net cash
(R$ million)
(R$ million)
1000
200
177,2
882,4
800
150
600
360,0
400
C o mm u n i cat i o n w i t h s o c i e t y
100,5
93,8
100
(GRI PR6)
323,3
50,2
259,5
50
200
26,1
94,6
0
48,7
26,7
11,0
1,2
4,0
2002 2003 2004 2005 2006 2007 2008 2009 2010
0
–50
operational margin (%)
2002 2003 2004 2005 2006 2007 2008 2009 2010
22,8
25
21,6
19,9
19,6
20
20
18,1
17,0
A reference in cancer treatment and research, in 2011 A.C.Camargo
Hospital launched a new website with content directed at different
types of public
10,5
10
10
I
5
3,5
5
Source of qualified information
16,3
15
11,1
1,5
0
18,4
14,7
14,0
15
2011
ebtida margin (%)
25
19,5
1,1
(13,3) (19,5) (20,1) (15,1)
2011
(7,4) (14,2) (5,8)
1,3
(6,8)
0
–5
–5
–10
–10
n 2011, the Hospital was mentioned in 960 articles in the press, 23% more
than in 2010. This number not only confirms the growing relevance of
the A.C.Camargo as a reference institution in the treatment and research
of cancer, but also the effectiveness of its investment to improve communi-
–15
2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
Aware of its role as a source of qualified information the A.C.Camargo
2002 2003 2004 2005 2006 2007 2008 2009 2010
2011
net margin (%)
launched, in 2011, a new website, with content directed at different audiences: patients, family members and caretakers; researchers and students;
assets
doctors and healthcare professionals; HR executives and journalists.
(R$ million)
25
23,0
19,2
20
Re-structured throughout a period of six months by Marketing Superin497,167
500
383,781
400
that work at the institution. The website also contains didactical informa-
236,373
183,225
200
8,0
5
100
2,0
the academic career and scientific production of the nearly 500 specialists
300
12,1
10
clusive pages on the more than 40 specialties as well as find information on
304,335
14,3
tion about risk factors, diagnosis and treatment of various types of cancer,
as well as multimedia resources and interactivity with the official profiles
65,901
26,782 21,950 23,121
0,7
(6,4)
on social networks, amongst them Twitter, which in 2011, had more than
39,189
0
2002 2003 2004 2005 2006 2007 2008 2009 2010
tendency, the website brings news about the advances in oncology, right from
basic research to clinical practice. On the website the viewer can access ex-
19,4
17,8
15
0
cation with society.
2011
2,7 thousand followers and Facebook, with more than five thousand users.
–5
–10
2002 2003 2004 2005 2006 2007 2008 2009 2010
82
2011
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
83
Campaigns for prevention and early diagnosis
healthy habits and the prevention of illnesses. The campaign was born from
the fact that 80% of patients in the Urology sector are accompanied by wom-
Apart from spreading information via its website, social networks and
journalists who are frequently attended by our institution, as a reference
in cancer treatment and research, the A.C.Camargo Hospital has promoted
prevention and early diagnosis campaigns aimed at the community.
Below are the actions that were carried out in 2011:
Health Ambassadors Program – Launched in March, in honor of International Women’s Day, the aim of the campaign was to attract even more
the female public to the important mission of spreading information about
en (generally wives, mothers or daughters) throughout all stages of treatment. It emerged that women play a decisive role in early diagnosis and in
assuring that the patient follows all the medical team’s recommendations
correctly. Throughout this campaign, the A.C.Camargo Hospital distributed
15 thousand badges together with cancer prevention manuals providing tips
Cancer prevention
campaigns,
organized by the
A.C.Camargo,
reach, each year,
a growing number
of people
on healthy habits that prevent cancer.
Participation in The Conarh / Expo Abrh 2011– In August the A.C.Camargo
Hospital participated in the largest Human Resources event held in the
country as the sponsor of the “Women’s Area”, where talks were given to
guide managers on how to offer support to a collaborator diagnosed with
cancer, during treatment and on return to work. The Hospital’s staff also
talked about the importance of early diagnosis of cancer, emphasizing the
need to carry out periodic exams. It was the fourth time the A.C.Camargo
Hospital participated in the Conarh/ExpoABRH, as part of the “Cancer Prevention in Companies Project”, through which the institution divulges information on health and quality of life in the corporative environment and
as part of the program “Health Tips”, which produces content for Intranet,
SMS, handouts and newsletters. It is estimated that this initiative reaches
nearly 125.000 people, collaborators of 26 partner companies. The prevention talks and the programs are divided into: Smoking, Skin Health, Men’s
Health and Women’s Health.
Run And Walk – On 21st August 2011, the Hospital promoted a sporting
event to spread information on cancer prevention. The “Corrida e Caminhada A.C.Camargo – Saúde do Homem” (A.C.Camargo Run and Walk – Men’s
Health) was held in São Paulo, with the starting and finishing lines in Ibirapuera Park. The participants received informative material about the prevention and early detection of cancer, especially in urological tumors.
Looking After Yourself Well – With the purpose of talking to the community about the importance of adopting habits for a healthy life on a daily basis in order to prevent cancer and other illnesses, in April 2008, the
A.C.Camargo Hospital signed a partnership with the Eldorado Radio Station,
known today as Eldorado Brasil and Estadão/ESPN. In 2011, this partnership
led to more than 100 new bulletins in one minute and in thirty second versions broadcast daily on AM and FM .
84
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
85
The Smoke’s Path – With the aim of alerting the population about the consequences of smoking, in 2011 the A.C.Camargo Hospital took the exhibition
“O Caminho da Fumaça” (The Smoke’s Path) to the São Paulo Underground.
The illustrative panels could be seen in the Sé, Clínicas, Luz and Largo Treze
Stations. Smoking increases the risk of cardiovascular illnesses, chronic obstructive lung illness (pulmonary emphysema), problems with the teeth and
gums, peptic ulcers, systemic arterial hypertension and osteoporosis. And
when we are talking about cancer, smoking is linked to about 30% of malignant tumors, being responsible for 30% of deaths due to the illness.
“O Caminho da Fumaça” The Smoke’s Path Exhibition
Underground stations
Estimated public/day
Period/day
Estimated total/public
82.000
21
1.722.000
132.000
21
2.772.000
Clínicas
33.000
21
693.000
Largo Treze
36.000
21
756.000
Estimated public/day
Period/day
Estimated total/public
30.000
15
450.000
Sé
Luz
“O Caminho da Fumaça” The Smoke’s Path Exhibition Conjunto Nacional 8th to 23rd April
Meeting With Specialists – In 2011 the program Meeting with Specialists
Exhibition
was held, an opportunity for the community to clear up any doubts about
the prevention, diagnosis and treatment of different types of cancer. Periodically, specialists from a clinical area get together with the public for a talk
and answer questions from the audience. During this year, this interaction
took place with doctors from the Mastology, Gynecology, Head and Neck,
Urology and Lung Departments as well as with the Smokers Support Group.
Probabilities Campaign – In 2011 A.C.Camargo Hospital launched a campaign to raise awareness: the video “Probabilidades” (Probabilities). Created
by the agency JWT and directed by Willy Biondani, the film alerts people
to the chances of cure of cancer when the illness is discovered in the initial stage. After showing different situations with very low probability, such
as winning the lottery or becoming President, the film points out that the
28th
June
9th
August
27th
September
29th
November
chances of success when the cancer is treated in its initial stages are greater
Theme
Women’s
Health
Men’s Health
Lung Health
and Support
for Smokers
Mouth and
Throat Health
factors and the lack of information; this is why, in its final message it states
Lung and
Thoracic
Nucleus
& Psychooncology
Head and
Neck Nucleus
Team
Nucleus of
Excellence in
Breast
Nucleus of
Excellence in
Prostate
than 90%. The advertisement draws a parallel between the belief in unlikely
that “with information and correct treatment probability is on your side”.
The soundtrack of the film is by composer Antônio Pinto, an artist who has
composed for films such as Central do Brasil (Central Station) and Cidade
de Deus (City of God) and who was indicated for the Golden Globe Award for
the soundtrack of Love in the Time of Cholera. (GRI SO1)
Nucleus
86
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
87
D o n at i o n s
Nota Fiscal Paulista Campaign
T
he A.C.Camargo Hospital carries out the campaign “Doe Sua Nota
Fiscal Paulista para a Pesquisa do Câncer” (Donate your São Paulo
tax bill to Cancer Research). The Nota Fiscal Paulista is a program
carried out by the state of São Paulo, which gives back to consumers 30% of
the ICMS (Imposto sobre Circulação de Mercadorias e Serviços – Tax on Circulation of Goods and Services).
For the A.C.Camargo, an institution that is constantly in search of a cure
for cancer through scientific development, the participation of society in a
project like this one brings even more and shared responsibility.
88
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
89
I n t e r n a l P u b l i c R e l at i o n s
Ind i cato r s (GRI LA1)
Commitment, dialogue and recognition:
the A.C.Camargo team
The A.C.Camargo Hospital’s strategic planning requires capacitated
talents, motivated by individual challenging targets and a profound sense
of commitment. This is why the institution seeks to value and keep the
professionals that standout in their jobs. In 2011 the A.C.Camargo was
included by the Exame magazine, published by Editora Abril, in the select
group of “the 150 best companies to work for”, repeating the recognition
received in 2007 and 2009.
E
xame Magazine’s recognition with regards to the management of Human Resources at the A.C.Camargo Hospital was based on data obtained through a methodology developed by the Fundação Instituto
de Administração, FIA, linked to the Economics and Administration Faculty
of the USP (São Paulo University).
One of the points that stood out in the evaluation was the A.C.Camargo’s
capacity to integrate a team of collaborators around one common goal. The
pride and commitment of all to the A.C.Camargo Hospital’s mission and social responsibility is a fact that appears even in the organizational surveys
that the institution carries out periodically.
Hirde Contesini
Head of A.C.Camargo
Hospital’s Medical
Archive and Statistical
Service –(SAME)
90
“I will never forget my first day at the A.C.Camargo Hospital, it was on the
1st June 1959. Since that day this is my second house, a school where I have
learnt to live and respect my neighbor. In the sector where I work we are in
contact with summaries of many life stories. Stories about people who were
face to face with cancer in different periods of time and as we read about
their experiences we see in practice how important the work of each one
of us is. My biggest achievement here is to know that I created an excellent
relationship with all those around me. The Hospital is part of our life and all
of us are the life of the A.C.Camargo”.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
This commitment is revealed in the day-to-day details that guide the Hospital’s activities, beginning with the choice and training of its employees, which
is done with extreme care. The A.C.Camargo Hospital, clearly going through
a moment of expansion, registered the employment of more than 1.211 new
employees in 2011, reaching a number of 2.444 collaborators, all of who participated in integration activities over a two-day period. In 2011, the total amount
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
91
The A.C.Camargo
Hospital employed
more than 1211 new
employees totalling
2444 colaborators
of time invested in training staff was 7.383 hours, totaling a training of 66.946
hours/person. Amongst the main events, it is worth mentioning:
»» Institutional integration;
»» Program of Leadership Development;
»» Technical training;
»» Training to spread the Canadian Accreditation;
»» Training to spread Strategic Planning, Performance Indicators and Capacities (pre-evaluation);
»» Training and sectorial meetings.
In 2011, the Hospital created the positions of chambermaid and captain
porter, in order to improve the quality of the services provided to patients
and those accompanying them. To fill the positions of chambermaid, the Human Resources sector invested in the Hospitals existing staff, by promoting
cleaning staff that stood out in their jobs.
The appreciation of individual talents is one of the targets of the Human Resources Department that has been taken to the Hospital’s managers,
through its Program of Leadership Development. Leaders of each department participate in group dynamics and courses where they develop their
abilities of relating to those they lead, starting from the understanding that
leadership has a key role in establishing a good working environment and
career appreciation. In 2011, the Program of Leadership Development began
in September, and will probably end in September 2012 with a predicted total
of 6,192 hours of training. (GRI LA10)
Also with the aim of improving interpersonal relationships and internal
communication, in August 2011, a new Intranet was launched, with excellent
evaluation and great adhesion by staff. And in 2011, the internal magazine
Entre Nós was given a new layout, more dynamic and attractive, and had nine
editions published throughout the year, with a print run between 2.600 and
3.200 copies per edition.
Some benefits are extended to interns and temporary collaborators, such
as the food voucher, group life insurance, partnerships with universities, lan-
Safety, healthcare and well-being (GRI LA8) – The A.C.Camargo Hospital
guage schools, gyms, children’s schools and crèches and the availability of a
offers a series of benefits with their collaborators well-being in mind, both
gynecologist and a nutritionist at the work place. The Occupational Health
inside and outside their working environment. The institution works not only
sector accompanies staff with chronic illnesses, such as hypertension and
in the prevention of occupational accidents and illnesses, but also in the
diabetes, including specific cancer prevention exams in its periodic exams
maintenance of their physical and emotional health. In this manner, hospital
and, in 2011, from October to November, carried out the “Abolindo o Tabaco”
staff have a healthcare plan that includes dental care, life insurance, food
(Abolishing Tabaco) Program.
vouchers, aid in paying for crèches, coffee service, Tai Chi Chuan classes, as
well as a gynecologist and nutritionist at the work place.
92
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
In 2011, the staff at the A.C.Camargo were also given new benefits. The
Medical Assistance Plan (through the health insurance) and Life Insurance
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
93
began to be offered with no additional cost to staff. And a Private Pension
had a total of 176 cases, amongst 2,352 employees, which represents a us-
Program is amongst the targets for 2012.
age rate of 7.48%.
The collaborators also participate in the PAE Program, Programa de Apoio
The employee or dependent is received by a social assistant who then di-
ao Empregado (Employee Support Program), which includes psychological,
rects him to the service he needs. The psychological assistance works with
social and judicial assistance for all employees and their dependents through
a brief psychotherapy method (12 to 18 sessions) and takes place out of the
a 0800 telephone number. Between January and December 2011, the PAE
work place, so as to guarantee treatment confidentiality.
There is also the Study Scholarship Program, which consists of the reimbursement of up to 80% on the employee’s first graduation, in a course aligned
with the institution’s area of work. In order to benefit from this scholarship,
the collaborator must obtain a minimum level in the three evaluations of
The Employee
Support Program
consists of the
availability of
psychological,
social and judicial
services, for all
employees and
their dependents
through a 0800
telephone number
his performance.
Canadian Accreditation – The institution was successful in obtaining this
important international certification due to teamwork. Eight work groups,
organized according to subjects – Communication and Information, Environment, Human Resources, Internment, Outpatient Attendance, Critical Care,
Surgical Care and Leadership –, worked directly on projects related to the Canadian Accreditation requirements. Each team had as an objective to plan and
implement innovation and improvement projects focusing on patient’s safety.
sponsorship program
(gri la8)
(Number of people who benefited)
107
88
59
53
2008
2009
2010
2011
The target for 2012 is the expansion of the Sponsorship Program for second graduation courses and also Post-Graduation.
This proposal for the training and appreciation of the staff at A.C.Camargo
is also applicable to those with special needs. The institution’s relationship
94
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
95
with those with special needs is not assistential, but seeks human and pro-
demographic profile
fessional development. In 2011, the A.C.Camargo established a partnership
January/December 2011
(gri la2)
with the AVAPE (Associação para Valorização de Pessoas com Deficiência –
Association for the Valorization of People with disabilities) and ended 2011
Working staff indicators
Year
with 125 employees with special needs, of which approximately 120 were
trained via this partnership.
increase in the number of collaborators
2010 × 2011 (employees hired)
2010
2011
Total number of employees at the end of the period
2007
2444
Number of employees hired throughout the period
664
1072
% of employees aged over 45
8%
8%
5
5
Number of women working at the institution
1357
1642
% of leadership positions occupied by women
19%
19%
Average age of women in leadership positions
40
40
2.232,43
2.298,46
38
36
2.137,19
2.122,18
Number of colored people working at the institution
72
139
% of leadership positions occupied by colored people
4%
3%
Average age of colored people in leadership positions
38
35
2.181,19
1.836,38
1410
1858
2.287,22
2.376,81
Number of interns
46
46
Number of young apprentices
25
45
Number of people with special needs
39
125
2.425,65
1.506,83
Average amount of time working at the institution
Year
Number
2010
2.007
2011
2.444
Increase in staff
437
Average women’s salary
Average age of men in leadership positions
Average men’s salary
admitted in the period
Number in 2011
People with Special Needs
125
Average salary of colored people
Interns
51
Number of white people working at the institution
Young Apprentice
63
Average salary of white people
total number of collaborators – 2011
Average amount of time working at the institution
Average amount of time
Average salary of people with special needs
Number
0 to 1 year
321
1 to 2 years
619
Distribution per type
of job position
3 to 4 years
609
Type of Position
5 to 6 years
275
Administrative
7 to 8 years
141
Head
9 to 10 years
95
11 to 12 years
101
13 to 14 years
43
More than 14 years
240
Female
Male
Female
306
402
366
479
4
24
3
25
Operational
307
882
394
1077
Coordinator
11
26
12
24
9
7
9
13
10
14
15
21
3
2
3
3
650
1357
802
1642
Manager
Leader
General total
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
2011
Male
Director
96
2010
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
97
E n v i r o n m e n ta l P e r f o r m a n c e
(GRI EN26)
On the path of environmental sustainability
With investments in staff training and looking for environmentally
sustainable solutions, the A.C.Camargo has ISO 14001 as a target
T
he A.C.Camargo Hospital, which has been providing healthcare services to the country for almost 60 years, always following principles
of social responsibility and humanization, recognizes the impor-
tance of being in line with international guidelines of environmental sustainability. Evolution and excellence, words that have been part of the day-to-day
activities of the A.C.Camargo throughout treatment, teaching and research
have also governed its environmental initiatives.
However, the implementation and maintenance of any project, above all
one founded in sustainable guidelines, is only possible with the involvement
of all collaborators. This is why the Environmental Sustainability Commit-
Average salary per
type of job position
Type of Position
tee was created. The aim is for the A.C.Camargo Hospital to align itself with
2011
the necessary norms so that in 2012 it can obtain environmental certification ISO 14001.
Male
Female
Male
Female
Administrative
1.465,48
1.625,40
1.566,28
1.675,21
Head
6.159,21
5.880,32
4.038,88
6.224,80
Waste management – Since 2005, waste produced by the hospital is treated
Operational
2.125,97
2.215,17
2.016,67
2.229,29
according to the Plano de Gerenciamento de Resíduos de Serviços de Saúde,
Coordinator
5.693,63
5.441,27
5.916,62
5.965,65
11.258,11
9.293,37
13.986,11
11.036,31
1.642,63
1.686,32
1.839,07
1.977,00
27.681,76
25.478,61
32.493,26
28.973,16
All employees who work with hygiene receive two days of training fo-
2.137,19
2.232,43
2.122,18
2.298,46
cused on the area’s duties, amongst them the handling of healthcare ser-
Manager
Leader
Director
General total
98
2010
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
PRGSS (Health Services Waste Management Plan), in line with resolutions
358/05 of the Conselho Nacional do Meio Ambiente (CONAMA) and 306/04 of
the Agência Nacional de Vigilância Sanitária (ANVISA), that establish measures to protect the environment and healthcare professionals.
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
99
It is estimated
that today, 70% of
what is bought in
terms of materials
and medications
are bought from
producers with
environmental
certification.
vices waste and waste recycling. Apart from this, every new employee at the
paulo (the electricity company) for the donation of a refrigerated water sys-
hospital, irrespective of his area, receives institutional training about this
tem to reduce the air-conditioning equipment’s consumption of electricity.
The various refurbishments and improvements carried out in 2011 also
activity. (GRI LA10)
Different types of residue are collected, at the institution’s headquarters,
reflect the institution’s concern with the environment. The pavement’s im-
by companies credited by the Municipality and contracted by Limpurb, body
permeable concrete floor was replaced for flooring that allows for draining,
responsible for the adequate removal of residues, according to the Certificate
and in this manner helps in the drainage of rainwater, preventing flooding.
given to the Hospital.
The new Tamandaré building was built using sustainable materials, such as
The implementation, at the end of 2009, of a new compacting system,
vinyl flooring made of recycled material and water based paints, without the
improved the process of throwing away common residues in 2011, reducing
use of solvents and was also given a rainwater tank for irrigating the garden.
the noise made during the collection process and avoiding disturbance to
The surgical center and the ICU of this building were given insulated glass,
neighboring inhabitants. In the previous method, common waste was placed
which, apart from guaranteeing more acoustic and thermic comfort, due to
in 100 litre plastic bags which were then taken to a pressing-truck, that car-
their nature, reduce the need for acclimatization.
ried out daily collections. With the acquisition of a compacting machine,
collecting began to be carried out only three times a week.
New alterations are awaiting legal authorization to be carried out. In 2011,
the A.C.Camargo Hospital protocolled, with the local government a request
The disposal of radioactive waste deserves special attention. The
to carry out a retrofit of the facades, with the aim of unifying Blocks A and
A.C.Camargo Hospital maintains an Institutional Committee for Radiologi-
B, which would allow for the standardization of the hospital facade and con-
cal Protection that has the participation of all departments involved in the
sequentially the strengthening of the Hospital’s name. On the new facade,
use of ionizing radiation.
reflective glass and brises which reduce the effects of sun rays will be used,
All radioactive waste is collected in specific containers and stored in
resulting in an economy in electricity and air-conditioning.
shielded rooms, where they wait until radioactivity has been reduced to
The goal, for the near future, is the installation of panels for capturing
levels that are compatible with the environment. After being liberated from
solar energy and the acquisition of new, more modern and economic diesel
the Radiological Protection sector, this material is removed from storage and
generators, all containing catalyzers and acoustic treatment, to be installed
deposited at an appropriate location. From this moment on, it is treated as
in a new station under the Hilda Jacob Building, in order to unify the gen-
healthcare service waste.
eration of electricity.
Green companies – The A.C.Camargo Hospital’s preference for the so-called
“green companies” is a natural result of its own mission and values. Green
companies also look to bring together the latest technology, high productivity and growth with the values of sustainability and human development
that the A.C.Camargo professes.
It is estimated that today, 70% of what is bought in terms of materials and
medications are bought from producers with environmental certification. For
example, all the wood used in the construction of the Tamandaré building and
the production of furniture was acquired from companies with certificates
of origin. And the Hospital also chose to change all the standard blankets for
Ecosoft Pet Thermo Pro blankets, made from recycled polyester fibers (PET).
Reduction in consumption – The A.C.Camargo Hospital seeks initiatives to
reduce the consumption of water and electricity, prioritizing the use of taps
with sensors, close coupled toilets and fluorescent lamps. In 2011, new measures were taken to reduce consumption. A contract was signed with Eletro-
100
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
101
TAR G ETS
(GRI 1.2)
The horizon at the reach of your hand
Sustainability, quality, philanthropy, teaching and research, human talents:
the guidelines that direct the Hospital’s strategic planning
A
ll the A.C.Camargo Hospital’s actions are directed by strategic guidelines established in the light of five fundamental concepts: sustainability, quality, philanthropy, excellence in teaching and research
and human talents. These concepts form the basis that sustains the Hospital’s strategic planning, whose objective is to be recognized as a world center of excellence for oncology treatment, teaching and research, prioritizing
quality, self-sustainability and human development.
Carried out with balance and good judgment, the A.C.Camargo’s strategic planning takes into consideration factors such as the incidence of new
cancer cases and their prevalence in the world, in Brazil and in the city of
São Paulo; the evaluation of new technologies and medical practices and
the definition of the necessary resources to attend the demands. Through a
participative process, validated by the Administrative Council, all decision
are taken in such a way as to guarantee the institution’s national relevance
and reach international markets with total financial sustainability.
In the quest of its objectives, the A.C.Camargo is also in a constant process of self-evaluation, conscious that in order to reach ones objectives it is
necessary to keep one’s eyes fixed on the path, step by step.
102
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
103
Institutional strategy
The A.C.Camargo uses the BSC (Balanced Scorecard) methodology to build
and accompany its strategic planning.
Below is a BSC table showing the Institution’s strategic guidelines to be
Scientific
Production 2011
present throughout the following years.
strategic objectives
(BSC table representation)
To be recognized as a world center of excellence in oncology treatment, teaching and research
prioritizing quality, self-sustainability and human development.
guarantee
financial
sustainability
finance
OE 10
Guarantee
market
leadership
Guarantee client
satisfaction
Be sociallyenvironmentally
responsible
Internationalize
the brand
OE 6
OE 7
OE 8
OE 9
Guarantee the
excellence and the
operational control
of internal and
contracted processes
Guarantee
excellence in
care processes
OE 4
OE 5
clients
processes
People development,
qualification and
motivation
Excellence in
information and
communication
management
Qualified and
self-sustaining
teaching and
research
OE 1
OE 2
OE 3
teaching
and learning
Strategic Guidelines
104
sustainability
quality
philanthropy
teaching and research
human talents
Performance Indicators
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
105
PUBLI CATIONS 2 0 1 1
Doctorate
publications in medline indexed
magazines
1. Bretas MC. Análise comparativa da qualidade de vida
Total
Impact
Factor
With a JCR
impact factor
183
578,358
3,463 (average)
Without an
impact factor
28
Total
e estratégias de enfrentamento de pacientes com disfonia decorrente ou não do câncer de laringe. [Comparative
analysis of quality of life and coping strategies in cancer and
behavioral dysphonia]. São Paulo; 2011. 102 pages. Thesis
(Doctorate)-Antônio Prudente Foundation. Tutor: Dr. Elisabete Carrara de Angelis
2. Silva FCC. Frequência de mutações nos genes MSH6,
211
PMS1, PMS2, TP53 e CHEK2 em pacientes suspeitos de Síndrome de Lynch. [Frequency of mutations in MSH6, PMS1,
PMS2, TP53 and CHEK2 in patients with hereditary nonpoly-
thesis and dissertations
»» 10 »» 45 »» 91 Doctorate Thesis
Masters Dissertations
monographies (Lato sensu)
posis colorectal cancer (HNPCC)]. São Paulo; 2011. 105 pages.
Thesis (Doctorate)- Antônio Prudente Foundation. Tutor: Dr.
Fábio de Oliveira Ferreira; Co-Tutor: Dr. Dirce Maria Carraro;
Co-Tutor: Prof. Dr. Benedito Mauro Rossi
3. Machado CF. Estudo funcional de mutantes da proteína
prion celular associados às doenças por prion. [Functional
study of mutant cellular prion protein associated with prion
international activities
»» 15 summaries published in indexed magazines
»» 233 presentations in scientific events
national activities
»» 18 summaries published in indexed magazines
»» 1 book
»» 36 chapters in books
»» 237 presentations in scientific events
»» 4 prizes
106
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
diseases]. São Paulo; 2011. 139 pages. Thesis (Doctorate)-Antônio Prudente Foundation. Tutor: Dr. Vilma Regina Martins
4. Shimoda S. Correlação de déficit cognitivo com Qualidade de Vida nos sobreviventes da leucemia linfóide aguda. [Correlation of cognitive impairment to quality of life in
survivors of acute lymphoblastic leukemia]. São Paulo; 2011.
132 pages Thesis (Doctorate)-Antônio Prudente Foundation.
Tutor: Prof. Dr. Beatriz de Camargo
5. Kagohara LT. Avaliação do perfil de hipermetilação dos
genes P16INK4a e MGMT em câncer de pênis. [Hypermethylation profile evaluation of the genes P16INK4a e
MGMT in penile cancer]. São Paulo; 2011. 111 pages. Thesis
(Doctorate)--Antônio Prudente Foundation. Tutor: Prof. Dr.
Fernando Augusto Soares
107
6. Costa-Silva B. Relevância funcional das proteínas príon
adaptation and validation of an instrument to measure cli-
cultural adaptation of the instrument Impact of Cancer
lo; 2011. 44 pages Dissertation (Masters)- Antônio Prudente
celular e STI1/HOP em tumores de cólon, pâncreas e me-
nic satisfaction among survivors of childhood cancer]. São
in survivors of colorectal cancer: an instrument for asses-
Foundation. Tutor: Dr. João Victor Salvajoli; Co–Tutor: João
lanomas. [Functional relevance of cellular prion protein and
Paulo; 2011. 150 pages Dissertation (Masters)- Antônio Pru-
sing quality of life]. São Paulo; 2011. 88 pages Dissertation
Fernando Gagliardi
STI1/HOP in colorectal and pancreatic tumors and melano-
dente Foundation. Tutor: Nurse Andréa Yamaguchi Kurashi-
(Masters)-Antônio Prudente Foundation. Tutor: Nurse Erika
16. Staniscia ACM. Coping do paciente com câncer de cabe-
mas]. São Paulo; 2011. 104 pages Thesis (Doctorate)- Antônio
ma; Co-Tutor: Dr. Beatriz de Camargo
Maria Monteiro Santos
ça e pescoço e sua relação com o hábito de beber ou fumar.
Prudente Foundation. Tutor: Dr. Vilma Regina Martins
3. Siqueira LDA. Análise eletromiográfica dos músculos
10. da Costa WH. Estudo do valor prognóstico e da ex-
[Coping of the Head and Neck Cancer Patient, and its rela-
7. Queiroz NGT. Estudo funcional da expressão de STI1/
masseter, infra-hióideos e submandibulares durante a
pressão imuno-histoquímica das células-tronco tumorais,
tion to drinking or smoking habits]. São Paulo; 2011. 66 pages
HOP e proteínas da cascata de SUMOilação em gliomas:
deglutição de indivíduos adultos saudáveis. [Electromyo-
através do CD133 e CD44 em carcinoma de células renais.
Dissertation (Masters)-Antônio Prudente Foundation. Tutor:
correlação com proliferação celular e características clínico-
graphy analysis of masseter, infrahioyds and submentual
[Evaluation of prognostic value and immunohistochemical
Dr. Célia Lídia da Costa; Co-Tutor: Dr. Luiz Fernando Lopes
-patológicas. [Functional study of STI1/HOP and SUMOyla-
muscles during healthy adult swallowing subjects]. São Pau-
expression of cancer stem cells with CD133 and CD44 in re-
17. Zeni LL. Tradução, adaptação cultural e validação do
tion cascade proteins expression in gliomas: correlation to
lo; 2011. 98 pages Dissertation (Masters)- Antônio Prudente
nal cell carcinoma]. São Paulo; 2011. 124 pages Dissertation
termômetro de angústia (Distress Thermometer). [Trans-
cell proliferation and clinico-pathological characteristics].
Foundation. Tutor: Dr. Elisabete Carrara de Angelis; Co-Tu-
(Masters)--Antônio Prudente Foundation. Tutor: Dr. Stênio
lation, cultural adaptation and validation of the Distress
São Paulo; 2011. 72 pages Thesis (Doctorate)-Antônio Pruden-
tor: Dr. José Guilherme Vartanian
de Cássio Zequi; Co-Tutor: Dr. Rafael Malagoli Rocha
Thermometer]. São Paulo; 2011. 48 pages Dissertation
te Foundation. Tutor: Dr. Vilma Regina Martins; Co-Tutors: Dr.
4. Lima LPAGES Análise eletromiográfica e funcional do
11. Faloppa CC. Análise Imunoistoquímica da expressão
(Masters)-Antônio Prudente Foundation. Tutor: Dr. Célia Lí-
Marilene Hohmuth Lopes, Prof. Dr. Fernando Augusto Soares
ombro em pacientes submetidos à cirurgia de esvazia-
do NF-KB e da COX-2 em alterações proliferativas endo-
diada Costa; Co-Tutor: Dr. Aldo L. Abbade Dettino
8. Souza MJL. Avaliação da transição epitélio-mesênqui-
mento cervical e tratamento fisioterapêutico. [Electromyo-
metriais. [Immunohistochemical analysis of NF-KB and the
18. Ramos MFT. Avaliação da reconstrução mandibular
ma no carcinoma de pênis. [Avaliation of epithelial me-
graphic analysis of shoulder function in patients undergoing
COX-2 expressions in endometrial proliferative lesions]. São
com retalho ósseo microcirúrgico: experiência do Hospi-
senchymal transition in penile carcinoma]. São Paulo; 2011.
surgery for neck dissection and physiotherapy]. São Pau-
Paulo; 2011. 107 pages Dissertation (Masters)- Antônio Pru-
tal A.C.Camargo. [Evaluation of mandibular reconstruc-
99 pages Thesis (Doctorate)- Antônio Prudente Foundation.
lo; 2011. 71 pages Dissertation (Masters)- Antônio Prudente
dente Foundation.
tion with microcirurgical bone free flap: experience from
Tutor: Prof. Dr. Fernando Augusto Soares; Co-Tutor: Prof. Dr.
Foundation. Tutor: Dr. José Guilherme Vartanian; Co-Tutor:
12. Kumagai LY. Avaliação de podoplanina/D2-40 e COX-2
A.C.Ca­margo Hospital]. São Paulo; 2011. 52 pages Disserta-
Ademar Lopes
Denise Carnieli Cazati
como marcadores de linfangiogênese em câncer de colo do
tion (Masters)-Antônio Prudente Foundation. Tutor: Prof. Dr.
9. Ayala FRR. Impacto prognóstico de aberrações cromos-
5. Freitas-Rodrigues AF. Estudo da resposta imune peritu-
útero. [Podoplanin/D2-40 and COX-2 expression as markers
Fábio de Abreu Alves
sômicas em tumores de Ewing/PNET. [Prognostic impact of
moral em carcinomas de pênis. [Study of peritumoral im-
of lymphangiogenesis in cancer of the uterine cervix]. São
19. Nakamoto LH. Tradução e validação do inventário de
chromosomal aberration in Ewing/PNET tumors]. São Paulo;
mune response in penile carcinoma]. São Paulo; 2011. 72
Paulo; 2011. 83 pages Dissertation (Masters)- Antônio Pru-
crescimento pós-traumático em população de sobreviven-
2011. 128 pages Thesis (Doctorate)-Antônio Prudente Foun-
pages Dissertation (Masters)-Antônio Prudente Foundation.
dente Foundation. Tutor: Dr. José Humberto Tavares Guerrei-
tes de câncer infantil. [Translation and validation of the In-
dation.Tutor: Prof. Dr. Fernando Augusto Soares; Co-Tutor:
Tutor: Dr. José Vassallo
ro Fregnani; Co-Tutor: Dr. Isabela Werneck da Cunha
ventory of posttraumatic growth in population of childhood
Dr. Isabela Werneck da Cunha
6. Castro CV. Estudo de receptores de tirosina quinase em
13. Ribeiro HSC. Resultados do tratamento cirúrgico e fa-
cancer survivors]. São Paulo; 2011. 120 pages Dissertation
10. Baiocchi Neto G. Perfil da expressão imunoistoquími-
cordomas. [Study of receptors tyrosine kinase in chordo-
tores prognósticos de sobrevida, morbidade e mortalidade
(Masters)-Antônio Prudente Foundation. Tutor: Dr. Célia Lí-
ca de HER-2, NF-kB e IKKa em câncer de colo uterio trata-
mas]. São Paulo; 2011. 85 pages Dissertation (Masters)-An-
em pacientes com metástases hepáticas de câncer colorre-
dia da Costa; Co-Tutor: Dr. Luiz Fernando Lopes
do com radioterapia [Immunohistochemical expression of
tônio Prudente Foundation. Tutor: Dr. Maria Dirlei Ferreira
tal. [Results of the surgical treatment and prognostic factors
20. Chiappini PBO. Estudo da expressão de mTOR, PTEN e
HER-2, NF-B and IKK in patients with cervical cancer trea-
de Souza Begnami
of survival, morbidity and mortality in patients with colo-
AKT na mucosa gástrica normal e carcinomas gástricos.
ted with radiation therapy]. São Paulo; 2011. 89 pages The-
7. Nicolau UR. Avaliação de preditores de eficácia de qui-
rectal liver metastasis]. São Paulo; 2011. 103 pages Disser-
[Study of the expression of mTOR, PTEN and AKT normal
sis (Doctorate)- São Paulo University. Tutor: Prof. Dr. Ade-
mioterapia associada à radioterapia em carcinoma epider-
tation (Masters)-Antônio Prudente Foundation. Tutor: Prof.
mucosa and gastric carcinomas]. São Paulo; 2011. 86 pages
mar Lopes
móide de orofaringe. [Analysis of predictors of chemora-
Dr. Paulo Herman; Co-Tutor: Dr Renata de Almeida Coudry
Dissertation (Masters)-Antônio Prudente Foundation. Tutor:
diation therapy eficacy on the treatment of locally advance
14. Silva MJB. Avaliação da expressão das proteínas CD74,
Dr Maria Dirlei Ferreira de Souza Begnami
oropharyngeal carcinoma]. São Paulo; 2011. 46 pages Disser-
TGFB1 e TGFB2 em tumores de pulmão de células não-
21. Rios Villacis RA. Identificação de marcadores molecu-
tation (Masters)-Antônio Prudente Foundation. Tutor: Prof.
-pequenas operados e correlação com evolução clínica.
lares úteis ao diagnóstico e prognóstico em leiomiossar-
Dr. Luiz Paulo Kowalski
[CD74, TGFB1 and TGFB2 protein expression analysis in re-
comas e sarcomas pleomór9cos. [Identification of potential
8. Moura-Martins LA. Definição dos dinucleotídeos CpG
sected non-small cell lung cancer and its correlation with
molecular markers for diagnosis and prognosis in leiomyo-
1. Braz KCC. Avaliação do impacto da quimioterapia no
metilados no promoter do gene PLCG2 e de sua influência
clinical outcomes]. São Paulo; 2011. 94 pages Dissertation
sarcomas and undifferentiated pleomorphic sarcoma]. São
consumo alimentar de mulheres com câncer de mama.
na repressão transcricional em tumores de Wilms. [Defi-
(Masters)-Antônio Prudente Foundation. Tutor: Dr. Jefferson
Paulo; 2011. 110 pages Dissertation (Masters)-Antônio Pru-
[Analyzing the impact of chemotherapy on food intake of
nition of methylated CpG sites in PLCG2 gene promoter and
Luiz Gross; Co-Tutor: Dr. Vladmir Cláudio Cordeiro de Lima
dente Foundation. Tutor: Prof. Dr. Silvia Regina Rogatto
women with breast cancer]. São Paulo; 2011. 65 pages Dis-
its influence on transcriptional silencing in Wilms tumors].
15. Pires DC. Avaliação da qualidade de vida e mudanças
sertation (Masters)-Antônio Prudente Foundation. Tutor: Dr
22. Souza MH. Trismo após maxilectomia em tratamento
São Paulo; 2011. 130 pages Dissertation (Masters)- Antônio
na composição corporal em pacientes com câncer locali-
Ludmilla Thomé Domingues Chinen
de câncer de cabeça e pescoço: um estudo retrospectivo.
Prudente Foundation. Tutor: Dr. Dirce Maria Carraro
zado da próstata em radioterapia associada à hormonio-
[Trismus after maxilectomy in the treatment of head and
2. Paterlini ACR. Adaptação transcultural e validação de
9. Mendes TL. Adaptação transcultural do instrumento
terapia. [Assessment of quality of life and changes in body
neck cancer: a retrospective studychemotherapy]. São Pau-
instrumento para mensuração de satisfação clínica de
impacto do câncer em sobreviventes de câncer colorretal:
composition of localized prostate cancer patients submitted
lo; 2011. 33 pages Dissertation (Masters)-Antônio Prudente
pacientes sobreviventes de câncer infantil. [Transcultural
instrumento para avaliação da qualidade de vida. [Cross-
to radiotherapy combined with hormonal therapy]. São Pau-
Foundation. Tutor: Dr. Dov Charles Goldenberg
Masters
108
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
109
23. Guerra RC. Análise retrospectiva dos aspectos epide-
29. Moyano Muñoz JJA. Análise de micro-RNAs reguladores
Paulo: validation of revised illness perception questionnaire
voice and swallowing in the short term in patients under-
miológicos e dos fatores de risco associados ao trismo após
de membros da família de transportadores SLC e de seus
for healthy people]. São Paulo; 2011. 115 pages Dissertation
going 131I (Iodine) for differentiated thyroid carcinoma]. São
mandibulectomias diferenciado de tireóide. [Retrospective
genes alvo em carcinomas de pênis. [Analysis of microR-
(Masters)-Antônio Prudente Foundation. Tutor: Dr. Erika Ma-
Paulo; 2011. 59 pages Dissertation (Masters)- Antônio Pru-
analysis of epidemiological aspects and risks factors associa-
NAs that regulate members of the SLC transporter fami-
ria Monteiro dos Santos; Co-Tutors: Dr. Dirce Maria Carraro
dente Foundation. Tutor: Dr. Eduardo Nobrega Pereira Lima;
ted with the development of trismus after mandibulectomy].
ly and their target genes in penile carcinomas]. São Paulo;
and Dra Simone Pallone de Figueiredo
Co-Tutor: Dr. Elisabete Carrara de Angelis
São Paulo, 2011. 62 pages Dissertation (Masters)-Antônio Pru-
2011. 153 pages Dissertation (Masters)- Antônio Prudente
36. Silva Netto AG. Valor prognóstico do tipo histológico de
42. Lima AJA. Fatores preditivos de complicações pós-ope-
dente Foundation. Tutor: Dr. Dov Charles Goldenberg
Foundation. Tutor: Prof. Dr. Silvia Regina Rogatto; Co-Tutor:
carcinoma de células grandes em pacientes com câncer de
ratórias em pacientes submetidos à cirurgia citorredutora
24. Nascente CM. A angiogênese elinfan9ogênese nos sar-
Dr. Sandra A. Drigo Linde
pulmão. [Prognostic value of the histologic type large cell
associada à quimioterapia intraperitoneal hipertérmica.
comas sinoviais e sua correlação clínico-patológica. [The
30. Hidalgo APAGES Comparação dos custos para diagnós-
carcinoma in patients with lung cancer]. São Paulo; 2011. 39
[Predictive factors for postoperative complications in pa-
angiogenesis and lymphangiogenesis in Synovial Sarcomas
tico e seguimento de famílias com diagnóstico clínico e/ou
pages Dissertation (Masters)- Antônio Prudente Foundation.
tients undergoing cytoreductive surgery associated with in-
and its clinic-pathological correlation]. São Paulo; 2011. 130
molecular para Síndrome de Lynch. [Comparison of costs
Tutor: Dr. Jefferson Luiz Gross
traperitoneal hyperthermic chemotherapy]. São Paulo; 2011.
pages Dissertation (Masters)-Antônio Prudente Foundation.
for diagnosis and follow-up of families with clinical and /
37. Camalionte L. Obstinação terapêutica: instituição e
125 pages Dissertation (Masters)- Antônio Prudente Foun-
Tutor: Prof. Dr. Fernando Augusto Soares; Co-Tutor: Dr Isa-
or molecular Lynch Syndrome]. São Paulo; 2011. 60 pages
manutenção de suporte em situações de 9m de vida em
dation. Tutor: Dr. Fabio de Oliveira Ferreira; Co-Tutor: Dr.
bela Werneck da Cunha
Dissertation (Masters)-Antônio Prudente Foundation. Tutor:
uma unidade de terapia intensiva de um hospital onco-
Samuel Aguair Júnior
25. Pompeu BF. Fatores prognósticos em pacientes por-
Prof. Dr. Ricardo Renzo Brentani; Co-Tutor: Prof. Dr. Alexan-
lógico terciário. [Medical futility: the institution and main-
43. Andrade WPAGES Análise dos fatores preditivos de
tadores de carcinoma bem diferenciado de tireóide com
dra Brentani
tenance of advanced life support in end-of-life situations
resposta clínica e patológica em pacientes com câncer de
recidiva loco-regional. [Prognostic factors in patients with
31. Stamboni HB. Agrupamento de sintomas e qualida-
in an intensive care unit of a tertiary cancer hospital]. São
mama localmente avançado submetidos a tratamentos
well-differentiated thyroid carcinoma with locoregional re-
de de vida em pacientes com câncer colorretal. [Symptom
Paulo; 2011. 52 pages [Masters Dissertation-Antônio Pruden-
com quimioterapia neoadjuvante: correlação entre PET/
currence]. São Paulo; 2011. 55 pages Dissertation (Masters)-
cluster and quality of life in colorectal cancer patients]. São
te Foundation]. Tutor: Dr. Pedro Caruso; Co-Tutor: Dr. Vasco
CT, classificação molecular e marcadores de ciclo celular.
-Antônio Prudente Foundation. Tutor: Prof. Dr. Luiz Paulo
Paulo; 2011. 86 pages Dissertation (Masters)- Antônio Pru-
Moscovici da Cruz
[Analysis of predictive factors of clinical and pathological
Kowalski; Co-Tutor: José Magrim
dente Foundation. Tutor: Dr Erika Maria Monteiro Santos
38. Ferderle D. Avaliação da qualidade de vida dos pacien-
response in patients with locally advanced breast cancer
26. Santiago KM. Caracterização de mutaçôes germinati-
32. Ianez RCF. Avaliação da presença de marcadores de
tes submetidos à iodoterapia por câncer de tireóide no
submitted to treatment with neoadjuvant chemotherapy:
vas presentes nos genes XPA e XPC em pacientes brasilei-
células-tronco no adenoma pleomórfico: estudo de mar-
Hospital A.C.Camargo. [Assessment of quality of life of pa-
correlation among PET/CT, molecular classification and
ros clinicamente diagnosticados com Xeroderma Pigmen-
cadores imunoistoquímicos e moleculares. [Investigation
tients undergoing radioiodine therapy for thyroid cancer in
cell cycle markers]. São Paulo; 2011. 110 pages Disserta-
toso. [Characterization of germline mutations in XPA and
of stem-cell markers in pleomorphic adenoma: immuno-
the Hospital A.C.Camargo]. São Paulo; 2011. 53 pages Dis-
tion (Masters)- Antônio Prudente Foundation. Tutor: Prof.
XPC genes in Brazilian patients clinically diagnosed with
histochemical and molecular study]. São Paulo; 2011. 95
sertation (Masters)- Antônio Prudente Foundation. Tutor: Dr.
Dr. Fernando Augusto Soares; Co-Tutor: Dr. Eduardo Nó-
Xeroderma Pigmentosum]. São Paulo; 2011. 162 pages Dis-
pages Dissertation (Masters)- Antônio Prudente Founda-
Eduardo Nóbrega Pereira Lima
brega Pereira Lima
sertation (Masters) -Antônio Prudente Foundation. Tutor: Dr.
tion. Tutor: Dr. Silvia Vanessa Lourenço; Co-Tutor: Dr. Mar-
39. Cuck G. Avaliação do comprometimento linfonodal
44. Rocha AML. Alterações em genes supressores de tu-
Maria Isabel Alves de Souza Waddington Achatz; Co-Tutor:
cilei E. C. Buim
através de análise imuno-histoquímica e sua importân-
mor em carcinoma de vulva: correlação com fatores prog-
Prof. Dr. Silvia Regina Rogatto
33. De Melo MDL. Investigação do valor prognóstico do pai-
cia como fator prognóstico em pacientes com câncer in-
nósticos anátomo-patológicos, dados clínicos, infecção por
27. Nogueira STS. Avaliação da detecção precoce das ne-
nel imunoistoquímico e dos marcadores (CEA, Vimentina,
vasivo de bexiga. [Evaluation of lymph node involvement
HPV e expressão de proteínas. [Tumor suppressor genes
oplasias em pacientes portadores da síndrome de Li-
RE e P16) utilizados no diagnóstico diferencial dos ade-
by immunohistochemical analysis and its importance as a
alterations in vulvar carcinoma: correlation with pathologi-
-Fraumeni e Li-Fraumeni like com o uso de PET-CT com
nocarcinomas do colo uterino. [Analysis of the prognostic
prognostic factor in patients with invasive bladder cancer].
cal and clinical data, HPV infection and protein expression].
18F-FDG. [Analysis of 18F-FDG PET-CT in early detection
value of immunohistochemical panel and markers (CEA, Vi-
São Paulo; 2011. 76 pages Dissertation (Masters)- Antônio
São Paulo; 2011. 134 pages Dissertation (Masters)- Antônio
of cancers in patients with Li-Fraumeni and Li-Fraumeni
mentin, ER and P16) currently used to differential diagnosis
Prudente Foundation. Tutor: Dr. Francisco Paulo da Fonseca
Prudente Foundation. Tutor: Dr. Rafael Malagoli Rocha; Co-
like syndromes]. São Paulo; 2011. 69 pages Dissertation
of adenocarcinomas of the cervix]. São Paulo; 2011. 68 pages
40. Moniz RM. Expressão imunoistoquímica e valor prog-
(Masters)-Antônio Prudente Foundation. Tutor: Dr. Maria
Dissertation (Masters)-Antônio Prudente Foundation. Tutor:
nóstico dos marcadores de células-tronco tumorais NA-
45. Maia BM. Alterações em oncogenes em carcinoma de
Isabel Alves de Souza Waddington Achatz; Co-Tutor: Dr.
Dr. João Victor Salvajoli
NOG, DPPA4 e CCND2 em tumores testiculares não se-
vulva: correlação com fatores prognósticos anatomo-pa-
Eduardo Nóbrega Pereira Lima
34. Bassi DU. Estudo sobre a realização de exames para a
minomatosos. [Immunohistochemical expression and
tológicos, dados clínicos e infecção por HPV. [Oncogenes
28. Cannavan MC. Diagnóstico molecular de mutações ger-
detecção precoce do câncer colorretal. [Study of early detec-
prognostic value of tumoral stem cells markers NANOG,
alterations in vulvar carcinoma: correlation with prognostic
minativas no gene TP53 em pacientes com múltiplos tu-
tion tests realization in colorectal cancer]. São Paulo; 2011.
DPPA4 and CCND2 in nonseminomatous testicular tumors].
factors, clinical data and HPV infection]. São Paulo; 2011. 185
mores primários ou com tumores isolados típicos da sín-
57 pages Dissertation (Masters)-Antônio Prudente Founda-
São Paulo; 2011. 112 pages Dissertation (Masters)- Antônio
pages Dissertation (Masters)-Antônio Prudente Foundation.
drome de Li-Fraumeni. [Molecular diagnosis of germline
tion. Tutor: Dr. Erika Maria Monteiro Santos; Co-Tutor:Dr.
Prudente Foundation. Tutor: Dr. Stênio de Cássio Zequi; Co-
Tutor: Dr. Rafael Malagoli Rocha; Co-Tutor: Dr. Emmanuel
mutations in TP53 gene in patients with multiple primary
Andréa Yamaguchi Kuraschima
-Tutor: Dr. Isabela Werneck da Cunha
Dias-Neto
tumors or with isolated tumors typical from the Li-Fraume-
35. Pinho CG. Percepção pública sobre o câncer entre a po-
41. Nascimento Junior JR. Perfil vocal e qualidade de vida
ni syndrome]. São Paulo; 2011. 123 pages Dissertation (Mas-
pulação do município de São Paulo: validação do questio-
relacionada à voz e à deglutição no curto prazo, em pa-
ters)- Antônio Prudente Foundation. Tutor: Dr. Maria Isabel
nário de percepção de doença entre indivíduos saudáveis.
cientes submetidos a iodoterapia por carcinoma diferen-
Alves Waddington Achatz; Co-Tutor: Dr. Dirce Maria Carraro
[Public perception about cancer between population of São
ciado de tireóide. [Vocal profile and life quality related to
110
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
-Tutor: Dr. Silvia Regina Rogatto
111
International indexed
publications 2011
1. A review of the epidemiology and treatment of Merkel
cell carcinoma. Duprat JP, Landman G, Salvajoli JV, Brechtbühl ER. Clinics (Sao Paulo) 2011;66(10):1817-23.
2. Absence of galectin-3 does not affect the development
of experimental tongue carcinomas in mice+D33. de Faria
PR, Chammas R, de Melo TL, Hsu DK, Liu FT, Nonogaki S,
Cardoso SV, Loyola AM. Exp Mol Pathol 2011;90(2):189-93.
B, Smith D, Abrahamsen M, Papenfuss M, Villa LL, Lazcano-
Ubajara (Ceará state, Brazil): genotoxic and cytogenetic
33. Clinical and imaging manifestations of hemorrhagic
-Ponce E, Giuliano AR. J Infect Dis 2011;203(1):49-57.
studies. Paiva JC, Cabral IO, Soares BM, Sombra CM, Ferreira
pulmonary leptospirosis: a state-of-the-art review. Marchi-
12. Alternative splicing and genetic diversity: silencers are
JR, Moraes MO, Cavalcanti BC, Pessoa C. Environ Mol Muta-
ori E, Lourenço S, Setúbal S, Zanetti G, Gasparetto TD, Hoch-
more frequently modified by SNVs associated with alternati-
gen 2011; 52(6):492-501.
hegger B. Lung 2011;189(1):1-9.
ve exon/intron borders. de Souza JE, Ramalho RF, Galante PA,
22. Breakpoint characterization of a novel large intragenic
34. Clinicopathological factors are predictors of distant me-
Meyer D, de Souza SJ. Nucleic Acids Res 2011; 39(12):4942-8.
deletion of MUTYH detected in a MAP patient: case report.
tastasis from major salivary gland carcinomas. Mariano FV,
13. Amyloid-beta oligomers increase the localization of pri-
Torrezan GT, da Silva FC, Krepischi AC, Santos ÉM, Ferreira
da Silva SD, Chulan TC, de Almeida OP, Kowalski LP. Int J Oral
on protein at the cell surface. Caetano FA, Beraldo FH, Hajj
Fde O, Rossi BM, Carraro DM. BMC Med Genet. 2011;12:128.
Maxillofac Surg 2011;40(5):504-9.
GN, Guimaraes AL, Jürgensen S, Wasilewska-Sampaio AP, Hi-
23. Cancer stem cell immunophenotypes in oral squamous
35. Clinicopathological features and proliferation mark-
rata PH, Souza I, Machado CF, Wong DY, De Felice FG, Ferreira
cell carcinoma. Oliveira LR, Oliveira-Costa JP, Araujo IM, So-
ers in tongue squamous cell carcinomas. Gueiros LA, Coletta RD, Kowalski LP, Lopes MA. Int J Oral Maxillofac Surg
ST, Prado VF, Rylett RJ, Martins VR, Prado MA. J Neurochem.
ave DF, Zanetti JS, Soares FA, Zucoloto S, Ribeiro-Silva A. J
3. Activation of sonic hedgehog signaling in oral squamous
2011; 117(3):538-53.
Oral Pathol Med 2011;40(2):135-42.
2011;40(5):510-5.
cell carcinomas: a preliminary study. Cavicchioli Buim ME,
14. Analysis of allelic differential expression in the human
24. Caspase expression in oral squamous cell carcinoma.
36. Common promoter elements in odorant and vomero-
genome using allele-specific serial analysis of gene expres-
Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski
nasal receptor genes. Michaloski JS, Galante PA, Nagai MH,
sion tags. Vidal DO, de Souza JE, Pires LC, Masotti C, Salim
LP, Soares FA. Head Neck 2011; 33(8):1191-8.
Armelin-Correa L, Chien MS, Matsunami H, Malnic B. PLoS
4. Activation of the Wnt/beta-catenin signaling pathway
AC, Costa MC, Galante PA, de Souza SJ, Camargo AA. Genome
25. CCND1 amplification and protein overexpression in oral
One 2011;6(12):e29065.
during oral carcinogenesis process is not influenced by the
2011; 54(2):120-7.
squamous cell carcinoma of young patients. Kaminagakura
37. Comparison of postmenopausal endogenous sex hormo-­
15. Antitumor effect of laticifer proteins of Himatanthus
E, Werneck da Cunha I, Soares FA, Nishimoto IN, Kowalski
nes among Japanese, Japanese Brazilians, and non-Japanese
drasticus (Mart.) Plumel-Apocynaceae. Mousinho KC, Olivei-
LP. Head Neck 2011; 33(10):1413-9.
Brazilians. Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishi-
ra Cde C, Ferreira JR, Carvalho AA, Magalhães HI, Bezerra DP,
26. Cell adhesion and communication proteins are dif-
mura H, Kusama R, Hamada GS, Nishimoto IN, Maciel Mdo S,
5. Acupuncture for the prevention of radiation-induced xe-
Alves AP, Costa-Lotufo LV, Pessoa C, de Matos MP, Ramos MV,
ferentially expressed in melanoma progression model.
Motola J Jr, Laginha FM, Anzai R, Tsugane S. BMC Med 2011;9:16.
rostomia in patients with head and neck cancer. Braga Fdo P,
Moraes MO. J Ethnopharmacol 2011; 137(1):421-6.
Rezze GG, Fregnani JH, Duprat J, Landman G. Hum Pathol
Lemos Junior CA, Alves FA, Migliari DA. Braz Oral Res 2011;
38. Comparison of three types of preparations for ab-
16. APC +/- alters colonic fibroblast proteome in FAP. Pa-
2011;42(3):409-18.
dominal sonography. Pinto PN, Chojniak R, Cohen MP, Yu
Gurgel CA, Gonçalves Ramos EA, Lourenço SV, Soares FA.
Hum Pathol 2011; 42(10):1484-90.
absence of galectin-3 in mice. Sant’ana JM, Chammas R, Liu
FT, Nonogaki S, Cardoso SV, Loyola AM, de Faria PR. Anticancer Res 2011;31(9):2805-11.
25(2):180-5.
tel BB, Li XM, Dixon MP, Blagoi EL, Nicolas E, Seeholzer SH,
27. Characterization of germline mutations of MLH1 and
LS, Queiroz-Andrade M, Bitencourt AG. J Clin Ultrasound
6. Acute treatment of uncompensated heart failure with
Cheng D, He YA, Coudry RA, Howard SD, Riddle DM, Cooper
MSH2 in unrelated south American suspected Lynch syn-
2011;39(4):203-8.
10% hypertonic saline and its subsequent effect on respi-
HC, Boman BM, Conrad P, Crowell JA, Bellacosa A, Knudson
drome individuals. Valentin MD, Silva FC, Santos EM, Lisboa
ratory patterns. Zampieri FG, Caruso P. Clinics (Sao Paulo)
39. Cortactin is associated with perineural invasion in the
A, Yeung AT, Kopelovich L. Oncotarget 2011; 2(3):197-208
BG, de Oliveira LP, Ferreira FD, Gomy I, Nakagawa WT, Aguiar
deep invasive front area of laryngeal carcinomas. Ambro-
2011; 66(4):717-8.
17. Arg72Pro TP53 polymorphism and cancer susceptibility:
Junior S, Redal M, Vaccaro C, Valle AD, Sarroca C, Carraro DM,
sio EP, Rosa FE, Domingues MA, Villacis RA, Coudry RD, Ta-
7. Adenosine deaminase inhibition prevents Clostridium di-
a comprehensive meta-analysis of 302 case-control studies.
Rossi BM. Fam Cancer 2011; 10(4):641-7.
gliarini JV, Soares FA, Kowalski LP, Rogatto SR. Hum Pathol
fficile toxin A-induced enteritis in mice. de Araújo Junqueira
Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Int J Can-
28. Childhood leukemia incidence in Brazil according to di-
2011;42(9):1221-9.
AF, Dias AA, Vale ML, Spilborghs GM, Bossa AS, Lima BB, Car-
cer 2011;129(4):920-30.
fferent geographical regions. de Souza Reis R Sr, de Camargo
valho AF, Guerrant RL, Ribeiro RA, Brito GA. Infect Immun
40. Craniofacial resection for malignant tumors involving the
18. Association Between HPV Types and Species Groups and
B, de Oliveira Santos M, de Oliveira JM, Azevedo Silva F, Pom-
skull base in the elderly: An international collaborative study.
2011; 79(2):653-62.
Cervical Neoplasia From a High-risk Area for Cervical Can-
bo-de-Oliveira MS. Pediatr Blood Cancer 2011; 56(1):58-64.
Ganly I, Patel SG, Singh B, Kraus DH, Cantu G, Fliss DM, Kow-
8. Advances and applications of oral cancer basic research.
cer, Goiânia, Brazil. Ribeiro AA, Figueiredo Alves RR, Costa
29. Cholinergic Hyperresponsiveness of Peripheral Lung Pa-
alski LP, Snyderman C, Shah JP. Cancer 2011; 117(3): 563-71
Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD,
MC, Villa LL, Zeferino LC, Mauricette Derchain SF, Dos San-
renchyma in Chronic Obstructive Pulmonary Disease. Lanças
41. CT-guided cutting needle biopsy of lung lesions-An ef-
Woolgar JA, Bradford CR, Rodrigo JP, Rinaldo A, Hier MP, Ko-
tos Carneiro MA, Rabelo-Santos SH. Int J Gynecol Pathol
T, Kasahara DI, Gross JL, Pires-Neto RC, Deheinzelin D, Mauad
fective procedure for adequate material and specific diag-
walski LP. Oral Oncol 2011;47(9):783-91.
2011; 30(3):288-94.
T, Negri EM, Dolhnikoff M Respiration 2011;82:177-84.
nose. Guimaraes MD, de Andrade MQ, da Fonte AC, Chojniak
9. Advanced hepatocellular carcinoma. Review of targeted
19. Associations of dietary dark-green and deep-yellow veg-
30. Claudin and p53 expression in vulvar lichen sclerosus
R, Gross JL. Eur J Radiol 2011; 80(3):e488-90.
molecular drugs. Alves RC, Alves D, Guz B, Matos C, Viana
etables and fruits with cervical intraepithelial neoplasia:
and squamous-cell carcinoma. Sadalla JC, Lourenço SV, Sotto
42. Cumulative coffee consumption and reduced risk of oral
M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P Ann
modification by smoking. Tomita LY, Roteli-Martins CM, Villa
MN, Baracat EC, Carvalho JP. J Clin Pathol 2011; 64(10):853-7.
and oropharyngeal cancer. Biazevic MG, Toporcov TN, An-
Hepatol 2011;10(1):21-7.
LL, Franco EL, Cardoso MA; BRINCA Study Team. Br J Nutr
31. Claudin expression is dysregulated in prostate adeno-
tunes JL, Rotundo LD, Brasileiro RS, Carvalho MB, Filho JF,
10. Advances in surgical treatment of colorectal liver me-
2011; 105(6):928-37.
carcinomas but does not correlate with main clinicopatho-
Kowalski LP. Nutr Cancer 2011;63(3):350-6.
tastases. Coimbra FJ, Pires TC, Costa Junior WL, Diniz AL, Ri-
20. Atypical mole syndrome and dysplastic nevi: identifica-
logical parameters. Coutinho-Camillo CM, Lourenço SV, da
43. Cyclooxygenase-2 contributes to functional changes
beiro HS. Rev Assoc Med Bras 2011;57(2):220-7.
tion of populations at risk for developing melanoma – review
Fonseca FP, Soares FA. Pathology 2011; 43(2):143-8.
seen on experimental hemorrhagic cystitis induced by ifos-
11. Age-specific prevalence of and risk factors for anal hu-
article. Silva JH, de Sá B, Avila AL, Landman G, Duprat Neto
32. Clinical and pathological implications of concurrent au-
famide in rat urinary bladder. Macedo FY, Mourão LT, Palhe-
man papillomavirus (HPV) among men who have sex with
JP. Clinics (Sao Paulo) 2011; 66(3):493-9.
toimmune thyroid disorders and papillary thyroid cancer.
ta RC Jr, Jucá DM, Lima RC Jr, Neto Jde S, Magalhães PJ, San-
women and men who have sex with men: the HPV in men
21. Biomonitoring of rural workers exposed to a complex
Cunha LL, Ferreira RC, Marcello MA, Vassallo J, Ward LS. J
tos AA, Souza MH, Brito GA, Ribeiro RA. Cancer Chemother
mixture of pesticides in the municipalities of Tianguá and
Thyroid Res 2011; 2011:387062.
Pharmacol. 2011 Apr;67(4):935-43.
(HIM) study. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Lu
112
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
113
44. Decreased AIRE Expression and Global Thymic Hypo-
and neck cancer. Lopes RVM, Zago MA, Eluf-Neto J, Curado
neutrophils. Chaves HV, Ribeiro Rde A, de Souza AM, Rodri-
Kaneno R, do Prado CH, Rocha Pde M. Cent Nerv Syst Agents
function in Down Syndrome. Lima FA, Moreira-Filho CA, Ra-
MP, Daudt MW, Silva Jr WA, Zanette DL, Levi JE, Carvalho MB,
gues e Silva AA, Gomes AS, Vale ML, Bezerra MM, Brito GA.
Med Chem 2011;11(1):8-30.
mos PL, Brentani H, Lima Lde A, Arrais M, Bento-de-Souza
Kowalski LP, Abrahão M, Gois Filho JF, Boffetta P, Wunsch
J Biomed Biotechnol. 2011;2011:707985.
74. Gene network analyses point to the importance of hu-
LC, Bento-de-Souza L, Duarte MI, Coutinho A, Carneiro-Sam-
Filho V. Braz J Med Biol Res 2011;44(10):1006-12.
64. Expression analysis of osteopontin mRNA splice vari-
man tissue kallikreins in melanoma progression. Martins
paio M. J Immunol 2011;187(6):3422-30.
54. Embryonal rhabdomyosarcoma of the uterine cervix
ants in prostate cancer and benign prostatic hyperplasia.
WK, Esteves GH, Almeida OM, Rezze GG, Landman G, Mar-
45. Deregulated expression of superoxide dismutase-2 cor-
in a 47-year-old woman. Baiocchi G, Faloppa CC, de Toledo
Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares
ques SM, Carvalho AF, L Reis LF, Duprat JP, Stolf BS. BMC Med
relates with different stages of cervical neoplasia. Termini L,
Osório CA, Kumagai LY, Fukazawa EM, Cunha IW. J Obstet
FA, da Silva EA, Neves AF, Goulart LR, Gimba ER. Exp Mol
Genomics 2011;4:76
Filho AL, Maciag PC, Etlinger D, Alves VA, Nonogaki S, Soares
Gynaecol Res 2011;37(7):940-6.
Pathol 2011;92(1):13-9.
75. Gingival squamous cell carcinoma mimicking periodon-
FA, Villa LL. Dis Markers. 2011;30(6):275-81.
55. Endoscopic treatment of esophageal varices in ad-
65. Ezrin expression as a prognostic marker in colorectal
tal disease. Molina AP, Cirano FR, Magrin J, Alves FA. Int J
46. 5q12.1 deletion: delineation of a phenotype including
vanced liver disease patients: band ligation versus cyano-
adenocarcinoma. Patara M, Santos EM, Coudry Rde A, Soares
Periodontics Restorative Dent 2011;31(1):97-100.
mental retardation and ocular defects. Jaillard S, Andrieux
acrylate injection. Santos MM, Tolentino LH, Rodrigues RA,
FA, Ferreira FO, Rossi BM. Pathol Oncol Res 2011;17(4):827-33.
76. Global oral health inequalities in incidence and out-
J, Plessis G, Krepischi AC, Lucas J, David V, Le Brun M, Bertola
Nakao FS, Rohr MR, de Paulo GA, Kondo M, Ferrari AP, Libera
66. Fluid balance and central venous pressure in sepsis: small
comes for oral cancer: causes and solutions. Johnson NW,
DR, David A, Belaud-Rotureau MA, Mosser J, Lazaro L, Tre-
ED. Eur J Gastroenterol Hepatol 2011;23(1):60-5.
pieces in an enormous puzzle. Zampieri FG, Park M, Azevedo
Warnakulasuriya S, Gupta PC, Dimba E, Chindia M, Otoh EC,
guier C, Rosenberg C, Odent S, Dubourg C. Am J Med Genet
56. Endostatin- and interleukin-2-expressing retroviral bi-
LC. Crit Care Med 2011;39(5):1238-9; author reply 1239.
Sankaranarayanan R, Califano J, Kowalski L. Adv Dent Res
A 2011;155(4):725-31
cistronic vector for gene therapy of metastatic renal cell car-
67. Fragment c gamma receptor gene polymorphisms and
2011;23(2):237-46.
47. Development of human minor salivary glands: expres-
cinoma. Rocha FG, Calvo FB, Chaves KC, Peron JP, Marques
breast cancer risk in case-control studies in Japanese, Jap-
77. GLUT1 expression in malignant tumors and its use
sion of mucins according to stage of morphogenesis. Teshi-
RF, de Borba TR, Braga MD, Pereira CB, Vicente EJ, Chammas
anese Brazilians, and non-Japanese Brazilians. Iwasaki M,
as an immunodiagnostic marker. Carvalho KC, Cunha
ma TH, Ianez RF, Coutinho-Camillo CM, Buim ME, Soares FA,
R, Schor N, Bellini MH. J Gene Med 2011;13(3):148-57.
Shimada N, Kasuga Y, Yokoyama S, Onuma H, Nishimura H,
IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, Vilela
Lourenço SV. J Anat 2011;219(3):410-7.
57. Enhanced Neural Progenitor/Stem Cells Self-Renewal
Kusama R, Hamada GS, Nishimoto IN, Iyeyasu H, Motola J
RS, Paiva GR, Andrade RG, Soares FA. Clinics (Sao Paulo)
48. Differential expression of HIF-1α in CD44+CD24-/low
via the Interaction of Stress Inducible Protein 1 with the
Jr, Laginha FM, Anzai R, Tsugane S. Breast Cancer Res Treat
2011;66(6):965-72.
breast ductal carcinomas. Oliveira-Costa JP, Zanetti JS, Sil-
Prion Protein. Santos TG, Silva IR, Costa-Silva B, Lepique AP,
2011;126(2):497-505.
78. High-dose-rate brachytherapy combined with hypo-
veira GG, Soave DF, Oliveira LR, Zorgetto VA, Soares FA, Zu-
Martins VR, Lopes MH. Stem Cells 2011; 29(7):1126-36.
68. Functional microarray analysis suggests repressed cell-
fractionated external beam radiotherapy for men with in-
coloto S, Ribeiro-Silva A. Diagn Pathol 2011;6(1):73.
58. European ancestry and polymorphisms in DNA repair
cell signaling and cell survival-related modules inhibit pro-
termediate or high risk prostate cancer: analysis of short-
49. Diffuse bronchiolitis pattern on a computed tomogra-
genes modify the risk of melanoma: a case-control study
gression of head and neck squamous cell carcinoma. Colo
and medium-term urinary toxicity and biochemical control.
phy scan as a presentation of pulmonary tumor thrombot-
in a high UV index region in Brazil. Gonsalves FT, Francisco
AE, Simoes AC, Carvalho AL, Melo CM, Fahham L, Kowalski
Pellizzon AC, Fogaroli RC, Silva ML, Castro DG, Maia MC, Lo-
ic microangiopathy: a case report. Arruda MF, J Med Case
G, Souza SP, Luiz OC, FestaNeto C, Sanches JA, Chammas
LP, Soares FA, Neves EJ, Reis LF, Carvalho AF. BMC Med Ge-
pes A. Int J Clin Exp Med 2011;4(1):43-52.
Reports 2011;5(1):575. Brelinger A, Barbosa PN, Chojniak R,
R, Gattas GJF, Eluf-Neto J. J Dermatol Sci 2011;64(1):59-66.
nomics 2011;4(1):33
79. Hippocampal CA3 transcriptome signature correlates
Gross JL, Guimaraes MD.
59. Evaluation of O6-methylguanine-DNA methyltransfer-
69. Gain of chromosome 7 by chromogenic in situ hybrid-
with initial precipitating injury in refractory mesial tempo-
50. Distinct patterns of somatic alterations in a lympho-
ase by immunohistochemistry: Best clinical and research
ization (CISH) in chordomas is correlated to c-MET expres-
ral lobe epilepsy. Bando SY, Alegro MC, Amaro E Jr, Silva AV,
blastoid and a tumor genome derived from the same in-
practices. Neto JC, Carvalho K, Olivieri E, Carraro D, Cunha
sion. Walter BA, Begnami M, Valera VA, Santi M, Rushing EJ,
Castro LH, Wen HT, Lima Lde A, Brentani H, Moreira-Filho
dividual. Galante PA, Parmigiani RB, Zhao Q, Caballero OL,
I, Vassallo J, Kagohara L, Soares F, Rocha R. Pathol Res Pract
Quezado M. J Neurooncol 2011; 101(2):199-206.
CA. PLoS One 2011;6(10):e26268.
de Souza JE, Navarro FC, Gerber AL, Nicolás MF, Salim AC,
2011;207(8):492-7.
70. Galectin-3 expression: a useful tool in the differential
80. HPV prophylactic vaccination: The first years and what
Silva AP, Edsall L, Devalle S, Almeida LG, Ye Z, Kuan S, Pin-
60. Evaluation of low-level laser therapy in the prevention
diagnosis of posterior fossa tumors in children. Borges CB,
to expect from now. Villa LL. Cancer Lett 2011; 305(2):106-12.
heiro DG, Tojal I, Pedigoni RG, de Sousa RG, Oliveira TY, de
and treatment of radiation-induced mucositis: A double-
Bernardes ES, Latorraca EF, Becker AP, Neder L, Chammas
Paula MG, Ohno-Machado L, Kirkness EF, Levy S, da Sil-
81. HPV-58 Molecular Variants Exhibit Different Transcrip-
blind randomized study in head and neck cancer patients.
R, Roque-Barreira MC, Machado HR, de Oliveira RS. Childs
va WA Jr, Vasconcelos AT, Ren B, Zago MA, Strausberg RL,
tional Activity. Raiol T, de Amorim RM, Galante P, Martins CR,
Carvalho PA, Jaguar GC, Pellizzon AC, Prado JD, Lopes RN,
Nerv Syst 2011;27(2):253-7.
Simpson AJ, de Souza SJ, Camargo AA. Nucleic Acids Res
Villa LL, Sichero L. Intervirology 2011;54(3):146-50.
Alves FA. Oral Oncol 2011; 47(12):1176-81.
2011;39(14):6056-68.
71. Gastric cancer in individuals with Li-Fraumeni syn-
82. How much do smoking and alcohol consumption ex-
61. Evaluation of ototoxicity in children treated for retino-
drome. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY,
51. EBV-Associated Polymorphic Posttransplant Lymphop-
plain socioeconomic inequalities in head and neck cancer
blastoma: preliminary results of a systematic audiological
Zheng H, Achatz MI, Riegert-Johnson D, Foretova L, Silva EM,
roliferative Disorder Presenting as Gingival Ulcers. León JE,
risk? Boing AF, Antunes JL, de Carvalho MB, de Góis Filho JF,
evaluation. Pecora Liberman PH, Schultz C, Schmidt Goffi-
Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, Garber
Takahama Júnior A, Vassallo J, Soares FA, Almeida OP, Lopes
Kowalski LP, Michaluart P Jr; Head and Neck Genome Pro-
Gómez MV, Antoneli CB, Motoro Chojniak M, Eduardo Novaes
JE, Syngal S. Genet Med 2011;13(7):651-7.
MA. Int J Surg Pathol 2011;19(2):241-6.
ject/GENCAPO, Eluf-Neto J, Boffetta P, Wünsch-Filho V. J Epi-
P. Clin Transl Oncol 2011;13(5):348-52
72. Gene expression analysis of blastemal component re-
demiol Community Health 2011;65(8):709-14.
52. Economic evaluation of strategies for managing women
62. Evaluation of prognostic factors in stage IIA breast tu-
veals genes associated with relapse mechanism in Wilms
with equivocal cytological results in Brazil. Vanni T, Legood
83. Human Papillomavirus (HPV) 6, 11, 16, and 18 Sero-
mors and their correlation with mortality risk. Carvalho ST,
tumour. Maschietto M, Piccoli FS, Costa CM, Camargo LP,
R, Franco EL, Villa LL, Luz PM, Schwartsmann G. Int J Can-
prevalence Is Associated with Sexual Practice and Age: Re-
Stiepcich MM, Fregnani JH, Nonogaki S, Rocha R, Soares FA.
Neves JI, Grundy PE, Brentani H, Soares FA, Camargo BD,
cer 2011;129(3):671-9.
sults from the Multinational HPV Infection in Men Study
Clinics (Sao Paulo) 2011;66(4):607-12.
Carraro DM. Eur J Cancer 2011;47(18):2715-22.
(HIM Study). Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazca-
53. Education, tobacco smoking, alcohol consumption, and
63. Experimental model of zymosan-induced arthritis in
73. Genetic and modifying factors that determine the risk
no-Ponce E, Carvalho da Silva RJ, Baggio ML, Quiterio M,
IL-2 and IL-6 gene polymorphisms in the survival of head
the rat temporomandibular joint: role of nitric oxide and
of brain tumors. Montelli Tde C, Peraçoli MT, Rogatto SR,
Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Sto-
114
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
115
ckwell HG, Giuliano AR. Cancer Epidemiol Biomarkers Prev.
93. International distribution and age estimation of the Por-
De Brot M, Gobbi H, Soares FA, Rocha RM. Exp Mol Pathol
111. Metanephric Adenoma: clinical, imaging, and Histo-
2011;20(5):990-1002.
tuguese BRCA2 c.156_157insAlu founder mutation. Peixoto
2011;92(1):20-6.
logical findings. Torricelli FC, Marchini GS, Campos RS, Gil
84. IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epider-
A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmão
102. Malignant phyllodes tumor of the breast: case report.
AO. Clinics (Sao Paulo) 2011;66(2):359-61.
mal keratinocytes of systemic lupus erythematosus skin le-
L, Amorim A, van der Hout A, Gerdes AM, Thomassen M,
de Souza JA, Marques EF, Guatelli C, Girão DS, Queroz T, Gra-
112. Methotrexate for high-grade osteosarcoma in children
sions. Carneiro JR, Fuzii HT, Kayser C, Alberto FL, Soares FA,
Kruse TA, Cruger D, Sunde L, Bignon YJ, Uhrhammer N,
ziano L, Macedo M, Iyeyasu H, Chojniak R. Rev Assoc Med
and young adults. van Dalen EC, van As JW, de Camargo B.
Sato EI, Andrade LE. Clinics (Sao Paulo) 2011; 66(1):77-82.
Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M,
Bras 2011;57(5):495-7.
Cochrane Database Syst Rev. 2011;5:CD006325.
85. Immunohistochemical analysis of vascular density
Narod S, Royer R, Costa MM, Lazaro C, Feliubadaló L, Graña
103. Malignant rhabdoid tumours of the kidney (MRTKs),
113. Methotrexate-induced intestinal mucositis delays
registered on recent SIOP protocols from 1993 to 2005: a re-
gastric emptying and gastrointestinal transit of liquids in
port of the SIOP renal tumour study group. van den Heuvel-
awake rats. Soares PM, Lopes LO, Mota JM, Belarmino-Fi-
-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte
lho JN, Ribeiro RA, Souza MH. Arq Gastroenterol. 2011 Jan-
C, de Camargo B, de Kraker J, Leuschner I, Lugtenberg R,
Mar;48(1):80-5.
Pritchard-Jones K, Sandstedt B, Spreafico F, Graf N, Vujanic
114. Metabotropic glutamate receptors transduce signals for
and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic
factors. Moreira LR, Schenka AA, Latuf-Filho P, Penná AL,
Lima CS, Soares FA, Trevisan MA, Vassallo J. Tumour Biol
2011;32(3):527-34.
86. Impact of a supervised strength training or walking training over a subsequent unsupervised therapy period on walking capacity in patients with claudication. Menêses AL, de
Lima GH, de Moraes Forjaz CL, de Andrade Lima AH, de Moraes Silva GQ, Cucato GG, Rodrigues SL, Wolosker N, de Fátima
Nunes Marucci M, Ritti Dias RM. J Vasc Nurs 2011;29(2):81-6.
87. Impact of endovascular technique in vascular surgery
training at a large university hospital in Brazil. Puech-Leão
P, Wolosker N, Zerati AE, Nascimento LD. J Surg Educ 2011;
68(1):19-23.
88. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Giuliano AR,
Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D. Lancet
2011;377(9769):932-40.
89. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men:
B, Blanco I, de la Hoya M, Caldés T, Maillet P, Benais-Pont
G, Pardo B, Laitman Y, Friedman E, Velasco EA, Durán M,
Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O,
Gutiérrez-Enríquez S, Balmaña J, Ramon Y Cajal T, Alonso
C, Baiget M, Foulkes W, Tischkowitz M, Kyle R, Sabbaghian
N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB,
Remenieras A, Benson C, Casadei S, King MC, Teugels E, Teixeira MR. Breast Cancer Res Treat 2011;127(3):671-9.
94. Intracerebral amyloidoma: imaging findings might support preoperative diagnosis. da Rocha AJ, Silva CJ, Leopoldino
JF, de Andrade VP. Arq Neuropsiquiatr 2011;69(2B):413.
95. Is it pre-enucleation chemotherapy or delayed enucleation of severely involved eyes with intraocular retinoblastoma that risks extraocular dissemination and death? Chanta-
GM. Pediatr Blood Cancer 2011;56(5):733-7.
inin γ1 chain. Beraldo FH, Arantes CP, Santos TG, Machado CF,
ed with increased production of procoagulant microvesicles.
Roffe M, Hajj GN, Lee KS, Magalhães AC, Caetano FA, Manci-
Lima LG, Oliveira AS, Campos LC, Bonamino M, Chammas R,
ni GL, Lopes MH, Américo TA, Magdesian MH, Ferguson SS,
Werneck C, Vicente CP, Barcinski MA, Petersen LC, Monteiro
Linden R, Prado MA, Martins VR. FASEB J 2011; 25(1):265-79.
RQ. Thromb Haemost 2011;106(4):712-23.
ced through genetic and epigenetic mechanisms in human
dations based on international consensus. Segers H, van den
breast cancer. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H,
Heuvel-Eibrink MM, Pritchard-Jones K, Coppes MJ, Aitchison
Rimner A, Chan TA, Comen E, Andrade VP, Kim SW, King TA,
M, Bergeron C, de Camargo B, Dome JS, Grundy P, Gatta G,
Graf N, Grundy P, Kalapurakal JA, de Kraker J, Perlman EJ, Rei-
I, de Antoneli CB, Tacyildiz N, Fineman SL, Lumbroso L, Doz
nhard H, Spreafico F, Vujanic G, Warwick AB; SIOP-RTSG and
the COG-Renal Tumour Committee. Expert Rev Anticancer
96. Is the gastrointestinal stromal tumor arising in the rec-
Ther 2011;11(7):1105-13.
tovaginal septum an extragastrointestinal entity? A time
106. Maternally inherited partial monosomy 9p (pter → p24.1)
for reflection. Fregnani JH, de Oliveira AT, de Lima Vazquez
and partial trisomy 20p (pter → p12.1) characterized by mi-
V, Viana CR, Longatto-Filho A, Reis RM. Int J Colorectal Dis
115. MicroRNA-335 inhibits tumor reinitiation and is silen-
105. Management of adults with Wilms’ tumor: recommen-
da G, Leal-Leal C, Brisse H, de Graaf P, Sitorus RS, Qaddoumi
F. J Clin Oncol 2011;29(24):3333-4; author reply 3335-6.
neurite outgrowth after binding of the prion protein to lam-
104. Malignant transformation in melanocytes is associat-
croarray comparative genomic hybridization. Freitas ÉL, Gri-
Hudis CA, Norton L, Hicks J, Massagué J, Tavazoie SF. Genes
Dev 2011;25(3):226-31.
116. Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Macedo
MP, Andrade LD, Coudry R, Crespo R, Gomes M, Lisboa BC,
Aguiar S Jr, Soares FA, Carraro DM, Cunha IW. Int J Colorectal Dis 2011;26(10):1241-8.
117. NFAT1 transcription factor is central in the regulation
2011;26(3):387-9.
bble SM, Simioni M, Vieira TP, Silva-Grecco RL, Balarin MA,
DE, Wu Y, Papenfuss MR, Villa LL, Lazcano-Ponce E, Gage C,
97. Lack of Galectin-3 Disturbs Mesenteric Lymph Node Ho-
Prigmore E, Krepischi-Santos AC, Rosenberg C, Szuhai K, van
Silva RJ, Baggio ML, Quiterio M, Salmerón J, Abrahamsen M,
meostasis and B Cell Niches in the Course of Schistosoma
Haeringen A, Carter NP, Gil-da-Silva-Lopes VL. Am J Med
Giuliano AR. J Infect Dis. 2011 Dec 15;204(12):1886-92.
mansoni Infection. Oliveira FL, Brand C, Paula AA, Arcanjo
Genet A 2011;155A(11):2754-61.
KD, Hsu DK, Liu FT, Takiya CM, Borojevic R, Chammas R, El-
107. Mathematical model to predict risk for lymphoedema
-Cheikh MC. PLoS One 2011;6(5):e19216.
after treatment of cutaneous melanoma. Campanholi LL,
venuti TT, Honda ST, Del Valle PR, Katayama ML, Brentani
98. Late side effects of radioactive iodine on salivary gland
Duprat Neto JP, Fregnani JH. Int J Surg 2011; 9(4):306-9.
HP, Carraro DM, Rozenchan PB, Brentani MM, de Lyra EC,
function in patients with thyroid cancer. Almeida JP, Sanabria
108. Mature autologous dendritic cell vaccines in advanced
Torres CH, Salzgeber MB, Kaiano JH, Góes JC, Folgueira MA.
AE, Lima EN, Kowalski LP. Head Neck 2011;33(5):686-90.
non-small cell lung cancer: a phase I pilot study. Perroud
Tumour Biol 2011;32(1):145-57.
99. Long-term results of the percutaneous transhepatic ve-
MW Jr, Honma HN, Barbeiro AS, Gilli SC, Almeida MT, Vas-
91. Infusion of recombinant human tissue plasminogen ac-
noplasty of portal vein stenoses after pediatric liver trans-
sallo J, Saad ST, Zambon L. J Exp Clin Cancer Res 2011;30:65
tivator through the superior mesenteric artery in the treat-
plantation. Carnevale FC, de Tarso Machado A, Moreira AM,
109. Meningeal carcinomatosis in breast cancer: prognostic
ment of acute mesenteric venous thrombosis. Mauricio da
Dos Santos AC, da Motta-Leal-Filho JM, Suzuki L, Cerri GG,
factors and outcome. de Azevedo CR, Cruz MR, Chinen LT,
Motta Leal Filho J, Barbosa Santos AC, Carnevale FC, de Oli-
Tannuri U. Pediatr Transplant 2011;15(5):476-81.
Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF,
veira Sousa W Jr, Pereira Grillo LS Jr, Cerri GG. Ann Vasc Surg
100. Low prevalence of HPV in Brazilian children with reti-
Gimenes DL. J Neurooncol 2011;104(2):565-72.
121. Overexpression of vimentin in canine prostatic car-
2011;25(6):840.e1-4.
noblastoma. Antoneli CB, Ribeiro KB, Sredni ST, Arias VE,
110. Mesenchymal and embryonic characteristics of stem
cinoma. Rodrigues MM, Rema A, Gärtner F, Soares FA, Ro-
92. Interleukin-10 but not interleukin-18 may be associated
Andreoli MA, de Camargo B, Sobrinho JS, Prado JC, Soares
cells obtained from mouse dental pulp. Guimarães ET, Cruz
with the immune response against well-differentiated thy-
FA, Villa LL. J Med Virol 2011;83(1):115-8.
GS, de Jesus AA, Lacerda de Carvalho AF, Rogatto SR, Pereira
2011;144(4):308-11.
roid cancer. Cunha LL, Tincani AJ, Assumpção LV, Soares FA,
101. MGMT and PTEN as potential prognostic markers in
Lda V, Ribeiro-Dos-Santos R, Soares MB. Arch Oral Biol 2011;
122. Palliative pelvic exenteration for patients with gyneco-
Vassallo J, Ward LS. Clinics (Sao Paulo) 2011;66(7):1203-8.
breast cancer. Neto JC, Ikoma MM, Carvalho KC, Vassallo J,
56(11):1247-55.
logical malignancies. Guimarães GC, Baiocchi G, Ferreira FO,
the HPV in men study. Anic GM, Lee JH, Stockwell H, Rollison
90. Influence of the interaction between nodal fibroblast
and breast cancer cells on gene expression. Santos RP, Ben-
116
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
of tissue microenvironment for tumor metastasis. Werneck
MB, Vieira-de-Abreu A, Chammas R, Viola JP. Cancer Immunol Immunother 2011; 60(4):537-46.
118. Objective evaluation of patients with palmar hyperhidrosis submitted to two levels of sympathectomy: T3 and
T4. Ishy A, de Campos JR, Wolosker N, Kauffman P, Tedde
ML, Chiavoni CR, Jatene FB. Interact Cardiovasc Thorac Surg
2011;12(4):545-8.
119. Oral lesions in four cases of subacute cutaneous lupus
erythematosus. Nico MM, Romiti R, Lourenço SV. Acta Derm
Venereol 2011;91(4):436-9.
120. Oral lichen planus. Nico MM, Fernandes JD, Lourenço
SV. An Bras Dermatol 2011;86(4):633-43.
gatto SR, De Mour VM, Laufer-Amorim R. J Comp Pathol
117
Kumagai LY, Fallopa CC, Aguiar S, Rossi BM, Soares FA, Lopes
133. Preservation of pregnancy in a patient with acute ab-
Bien S, Woolgar JA, Zbären P, Betka J, Folz BJ, Genden EM, Tal-
154. Role of inducible nitric oxide synthase pathway on
A. Arch Gynecol Obstet 2011;283(5):1107-12.
dominal pain secondary to advanced and hemorrhagic yolk
mi YP, Strome M, González Botas JH, Olofsson J, Kowalski LP,
methotrexate-induced intestinal mucositis in rodents. Lei-
123. Pathologic complete response with neoadjuvant ima-
sac tumor of the right ovary. Viana LS, Tsunoda AT, Nunes
Holmes JD, Hisa Y, Rinaldo A. Head Neck 2011;33(3):445-50.
tão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Sil-
tinib for locally advanced pelvic GIST. de Azevedo CR, Paiva
JS, Fregnani JH, Vieira MA, Borges AK, Andrade CE, Serrano
va JV, Gomes AS, Lima-Júnior RC, Siqueira FJ, Freire RS, Vale
TF Jr, Rossi BM, Guimarães GC, de Souza Begnami MD, Oli-
SV. J Clin Oncol 2011;29(30):e758-62.
144. PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression. Cerutti JM, Oler G, Delcelo R,
ML, Ribeiro RA. BMC Gastroenterol. 2011 Aug;11:90.
veira TB, Barros E Silva MJ, Fanelli MF, de Mello CA. Int J Clin
134. Prevalence of anxiety in patients awaiting diagnostic
Gerardt R, Michaluart P Jr, de Souza SJ, Galante PA, Huang P,
155. Role of platelet-activating factor in the pathogenesis of
Oncol 2011;16(3):279-83.
procedures in an oncology center in Brazil. Yu LS, Chojniak
Riggins GJ. J Clin Endocrinol Metab 2011;96(1):E151-60.
5-fluorouracil-induced intestinal mucositis in mice. Soares
124. Penile cancer: epidemiology and treatment. Guimarães
R, Borba MA, Girão DS, Lourenço MT. Psychooncology. 2011
PM, Lima-Junior RC, Mota JM, Justino PF, Brito GA, Ribeiro
Nov;20(11):1242-5.
145. Q8IYL2 is a candidate gene for the familial epilepsy
GC, Rocha RM, Zequi SC, Cunha IW, Soares FA. Curr Oncol
Rep 2011;13(3):231-9.
135. Primary Hodgkin’s lymphoma of the rectum: an unu-
125. Penile carcinoma: risk factors and molecular altera-
sual presentation. da Costa AA, Flora AC, Stroher M, Soares
tions. Calmon MF, Tasso Mota M, Vassallo J, Rahal P. Scien-
FA, de Lima VC. J Clin Oncol 2011;29(10):e268-70.
tificWorldJournal 2011;11:269-82.
136. Primary transpupillary thermotherapy for small cho-
126. Perioperative Temporary Occlusion of the Internal Il-
roidal melanoma. Chojniak MM, Chojniak R, Nishimoto IN,
iac Arteries as Prophylaxis in Cesarean Section at Risk of
Allemann N, Erwenne CM. Graefes Arch Clin Exp Ophthal-
Hemorrhage in Placenta Accreta. Carnevale FC, Kondo MM,
mol 2011;249(12):1859-65.
de Oliveira Sousa W Jr, Santos AB, da Motta Leal Filho JM,
137. Prognostic impact of MUM1 expression by immunohis-
Moreira AM, Baroni RH, Francisco RP, Zugaib M. Cardiovasc
tochemistry on primary mediastinal large B-cell lymphoma.
Intervent Radiol 2011;34(4):758-64
De Mello CA, De Andrade VP, De Lima VC, Carvalho AL, Soa-
127. Persistence and clearance of HPV from the penis of
res FA. Leuk Lymphoma 2011;52(8):1495-503.
men infected and non-infected with HIV. Silva RJ, Casseb J,
138. Prognostic implications of altered human epidermal
Andreoli MA, Villa LL. J Med Virol 2011;83(1):127-31.
growth factor receptors (HERs) in gastric carcinomas: HER2
128. P-glycoprotein expression, tumor weight, age, and
and HER3 are predictors of poor outcome. Begnami MD,
relapse in patients with stage I and II favorable-histology
Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Cos-
syndrome of Partial Epilepsy with Pericentral Spikes (PEPS).
Wilms’ tumor. Teixeira RA, Odone-Filho V, de Camargo B,
ta WL Jr, Soares FA. J Clin Oncol 2011;29(22):3030-6.
Zerbini MC, Fillipi R, Alencar A, Cristofani L. Pediatr Hema-
139. Prognostic significance of beta-2 adrenergic receptor in
tol Oncol. 2011 Apr;28(3):194-202.
oral squamous cell carcinoma. Bravo-Calderón DM, Oliveira
129. Phosphodiesterase 11A (PDE11A) genetic variants may
DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP. Can-
Leschziner GD, Coffey AJ, Andrew T, Gregorio SP, Dias-Neto
RA, Cunha FQ, Souza MH. Cancer Chemother Pharmacol
2011 Sep;68(3):713-20.
E, Calafato M, Bentley DR, Kinton L, Sander JW, Johnson MR.
156. Role of ultrasound, clinical and scintigraphyc parame-
Epilepsy Res 2011;96(1-2):109-15.
ters to predict malignancy in thyroid nodule. Maia FF, Matos
146. Questioning the work “does an incomplete excision of
the eyelid basal cell carcionoma mean tumor recurrence?”.
Brechtbühl ER. An Bras Dermatol 2011;86(2):401.
147. Recurrent copy number gains of ACVR1 and corresponding transcript overexpression are associated with survival in head and neck squamous cell carcinomas. Ambrosio
EP, Drigo SA, Bérgamo NA, Rosa FE, Bertonha FB, de Abreu
FB, Kowalski LP, Rogatto SR. Histopathology 2011;59(1):81-9.
148. Regional odontodysplasia: Management of an acute
case with a scanning electron microscope. Gallo Cde B, Alves FA, Junior Ddos S, Marques MM, Sugaya NN. Gen Dent
2011;59(4):e178-81.
149. Repeated cisplatin treatments inhibit gastrointestinal
motility and induces baroreflex changes and mechanical
hyperalgesia in rats. Viana-Cardoso KV, da Silva MT, Júnior
RC, Peixoto Junior AA, Pinho LG, Santos AA, Ribeiro RA, Rola
PS, Silva BP, Pallone AT, Pavin EJ, Vassallo J, Zantut-Wittmann
DE. Head Neck Oncol 2011;3:17.
157. Schistosoma mansoni infection in the liver graft: Impact on donor and recipient outcome after transplantation.
Vincenzi R, Neto JS, Fonseca EA, Pugliese V, Leite KR, Benavides MR, Cândido HL, Porta G, Miura IK, Pugliese R, Danesi
VB, Guimarães TC, Porta A, Kondo M, Carone E, Chapchap P.
Liver Transpl 2011;17(11):1299-303.
158. Second primary tumors in patients with head and neck
cancer. Priante AV, Castilho EC, Kowalski LP. Curr Oncol Rep
2011;13(2):132-7.
159. Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a
prospective, placebo-controlled, double-blind trial. Mattar
A, Logullo AF, Facina G, Nonogaki S, Soares FA, Gebrim LH. J
Cancer Res Clin Oncol 2011;137(5):897-905.
increase susceptibility to prostatic cancer. Faucz FR, Horvath
cer Biomark 2011-2012;10(1):51-9.
A, Rothenbuhler A, Almeida MQ, Libé R, Raffin-Sanson ML,
140. Prognostic significance of GRP78 expression patterns
Bertherat J, Carraro DM, Soares FA, Molina Gde C, Campos
in breast cancer patients receiving adjuvant chemotherapy.
150. Risk perception among Brazilian individuals with high
AH, Alexandre RB, Bendhack ML, Nesterova M, Stratakis CA.
Baptista MZ, Sarian LO, Vassallo J, Pinto GA, Soares FA, de
risk for colorectal cancer and colonoscopy. Santos EM, Lou-
J Clin Endocrinol Metab 2011;96(1):E135-40.
Souza GA. Int J Biol Markers 2011; 26(3):188-96.
renço MT, Rossi BM. Hered Cancer Clin Pract 2011;9:4.
130. Poly (A) Transcriptome Assessment of ERBB2-Induced Al-
141. Prognostic value of NDRG1 and SPARC protein expres-
151. Role of capsaicin-sensitive primary afferent neurons
9):823-34.
terations in Breast Cell Lines (Correction). Carraro DM, Ferreira
sion in breast cancer patients. Nagai MA, Gerhard R, Freg-
and non-protein sulphydryl groups on gastroprotective ef-
161. Simultaneous left colectomy and standard hepatec-
EN, de Campos Molina G, Puga RD, Abrantes EF, Trapé AP, Ekhar-
nani JH, Nonogaki S, Rierger RB, Netto MM, Soares FA. Breast
fect of amifostine against ethanol-induced gastric damage
tomy reformed by laparoscopy. Lupinacci RM, Machado MA,
dt BL, Nunes DN, Brentani MM, Arap W, Pasqualini R, Brentani
Cancer Res Treat 2011;126(1):1-14.
in rats. Junqueira-Júnior J, Junqueira AF, Medeiros JV, Barbosa
Lupinacci RA, Herman P. Rev Col Bras Cir 2011;38(2):139-41.
H, Dias-Neto E, Brentani RR. PLoS One 2011;6(7):e21022.
142. Prolonged time to progression with fulvestrant for
SH, Nogueira AC, Mota JM, Santana AP, Brito GA, Ribeiro RA,
131. Portal vein obstruction after liver transplantation in
metastatic breast cancer. Mello CA, Chinen LT, da Silva SC,
Lima-Júnior RC, Souza MH. Dig Dis Sci. 2011 Feb;56(2):314-22.
children treated by simultaneous minilaparotomy and tran-
do Nascimento Matias C, Benevides CF, Gimenes DL, Fanelli
152. Role of fos-related antigen 1 in the progression and
the HPV in men study. Nyitray AG, Carvalho da Silva RJ, Bag-
shepatic approaches: initial experience. Carnevale FC, Santos
MF. Med Oncol 2011;28(2):416-9.
prognosis of ductal breast carcinoma. Logullo AF, Stiepcich
gio ML, Smith D, Abrahamsen M, Papenfuss M, Lin HY, Qui-
AC, Seda-Neto J, Zurstrassen CE, Moreira AM, Carone E, Mar-
143. Proposal for a rational classification of neck dissec-
MM, de Toledo Osório CA, Nonogaki S, Pasini FS, Rocha RM,
terio M, Salmerón J, Lazcano-Ponce E, Villa LL, Giuliano AR.
celino AS, Porta G, Pugliese R, Miura I, Baggio VD, Guimarães
tions. Ferlito A, Robbins KT, Shah JP, Medina JE, Silver CE,
Soares FA, Brentani MM. Histopathology 2011;58(4):617-25.
J Infect Dis 2011;204(11):1711-22.
T, Cerri GG, Chapchap P. Pediatr Transplant 2011;15(1):47-52.
Al-Tamimi S, Fagan JJ, Paleri V, Takes RP, Bradford CR, Dev-
153. Role of the haem oxygenase/carbon monoxide path-
aney KO, Stoeckli SJ, Weber RS, Bradley PJ, Suárez C, Leemans
163. Socioeconomic status and the incidence of non-cen-
132. Post-resistance exercise hypotension in patients with
way in Clostridium difficile toxin A-induced enteritis in
CR, Coskun HH, Pitman KT, Shaha AR, de Bree R, Hartl DM,
tral nervous system childhood embryonal tumours in Bra-
intermittent claudication. Cucato GG, Ritti-Dias RM, Wo-
mice. Medeiros CA, Warren CA, Freire R, Vieira CA, Lima BB,
Haigentz M Jr, Rodrigo JP, Hamoir M, Khafif A, Langendijk JA,
zil. de Camargo B, Ferreira JM, de Souza Reis R, Ferman S,
losker N, Santarem JM, Jacob Filho W, Forjaz CL. Clinics (Sao
de Oliveira Santos M, Pombo-de-Oliveira MS. BMC Cancer
Paulo) 2011;66(2):221-6.
Owen RP, Sanabria A, Strojan P, Vander Poorten V, Werner JA,
Vale ML, Ribeiro RA, Souza MH, Brito GA. J Med Microbiol.
2011 Aug;60(Pt 8):1146-54.
2011;11(1):160.
118
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
FH, Gondim Fde A. Cancer Invest 2011 Aug;29(7):494-500.
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
160. Sialylation regulates galectin-3/ligand interplay during
mammary tumour progression--a case of targeted uncloaking. de Oliveira JT, de Matos AJ, Santos AL, Pinto R, Gomes
J, Hespanhol V, Chammas R, Aki M, Bernardes ES, Albuquerque Reis C, Rutteman G, Gärtner F. Int J Dev Biol. 2011;55(7-
162. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men:
119
164. Steady-state level of epidermal growth factor (EGF)
tric cancer: results of a single cancer center in Brazil. Coim-
186. Treatment of rectal adenocarcinoma by laparoscopy
mRNA and effect of EGF on in vitro culture of caprine
bra FJ, Costa WL Jr, Montagnini AL, Diniz AL, Ribeiro HS, Silva
and conventional route: a brazilian comparative study on
preantral follicles. Celestino JJ, Bruno JB, Saraiva MV, Ro-
MJ, Begnami MF. Eur J Surg Oncol 2011;37(1):47-54.
operative time, postoperative complications, oncological
cha RM, Brito IR, Duarte AB, Araújo VR, Silva CM, Matos
175. The prevalence of genital HPV and factors associated
radicality and survival. Melani AG, Fregnani JH, Matos D.
Non-Medline indexed
magazines
with oncogenic HPV among men having sex with men and
Rev Col Bras Cir 2011;38(4):245-52.
1. Acupuncture for the prevention of radiation-induced
2011;344(3):539-50.
men having sex with women and men: the HIM study. Nyi-
187. Ultrasound-guided fine-needle aspiration detects non-
xerostomia in patients with head and neck cancer. Braga
165. Surgical implications of mesenteric lymph node me-
tray AG, da Silva RJ, Baggio ML, Lu B, Smith D, Abrahamsen M,
palpable axillary metastases in breast cancer patients who
tastasis from advanced ovarian cancer after bowel resec-
Papenfuss M, Quiterio M, Villa LL, Giuliano AR. Sex Transm
are candidates for the sentinel lymph node procedure. Maia
2011;25(2):180-5.
tion. Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukaza-
Dis 2011;38(10):932-40.
MA, Chojniak R, Lima EN, Marques EF, Maciel Mdo S. Breast
2. Ansiedade na performance musical: tradução, adaptação
J 2011;17(3):317-8.
e validação do Kenny Music. Rocha SF, Dias-Neto E, Wagner
jected to hepatectomy due to colorectal metastasis. Viana
188. Use of sodium iodide symporter expression in differen-
Farid Gattaz WF. Rev Psiq Clín 2011;38(6):217-21.
166. Syndecan-1 (CD138) and Ki-67 expression in odonto-
EF, Herman P, Coelho FF, Taka TA, D’Albuquerque LA, Cec-
tiated thyroid carcinomas. Morari EC, Marcello MA, Guilhen
3. Biópsias de lesões pulmonares com agulha grossa guia-
genic cystic lesions. Nadalin MR, Fregnani ER, Silva-Sousa
conello I. Arq Gastroenterol 2011;48(3):217-9
AC, Cunha LL, Latuff P, Soares FA, Vassallo J, Ward LS. Clin
das por tomografia computadorizada: a experiência de um
Endocrinol (Oxf) 2011; 75(2):247-54.
centro oncológico. Guimarães MD, Fonte AC, de Andrade MQ;
galectin-3 depends on the activation of PI-3 kinase. Melo FH,
189. VEGF-A and Tenascin-C produced by S100A4+ stromal
Chojniak R; Gross JL. Radiol Bras 2011; 44(2):75-80.
Butera D, Junqueira Mde S, Hsu DK, da Silva AM, Liu FT, San-
cells are important for metastatic colonization. O’Connell
4. Biópsia transtorácica de nódulos e massas pulmonares
tos MF, Chammas R. PLoS One 2011;6(12):e29313.
JT, Sugimoto H, Cooke VG, Macdonald BA, Mehta AI, Le-
dirigida por tomografia computadorizada. Chojniak R, Pinto
bleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, Neil-
PNV, Ting CJ, Cohen MP, Guimarães MD, Yu LS, Almir Biten-
son EG, Zeisberg M, Kalluri R. Proc Natl Acad Sci U S A
court GV. Radiol Bras 2011; 44(5):315-20.
MH, Campello CC, Silva JR, Figueiredo JR. Cell Tissue Res
wa EM, Faloppa CC, Kumagai LY, Badiglian-Filho L, Menezes
AN, Cunha IW, Soares FA. J Surg Oncol 2011;104(3):250-4.
YTC, Perez DEC. Braz Dent J 2011; 22(3):223-9.
167. TNF-R2 expression in acquired middle ear cholesteatoma. Vitale RF, Pereira CS, Alves AL, Fregnani JH, Ribeiro FQ.
Braz J Otorhinolaryngol 2011;77(4):531-6.
168. TP53 mutation p.R337H in gastric cancer tissues of a
12-year-old male child – evidence for chimerism involving
a common mutant founder haplotype: case report. da Silva
EM, Achatz MI, Martel-Planche G, Montagnini AL, Olivier M,
Prolla PA, Hainaut P, Soares FA. BMC Cancer 2011;11(1):449.
169. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple
myeloma cell lines. de Carvalho F, Costa ET, Camargo AA,
176. The role of hilar lymphadenectomy in patients sub-
177. The promigratory activity of the matricellular protein
178. The role of eosinophils and eosinophil cationic protein
in oral cancer: A review. Pereira MC, Oliveira DT, Kowalski LP.
Arch Oral Biol 2011;56(4):353-8.
179. The Role of Surgical Treatment in Orbital Vascular
Anomalies. Dutra AK, Lopes A, Ikeda MK, do Amaral Campos HG, Carvalho AL, Curado JH. Aesthetic Plast Surg
2011;35(6):1087-960.
180. Three-year-old child with meroacrania – neurological
FPF; Lemos Junior CA, Alves FA, Migliari DA. Braz Oral Res
2011;108(38):16002-7.
5. Cirurgia citorredutora associada a quimioterapia in-
190. Vascular ligand-receptor mapping by direct combi-
traperitoneal hipertérmica (QtIPH) no tratamento da car-
natorial selection in cancer patients. Staquicini FI, Cardó-
cinomatose peritoneal. Lopes A, Carneiro A. Rev Onco&
-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Ser-
2011;1(6)26-35. [Online periodical]. Available at: <http://re-
geeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH,
vistaonco. com.br/wp-content/uploads/2011/05/p26-34-ab-
Wallace MJ, O’Connell DJ, Krajewski S, Gershenwald JE,
domen_Onco.pdf> [06/06/2011].
Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto
signs. Funayama CA, Pfeifer LI, Ramos ES, Santucci PZ, Gomy
6. Clinical factors that predict biochemical control after
E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Si-
I, Neto AM. Brain Dev 2011;33(1):86-9.
high dose dose rate brachytherapy and hypofractionated
dman RL, Pasqualini R, Arap W. Proc Natl Acad Sci U S A
radiotherapy. Pellizzon AC, Lopes A. ISO 2011; 1(1):47-53.
181. Thymic hyperplasia in Graves’ disease. Danilo-
2011;108(46):18637-42
vic DL, Martin RM, Caruso P, Marui S. Clinics (Sao Paulo)
7. Diagnosis and management of Lynch syndrome. Silva FC,
genes to be essential for Wilms’ tumor onset. Maschietto M,
191. Value of HPV-DNA test in women with cytological diag-
Valentin MD, Santos EMM, Ferreira FO, Aguiar Jr S, Palmero EI,
Trapé AP, Piccoli FS, Ricca TI, Dias AA, Coudry RA, Galante
2011;66(12):2177-8.
nosis of atypical glandular cells (AGC). Zeferino LC, Rabelo-
Rossi BM. Recent Patents Regenerative Medicine 2011; 1:60-71.
PA, Torres C, Fahhan L, Lourenço S, Grundy PE, de Camargo
182. Transcriptome signature of the adult mouse choroid
-Santos SH, Villa LL, Sarian LO, Costa MC, do Amaral Westin
plexus. Marques F, Sousa JC, Coppola G, Gao F, Puga R, Bren-
MC, de Ângelo-Andrade LA, Derchain S. Eur J Obstet Gynecol
8. Estratégicas genômicas para determinação do prognós-
B, de Souza S, Neves EJ, Soares FA, Brentani H, Carraro DM.
Cell Death Dis 2011;2:e224.
tani H, Geschwind DH, Sousa N, Correia-Neves M, Palha JA.
Reprod Biol 2011;159(1):160-4.
171. The best approach for splenectomy in portal hyper-
Fluids Barriers CNS 2011;8(1):10.
192. Value of ultrasound and cytological classification sys-
2011; XIII(74):49-57.
tension. Andraus W, Pinheiro RS, Haddad LB, Herman P,
183. Transcriptional profile and response to neoadjuvante
tem to predict the malignancy of thyroid nodules with in-
9. Estudo da reação inflamatória pleural produzida por dre-
D’Albuquerque LA. Surgery 2011;149(6):853.
chemotherapy in breast cancer. Folgueira MA, Snitcovsky
determinate cytology. Maia FF, Matos PS, Pavin EJ, Vassallo J,
IM, Del Valle PR, Katayama ML, Brentani MM, Vieira RA. Rev
Zantut-Wittmann DE. Endocr Pathol 2011; 22(2):66-73.
nos de tórax confeccionados com diferentes materiais. Car-
172. The bone marrow compartment is modified in the absence of galectin-3. Brand C, Oliveira FL, Ricon L, Fermino
Assoc Med Bras 2011;57(3):347-52.
193. Value of repeat ultrasound-guided fine-needle aspira-
Paula RA. Perspectivas Medicas 2011; 22(1):5-8.
ML, Boldrini LC, Hsu DK, Liu FT, Chammas R, Borojevic R,
184. Transfusion-transmitted malaria: case report of as-
tion in thyroid nodule with a first benign cytologic result:
Farina M, El-Cheikh MC. Cell Tissue Res 2011;346(3):427-37.
10. Identificação do papilomavírus humano em doentes com
ymptomatic donor harboring Plasmodium malariae. Scu-
Impact of ultrasound to predict malignancy. Maia FF, Ma-
racchio P, Vieira SD, Dourado DA, Bueno LM, Colella R, Ra-
tos PS, Pavin EJ, Vassallo J, Zantut-Wittmann DE. Endocrine
carcinoma de células escamosas do canal anal e sua relação
173. The epidemiology of oral HPV infection among a multinational sample of healthy men. Kreimer AR, Villa A, Ny-
mos-Sanchez EM, Lima GF, Inoue J, Sanchez MC, Di Santi SM.
2011;40(2):290-6.
Ferreira S, Villa LL, Matos D. Rev Bras Coloproct 2011 31(1):8-16.
itray AG, Abrahamsen M, Papenfuss M, Smith D, Hildesheim
Rev Inst Med Trop Sao Paulo 2011;53(1):55-9.
194. Who are the low-risk patients that could benefit from
A, Villa LL, Lazcano-Ponce E, Giuliano AR. Cancer Epidemiol
11. Impact of enteral nutrition on acute toxicity and treat-
185. Treatment of inflammatory external root resorption re-
watch-and-wait regarding the neck? Kohler HF, Kowalski LP.
Sao Paulo Med J 2011;129(5):285-90.
ment continuity in head and neck cancer patients submit-
sulting from dental avulsion and pulp necrosis: clinical case
Gregorio JC, Masotti C, Andrade VC, Strauss BE, Caballero OL,
Atanackovic D, Colleoni GW. PLoS One 2011;6(11):e27707.
170. Temporal blastemal cell gene expression analysis in
the kidney reveals new Wnt and related signaling pathway
Biomarkers Prev 2011;20(1):172-82.
tico de câncer de pulmão não-pequenas células ressecado cirurgicamente. Fares AL, Younes RN. Prática Hospitalar
valho MVH, Pinto CAL, Marchi E, Caboclo FF, Pinheiro TC,
com o grau de diferenciação celular e estadiamento. Soares PC,
ted to intensity-modulated radiotherapy. Rebouças LM, Cal-
174. The interaction between N-category and N-ratio as a
report. Cunha RS, Abe FC, Araujo RA, Fregnani ER, Bueno CE.
legaro E, Gil GOB, Silva GML; Maia, MAC, Salvajoli JV. Radiol
new tool to improve lymph node metastasis staging in gas-
Gen Dent 2011;59(3):e101-4.
Bras 2011; 44(1):42-6.
120
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
121
12. Indicações de ressonância magnética das mamas em
4. Bases anatômicas e fisiológia da cirurgia de intestino em
Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
dedo RN. In: Caldas Neto S, editor. Tratado de otorrinola-
um centro de referência em oncologia. Marques EF, Medei-
pacientes oncológicos. Bressan AK, Carneiro VCG . In: Matsu-
oncologia. São Paulo: Lemar, 2011. p. 161-68.
ringologia, volume II. 2 ed. São Paulo: Roca, 2011. p.583-90.
ros MLL, Souza JA; Mendonça MC, Bitencourt AGV, Chojniak
bara MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA,
16. Interveção nutricional: o nutricionista na avaliação e tra-
26. Patologia Molecular dos carcinomas de mama. Soares
R. Radiol Bras 2011; 44(6):363-66.
Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
tamento ao portador de feridas e estomas Miyakawa CAI, Pe-
FA, Rocha RM, Osório CABT, Cunha IW. In Chagas CR, Menke
13. Mucosite induzida pelo metotrexato retarda o esvazia-
oncologia. São Paulo: Lemar, 2011. p. 151-59.
reira MS.. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis
CH, Vieira RJS, Boff RA, editors. Tratado de mastologia da
mento gástrico e o trânsito gastrointestinal de líquidos em
5. Bases morfológicas da cicatrização em oncologia. Ferreira
HCS, Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas
SBM. Rio de Janeiro: Revinter; 2011. p.649-61.
ratos acordados. Soares PMG, Lopes LO, Mota JMSC, Belar-
JCD. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS,
e estomas em oncologia. São Paulo: Lemar, 2011. p. 207-15.
27. Principais cuidados com o extravasamento de drogas
mino-Filho JN, Ribeiro RA, Souza MHLP. Arq Gastroenterol
Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas
17. Intervenção da enfermagem: o papel do enfermeiro como
antineoplásicas. Fernandes PCL. In: Matsubara MGS, Vilela
2011; 48(1):80-5.
e estomas em oncologia. São Paulo: Lemar, 2011. p. 29-31.
educador no cuidado de feridas e estomas. Bicudo FG, Silvei-
DL, Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Ban-
14. Neoplasia localmente avançada de laringe na era da
6. Câncer de ovário avançado: visão do cirurgião oncológi-
ra CT. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS,
deira RC, Bozza VC. Feridas e estomas em oncologia. São
preservação de órgão: qual a melhor estratégia terapêutica?
co. Ferreira FO, Barrozo AJJ. In: Raslan S, Birolini D, Utiyama
Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas
Paulo: Lemar, 2011. p. 103-09.
Carvalho GB, Mannarini L, Kowalski LP. Rev Onco & 2011;28-
EM, editores. Atualização em cirurgia geral, emergência e
e estomas em oncologia. São Paulo: Lemar, 2011. p. 263-6.
28. Qualidade de vida para o paciente estomizado. Paula
35. [Online periodical]. Avaibale at: <http://revistaonco.com.
trauma. São Paulo: Cbee; 2011. p.257-62.
18. Intervenção do estomatologista: o papel do estomatologis-
MAB. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS,
br/wp-content/uploads/2011/04/p28-35-cabeca-pescoco_
7. Cuidados intensivos com a pele de pacientes oncológicos.
ta nas lesões da cavidade oral. Jaguar GC, Carvalho PAG, Alves
Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas
Onco.pdf> [06/06/2011].
Camalionte L. In: Matsubara MGS, Vilela DL, Hashimoto SY,
FA. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS, Sa-
e estomas em oncologia. São Paulo: Lemar, 2011. p. 201-4.
15. Papel da nutrição na cicatrização. Bottoni A, Bottoni A, Ro-
Reis HCS, Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feri­-
conato RA, Denardi UA, Bandeira RC, Bozza VC, editores. Feri-
29. Radiodermite: aspectos preventivos e terapêuticos.De-
drigues RC, Celano RMG. Rev Ciências Saúde 2011; 1(1):98-103
das e estomas em oncologia. São Paulo: Lemar, 2011. p. 95-101.
das e estomas em oncologia. São Paulo: Lemar, 2011. p.237-41.
nardi UA, Matsubara MGS. In: Matsubara MGS, Vilela DL,
16. Princípios de cirurgia oncológica. Lopes A, Bressan AK,
8. Dispositivos e acessórios para o cuidado do estomizado.
19. Intervenção do médico nutrólogo: o papel do nutrólogo
Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Bandeira
Costa AC. Prática Hospitalar 2011; XIII(74):60-66.
Hahimoto SY, Rodrigues MA. In: Matsubara MGS, Vilela DL,
frente ao paciente portador de feridas e estomas. Almeida
RC, Bozza VC. Feridas e estomas em oncologia. São Paulo:
Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Bandeira
JR. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS,
Lemar, 2011. p. 111-25.
RC, Bozza VC. Feridas e estomas em oncologia. São Paulo:
Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas e
30. Reabilitação fonatória e de deglutição em cabeça e pes-
Lemar, 2011. p. 185-94.
estomas em oncologia. São Paulo: Lemar, 2011. p. 217-22.
coço: abordagem fonoaudiológica. Carrara-de Angelis E. In:
9. Doenças traumáticas da boca. Alves FA. In: Caldas Neto S,
20. Intervenção do psicólogo: aspectos do paciente porta-
Caldas Neto S, editor. Tratado de otorrinolaringologia, vo-
editor. Tratado de otorrinolaringologia, volume IV. 2 ed. São
dor de câncer de cabeça e pescoço. Antunes KR. In: Matsu-
lume IV. 2 ed. São Paulo: Roca, 2011. p.909-19.
Paulo: Roca, 2011. p.108-18. ISBN=978-85-7241925-3.
bara MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA,
31. Terapias utilizadas no cuidado com feridas. Santana
Book published
10. Estomas em pediatria: peculiaridades do cuidado. Mela-
Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
FAS, Matsubara MGS, Villela DL. In: Matsubara MGS, Vilela
ragno ALP. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis
oncologia. São Paulo: Lemar, 2011. p. 247-54.
DL, Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Ban-
1. Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS, Saco-
HCS, Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas
21. Intervenção do psicólogo: o papel do psicólogo frente ao
deira RC, Bozza VC. Feridas e estomas em oncologia. São
nato RA, Denardi UA, Bandeira RC, Bozza VC, editors. Feridas
e estomas em oncologia. São Paulo: Lemar, 2011. p. 195-99.
paciente oncológico . Tarabay CH. In: Matsubara MGS, Vilela
Paulo: Lemar, 2011. p. 137-47.
e estomas em oncologia: uma abordagem interdisciplinar.
11. Feridas em pacientes de cuidados paliativos. Yamashita
DL, Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Ban-
32. Tumor de mama. Reis HC, Fortes SN. In: Matsubara MGS,
São Paulo: Lemar, 2011.
CC, Kurashima AY. In: Matsubara MGS, Vilela DL, Hashimo-
deira RC, Bozza VC. Feridas e estomas em oncologia. São
Vilela DL, Hashimoto SY, Reis HCS, Saconato RA, Denardi UA,
to SY, Reis HCS, Saconato RA, Denardi UA, Bandeira RC, Bo-
Paulo: Lemar, 2011. p. 243-6.
Bandeira RC, Bozza VC. Feridas e estomas em oncologia. São
zza VC. Feridas e estomas em oncologia. São Paulo: Lemar,
22. Intervenção fisioterápica: o papel do fisioterapeuta nos
Paulo: Lemar, 2011. p. 67-75.
Chapters in books
2011. p. 87-93.
tumores de mama. Friedrich CF, Denari SC. In: Matsubara
33. Tumores cutâneos. Bozza VCC, César GW. In: Matsuba-
12. Feridas neopláticas. Matsubara MGS. In: Matsubara
MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA, De-
ra MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA,
1. Assistência de enfermagem ao estomizado. Bandeira RCF.
MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA, De-
nardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS, Sa-
nardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
oncologia. São Paulo: Lemar, 2011. p. 231-6.
oncologia. São Paulo: Lemar, 2011. p. 77-86.
conato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas e
oncologia. São Paulo: Lemar, 2011. p. 33-46.
23. Intervenções fonoaudiológica: o papel do fonoaudiólogo
34. Tumores de cabeça e pescoço. Saconato RA. In: Matsu-
estomas em oncologia. São Paulo: Lemar, 2011. p.175-83.
13. Fisiologia da pele. Villela DL. In: Matsubara MGS, Vilela
nos tumores de cabeça e pescoço. Netto IP, Bretas MC, Ange-
bara MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA,
2. Assistência de enfermagem nas gastrostomias. Oliveira
DL, Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Ban-
lis EC. In: Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS,
Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
deira RC, Bozza VC. Feridas e estomas em oncologia. São
Saconato RA, Denardi UA, Bandeira RC, Bozza VC. Feridas e
oncologia. São Paulo: Lemar, 2011. p. 47-66.
Hashimoto SY, Reis HCS, Saconato RA, Denardi UA, Bandeira
Paulo: Lemar, 2011. p. 17-21.
estomas em oncologia. São Paulo: Lemar, 2011. p. 223-30.
35. Tumores primários múltiplos do trato aerodigestivo su-
RC, Bozza VC. Feridas e estomas em oncologia. São Paulo:
14. Fisiologia do processo cicatricial. Rocha TM. In: Matsu-
24. Mucosite: aspectos preventivos e terapêuticos. Machado
perior. Priante AVM, Castilho EC, Kowalski LP. In: Caldas Neto
Lemar, 2011. p. 169-74.
bara MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA,
LN, Camandoni VO. In: Matsubara MGS, Vilela DL, Hashimo-
S, editor. Tratado de otorrinolaringologia, volume IV. 2 ed.
3. Atuação do grupo oncológico de pele. Matsubara MGS. In:
Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas em
to SY, Reis HCS, Saconato RA, Denardi UA, Bandeira RC, Bo-
São Paulo: Roca, 2011. p.867-70.
Matsubara MGS, Vilela DL, Hashimoto SY, Reis HCS, Sacona-
oncologia. São Paulo: Lemar, 2011. p. 23-7.
zza VC. Feridas e estomas em oncologia. São Paulo: Lemar,
36. Vias aerodigestivas superiores. Kowalski LP, Carvalho AY.
to RA, Denardi UA, Bandeira RC, Bozza VC. Feridas e estomas
15. Gastrostomias: tipos e indicações. Zitron C. In: Matsu-
2011. p. 127-35.
In: Caldas Neto S, editor. Tratado de otorrinolaringologia,
em oncologia. São Paulo: Lemar, 2011. p. 267-75.
bara MGS, Vilela DL, Hashimoto SY, Reis HCS, Saconato RA,
25. Neoplasias malignas do osso temporal. Testa JRG, To-
volume IV. 2 ed. São Paulo: Roca, 2011. p.652-70.
17. Prognostic value of cell cycle proteins in squamous cell
carcinomas of the oral cavity. Buim MEC, Fregnani JH, Lourenço SV, Nagano CP, Carvalho AL, Soares FA. J Mol Biomark
Diagn 2011; 2(3):111-9.
EM, Costa CPM, Morrone FMC. In: Matsubara MGS, Vilela DL,
122
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
123
Medical
Staff
124
Scientific Production 2011
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
125
M e d i ca l S ta ff 2 0 1 1
ABDOMEN
Alessandro Landskron Diniz
Carlos Felipe Bernardes Silva
Evandra Cristina Vieira da Rocha
Felipe José Fernández Coimbra
Heber Salvador de Castro Ribeiro
Valdinélia Bomfim Barban Sposeto
Wilson Luiz da Costa Jr
A D M I S S I O N S S E RV I C E
André Eduardo Nunes Ferrari
Antonio Grimailoff Junior
Marcon Censoni de Avila e Lima
Roberta Avelino de Morais
Samuel Minucci Camargo
Wagner Longo Rodrigues
A D U LT E N D O C R I N O L O G Y
Felipe Hennig Gaia Duarte
Joilma Rodrigues de Lima
Márcio Carlos Machado
A D U LT I N T E N S I V E C A R E U N I T
Adriano José Pereira
André Apanavicius
André Nathan Costa
Andréa Remígio de Oliveira Leite
Bruno Arantes Dias
Bruno Ferreira Cordeiro de Almeida
Ciro Parioto Neto
126
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Danielle Nagaoka
Felipe Aires Duarte
Fernando Santinoni
José Antonio Manetta
Julia Maria de Campos Coelho
Juliana Carvalho Ferreira
Lúcio Souza Santos
Marcos Vinicius Perini
Maria Cristina França de Oliveira
Maria Eudóxia Pilotto de Carvalho
Mauro Roberto Tucci
Pauliane Vieira Santana
Pedro Caruso
Pedro Medeiros Jr.
Ramon Teixeira Costa
Rodrigo Alves dos Santos
Sérgio Eduardo Demarzo
Suzana Pinheiro Pimenta
Valdelis Novis Okatmoto
Vasco Moscovici da Cruz
A D U LT N E P H R O L O G Y
Benedito Jorge Pereira
Luis André Silvestre de Andrade
Marina Harume Imanishe
Renato Antunes Caires
A D U LT N E U R O L O G Y
Antonio Alberto Zambon
Marcos Aurélio Peterlevitz
127
ANESTHESIOLOGY
C A R D I O VA S C U L A R S U R G E R Y
Adriana Mayumi Handa
Alex Madeira Vieira
Ana Alice Sant’anna Nunes
André Sarlo
Bruno Zacchi
Carlos Eduardo Pereira Perillo
Carlos Roberto Mazzilli
Christian Michael Miklos
Eduardo Henrique Giroud Joaquim
Eliza Higa
Franco Yasuhiro Ito
Giane Nakamura
Jaqueline Costa Reis
José Eduardo de Assis Silva
José Mauro Vieira dos Reis
Karina Gordon
Leonardo Jorge Barboza Cava
Luiz Antonio Mandadori
Marcelo Sperandio Ramos
Maria Helena Menezes Jales
Marina Romanello Giroud Joaquim
Maurício Valentini de Melo
Mauro Mauro
Milton Mitsuyoshi Ito
Mírian Gomes Barcelos
Nilton Pinto Sanchez Junior
Paulo Jundo Oyama
Raquel Marcondes Bussolotti
Ronaldo Antonio da Silva
Servio Broca
Carolina Baeta Neves Duarte Ferreira
Diego Felipe Gaia dos Santos
Izandro Regis de Brito Santos
Marcelo Henrique Cavalcanti Lins
Mituro Hattori Jr.
Rogério Bagietto
Tatiane Cristine Ishida
CLINICAL ONCOLOGY
Aldo Lourenço Abbade Dettino
Ana Carolina Sigolo Levy
Andréa Paiva Gadêlha Guimarães
Celso Abdon Lopes de Mello
Garles Miller Matias Vieira
José Augusto Rinck
Júlio César Prestes
Leila Maria Magalhães Pessoa de Melo
Marcello Ferretti Fanelli
Maria Nirvana da Cruz Formiga
Milton José de Barros e Silva
Solange Moraes Sanches
Tadeu Ferreira de Paiva Jr.
Thiago Bueno de Oliveira
Ulisses Ribaldo Nicolau
Vladmir Claudio Cordeiro de Lima
G E N E R A L P R AC T I C E
Arlete Rita Siniscalchi Rigon
Daniel Camis Buratti
Diogo Souza Domiciano
Humberto João Rigon Jr
GYNAECOLOGY
Ademir Narcizo Oliveira Menezes
Carlos Chaves Faloppa
Elza Mieko Fukazawa
Glauco Baiocchi Neto
Levon Badiglian Filho
Lillian Yuri Kumagai
HEAD AND NECK
André Ywata de Carvalho
Dov Charles Goldenberg
Genival Barbosa de Carvalho
João Gonçalves Filho
José Carlos Marques de Faria
José Guilherme Vartanian
José Magrin
José Ricardo Gurgel Testa
Luiz Paulo Kowalski
Mauro Kasuo Ikeda
Mônica Lúcia Rodrigues
Paula Angélica Lorenzon Silveira
Ronaldo Nunes Toledo
DIGESTIVE ENDOSCOPY
Adriane Graicer Pelosof
Cláudia Zitron Sztokfisz
Daniel Moribe
Felipe Alves Retes
Mauricio Saab Assef
Robson Kiyoshi Ishida
Savério Tadeu de Noce Armellini
Vanessa Assis do Vale
Wilson Toshihiko Nakagawa
AU D I O L O G Y
Christiane Schultz
Maria Valéria Schmidt Goffi Gomez
Patrícia Helena Pecora Liberman
BLOOD BANK
Denise Albuquerque Dourado
Marcello Augusto César
Mônica Caamaño Cristovão Poli
Rafael Colella
Rivania Almeida de Andrade
CA R D I O L O G Y / CA R D I AC R H Y T H M
Sérgio Clemente Cervone
128
EMERGENCY
Alessandro José Alves Lima
André Sapata Molina
Arlete Rita Siniscalchi Rigon
Barbara Silva de Sousa
Carlos Chaves Faloppa
Daniela de Oliveira Morais
Fernanda de Oliveira Santos
Fernanda Lemos Moura
Fernando Nunes Galvão de Oliveira
Filipe Minzon Rodrigues
Genival Barbosa de Carvalho
Heber Salvador de Castro Ribeiro
Humberto João Rigon Jr
H E M AT O L O G Y
Fernanda de Oliveira Santos
I M AG I N G
Alex Dias de Oliveira
Andréa Maria Barbosa e Silva
Benjamin Carneiro Rodrigues
Carlos Marcelo Gonçalves
Chiang Jeng Tyng
Cristiane Maschietto Elias de Almeida
Eduardo Nóbrega Pereira Lima
Elvira Ferreira Marques
Francisco Cesar Carnevale
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Ivone do Carmo Gonçalves Torres
Juliana Alves de Souza
Júlio César Santin
Liao Shin Yu
Marcela Pecora Cohen
Marcelo Cavicchioli
Marco Antonio Tannus Bueno Maia
Marcos Duarte Guimarães
Míriam Rosalina Brites Poli
Paula Nicole Vieira Pinto
Rubens Chojniak
Tjioe Tjia Min
Waldinai Pereira Ferreira
I N F E C T O L O G Y / H O S P I TA L I N F E C T I O N
C O N T R O L S E RV I C E
Barbara Silva de Sousa
Beatriz Quental Rodrigues
Ivan Leonardo Avelino França e Silva
Maristela Pinheiro Freire
LIVER TRANSPLANT
Carla Adriana Loureiro de Matos
Eduardo Antunes da Fonseca
Gilda Porta
Irene Kazue Miura
João Seda Neto
Mário Kondo
Renata Pereira Sustovich Pugliese
Rogério Camargo Pinheiro Alves
Vera Lúcia Baggio
MASTOLOGY
André Luis de Freitas Perina
Hirofumi Iyeyasu
Juan Bautista Donoso Collins
Lilian Fraianella
Maria Auxiliadora Bernardi
Maria do Socorro Maciel
Maurício Doi
Wesley Pereira Andrade
MEDICAL PHYSICS
Cássio de Queiroz Tannous
Homero Lavieri Martins
Karina Waiswol Boccaletti
Petrus Paulo Combas Eufrazio da Silva
129
N E U R O P E D I AT R I C S
P E D I AT R I C I N T E N S I V E C A R E U N I T
PHYSIOTHERAPY
Carlos Alberto Martinez Osório
Amine Barbella Saba
Carla Francine Aricó Mori
Fabíola Peixoto Ferreira La Torre
Larissa Monteiro Gondim Teixeira
Maria Emilia Navajas Telles Pereira
Michelle Farias Gobbi De Martino
Regina Grigolli Cesar
Thais Netto de Mello Cesar
Alinne Martins dos Santos
Ana Carolina Serigatto de Oliveira
Ana Paula Pires Bolsoni
Anderson Vendramini de Lima
Angela Martins Fernandes
Anuana Lohn
Celena Freire Friedrich
Daniella Rodrigues Gomes
Denise Simão Carnieli
Diana Módena Moreira de Araújo
Diego Brito Ribeiro
Eliana Louzada Petito
Erica Mie Okumura
Fernanda Rahal Tocci
Grazielli Rossi Soler
Helen Cattaruzzi
Helena Colleen Talanskas Marinheiro
Juliana Chiancone Franzotti
Juliana Corage Figueredo
Juliana Elda Lotto
Leticia Zumpano Cardenas
Lívia Lamounier de Moraes
Luciane Sato Anitelli
Rachel Roberta Zeituni
Telma Ribeiro Rodrigues
Viviane Aparecida Ohasi
Yone Onuma
N E U R O S U R G E RY
Daniel Alvarez Estrada
José Eduardo Souza Dias Jr
Paulo Issamu Sanematsu Jr.
Sérgio Hideki Suzuki
NUTROLOGY
Andréa Faiçal
Eliana Melo de Brito Carvalho
Ieda Maria Berriel de Abreu Trombino
Jone Robson de Almeida
Marcelo Eduardo Sproesser
P E D I AT R I C N E P H R O L O G Y
ONCOGENETICS
P E D I AT R I C S
Maria Isabel A. de S. Waddington Achatz
Rima Jbili
Cecília Maria Lima da Costa
Cesar Iracil Casagranda
Edwin Adolfo Silva Tito
Fabianna Barbosa Cassulino
Fábio De Simone Piccoli
Isis de Medeiros
Neviçolino Pereira de Carvalho Filho
Renata Grizzo Feltrin de Abreu
Viviane Sonaglio
OPHTHALMOLOGY
Márcia Motono
Maria Alice Fernandes da Costa Freitas
Martha Maria Motono Chojniak
Mirna Hatanaka Kikawa
Helena Maria Silva do Nascimento
P E D I AT R I C S U R G E R Y
Maria Lúcia de Pinho
PA I N
André Luís Domingues Costa
José Oswaldo de Oliveira Júnior
PA L L I AT I V E C A R E
Bethina Aronovich Dana
Fabiana Gomes
Sandra Caires Serrano
PAT H O L O G I C A L A N AT O M Y
Antônio Hugo José Fróes Marques Campos
Clóvis Antonio Lopes Pinto
Cynthia Aparecida Bueno de Toledo Osório
Fernando Augusto Soares
Isabela Werneck da Cunha
Maria Dirlei Ferreira de Souza Begnami
Victor Piana de Andrade
P E D I AT R I C E N D O C R I N O L O G Y
Fabiana de Moraes Penteado
130
P E LV I S
Ademar Lopes
Adriano Carneiro da Costa
Alexsander Kuroiwa Bressan
Carlos Alberto Ricetto Sacomani
Celso Augusto Milani Cardoso Filho
Fábio de Oliveira Ferreira
Fábio Fernando Eloi Pinto
Francisco Paulo da Fonseca
Gustavo Cardoso Guimarães
Ranyell Matheus Spencer Sobreira Batista
Ricardo de Lima Favaretto
Rodrigo Sousa Madeira Campos
Samuel Aguiar Jr.
Stênio de Cássio Zequi
Suely Akiko Nakagawa
Thiago Borges Marques Santana
Wilson Bachega Jr.
Wu Tu Chung
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
P S Y C H I AT R Y / P S Y C H O L O G Y
Christina Haas Tarabay
Katia Rodrigues Antunes
Maria Teresa Duarte Pereira da Cruz
Thiago Marques Fidalgo
RADIOTHERAPY
Antônio Cássio de Assis Pellizzon
Douglas Guedes de Castro
Maria Aparecida Conte Maia
Maria Letícia Gobo Silva
Ricardo César Fogaroli
R E PA R AT I V E S U R G E R Y
Alexandre Katalinic Dutra
Eduardo Koiti Yoshimatsu
Heloisa Galvão do Amaral Campos
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
José Hermílio Curado
José Luiz Orlando
Mauricio Castello Domingues
SKIN ONCOLOGY
Adriana Pessoa Mendes Eris
André Sapata Molina
Bianca Costa Soares de Sá
Cristiano Luiz Horta de Lima Jr.
Eduard Rene Brechtbühl
Elimar Elias Gomes
Fernando Henrique Sgarbi Parro
Gisele Gargantini Rezze
João Pedreira Duprat Neto
Juliana Arêas de Souza Lima Beltrame Ferreira
Juliana Casagrande Tavoloni Braga
Juliana Machado Canosa
Marcelo Norio Inada
Marco Antonio de Oliveira
SPEECH THERAPY
Elisabete Carrara de Angeli
Irene de Pedro Netto
Neyller Patriota Cavalcante Montoni
Simone Aparecida Claudino da Silva
S T O M AT O L O G Y
André Caroli Rocha
Fábio de Abreu Alves
Graziella Chagas Jaguar
José Divaldo Prado
THORAX
Bruno Arantes Dias
Fábio José Haddad
Iunis Suzuki
Jefferson Luiz Gross
Lúcio Souza Santos
Vascular
Christiano Vinicius Bernardi
Guilherme André Zottele Bomfim
Guilherme Yazbek
Kenji Nishinari
131
GRI
Ta b l e o f
Contents
132
Medical Staff
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
GRI Table of Contents
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
133
G RI I n d e x
(GRI 3.12)
INDICATOR
TOPIC
LEVEL
PAGE
profile
Strategy and analysis
1.1
Statement by holder of highest decision-making power in the organization on the
relevance of sustainability
1.2
Description of key impacts, risks and opportunities
2.1
Name of the organization
5
2.2
Products and services, including brands
37
2.3
Operational structure
31
2.4
Location of the organization’s headquarters
144
2.6
Type and legal nature of the property
25
2.7
Markets attended
37
11 and 13
103-104
Organizational profile
2.8
Size of the organization
79-80
2.10
Prizes received during the period of time covered by the report
21-23
3.1
Period covered by the report
2nd cover
3.3
Cycle of report issue
2nd cover
3.12
Table that identifies the location of the information in the report
135 and
136
Report Parameters
Governance, Commitments and Engagement
4.1
Governance structure of the organization
25
4.8
Statements of mission and values, codes of conduct and relevant in-company principles
29
4.14
List of stakeholders groups engaged by the organization
61, 65 and
69
performance indicators
Economic Performance
134
GRI Table of Contents
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
EC1
Direct economic value earned and distributed, including revenues, operating costs,
salaries, donations and other community investments, accumulated surplus
79
EC8
Development and impact of infrastructure investments and services provided
primarily for public benefit through commercial, in kind or pro bono engagement.
33
GRI Table of Contents
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
135
INDICATOR
TOPIC
LEVEL
PAGE
Environmental Performance
Products and Services
EN26
Initiatives to mitigate environmental impacts of products and services and extent of
impact mitigation.
99-101
Social Performance – Labor Practices
Employment
LA1
Total number of employees, by employment type, work contract and region
91
LA2
Total number and rate of employee turnover by age group, gender and region
97
I n d e p e n d e n t Au d i t o r s
Report on Limited
Assurance
M A A / VA B
Health and Safety at work
LA8
Education, training, counseling, prevention and risk control programs in place to
assist employees, their families or community members regarding serious illnesses
LA10
Average hours of training per year per employee by employee functional category
76, 77,92
and 95
92 and
100
Society
71 and 87
SO1
Nature, scope, and effectiveness of any programs and practices that assess and
manage the impacts of operations on the communities, including entering,
operating, and exiting
PR1
Policies to safeguard the health and safety of the consumer whilst using the product
23, 42 and
62
PR5
Practices related to client satisfaction, including results of surveys
65 and 66
PR6
Programs for adherence to laws, standards and voluntary codes related to marketing
communications, including advertising, promotion and sponsorship
Client Health and Safety
GRI Attended
136
GRI Partially Attended
83
GRI Not Attended
GRI Table of Contents
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Independent Auditors Report on Limited Assurance
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
137
I n d e p e n d e n t Au d i to r s ’ R e p o rt
o n L i m i t ed A s s u r ance o n
3 1 s t D ece m be r 2 0 1 1
To Board Members, Directors and other Interested Parties
Antônio Prudente Foundation – A.C.Camargo Hospital
São Paulo – SP
Introduction
W
e were contracted with the aim of applying procedures of limited assurance on the Antônio Prudente Foundation’s (AC.Camargo Hospital) Sustainability Report, relative to the period
ending on 31st December 2011, prepared under the responsibility of the
Administration. Our responsibility is to issue a limited assurance report on
this Sustainability Report.
Procedures adopted
The limited assurance procedures were carried out in accordance with
standard NBC TO 3000 – Trabalho de Asseguração Diferente de Auditoria e
Revisão, issued by the Conselho Federal de Contabilidade (CFC) and ISAE
3000 – International Standard on Assurance Engagements, issued by the
International Auditing and Assurance Standards Board (IASB), both related
to assurance engagements other than audits or reviews of historical financial information.
The limited assurance procedures comprised: (a) planning the work, considering the importance, coherence, volume of quantitative and qualitative
138
Independent Auditors Report on Limited Assurance
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Independent Auditors Report on Limited Assurance
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
139
information, and operational and internal control systems that served as
lanthropy, including gratuities with expenses of SUS procedures, subsidies
a basis for the preparation of the Sustainability Report of the A.C.Camargo
to the areas of research, courses, scholarships and donations, which were
Hospital; (b) understanding the calculation methodology and the consoli-
reviewed by us and whose values are presented correctly.
dation of the indicators through meetings and interviews with the managers responsible for the preparation of information; (c) the comparison, on a
sample basis, of the quantitative and qualitative information disclosed in the
Application Level of the GRI-G3.1
Sustainability Report of the A.C.Camargo Hospital; and (d) the comparison
of the financial indicators with the financial statements and/or account-
Following the guidelines of the GRI-G3.1, the A.C.Camargo Hospital declares
ing records audited by other independent auditors, who published a report
a level of application C+ in its Sustainability Report relative to the year end-
dated 17th February 2012. The work of assurance also included the analysis
ing on the 31st December 2011.
of adherence to the guidelines established by the Global Reporting Initiative
(GRI-G3.1) for reports with an Application Level C.
The A.C.Camargo Hospital reported the profile indicators, the performance indicators, essential and additional indicators relevant to the organization and the indicators of sectorial supplement, such as, for example,
the supplement that details all its scientific production.
Criteria for preparation of the information
The Sustainability Report offers answers to the items related to its structure and performance indicators that attend to criteria established by the
The information in the A.C.Camargo Hospital’s Sustainability Report and the
Global Reporting Initiative (GRI-G3.1) for classification as level of application.
Social Balance was prepared in accordance with the guidelines for sustain-
In this way, the procedures applied were considered sufficient for us to cer-
ability reports issued by the global reporting initiative (GRI-G3.1).
tify that the level of application stated by the A.C.Camargo Hospital is in
conformity with the orientation of the GRI-G3.1 guidelines.
Scope and restrictions
Conclusion
The purpose of our work was to apply limited assurance procedures to
the sustainability information relative to the year of 2011 disclosed in the
Based on our work, described in this report, we are not aware of any fact that
A.C.Camargo Hospital’s Sustainability Report, on profile items (informa-
leads us to believe that the information presented in the 2011 Sustainability
tion that provides the overall context for understanding the organization-
Report of the Antônio Prudente Foundation (A.C.Camargo Hospital), rela-
al performance, including its strategy, profile, and governance), on man-
tive to the year ending on the 31st December 2011, is not presented in all its
agement approach, and to the sustainability performance indicators of the
relevant aspects, according to the GRI-G3.1 guidelines and with the records
A.C.Camargo Hospital, not including the assessment and the appropriate-
and files which were used as the basis for its preparation.
ness of its policies, practices, and sustainability performance.
São Paulo, 13th March 2012.
The procedures that were applied do not constitute an examination in accordance with the financial statement auditing standards. Additionally, our
report does not offer any type of assurance on the scope of future information (such as goals, expectations, strategies and projections) and descriptive
information that is subject to subjective evaluation.
BDO RCS Auditores Independentes SS
We stress that data prior to 2011 were not the aim of our analysis. Addi-
CRC 2SP 013846/O-1
tionally, the financial and accounting information, presented in some tables
Mauro de Almeida Ambrosio – Partner
and boxes, for comparative reasons and comments, extracted from account-
Accountant CRC 1SP 199692/O-5
ing, were examined by other independent auditors, with the exception of the
items in the Added Value Statement (AVS) and the table with data about phi-
140
Independent Auditors Report on Limited Assurance
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
Independent Auditors Report on Limited Assurance
A . C. C a m a r g o H o s p i ta l s u s ta i n a b i l i t y r e p o r t 2 0 1 1
141
A N T Ô N I O P R U D E N T E F O U N D AT I O N
B o a r d of t ru s t e e s
Executive management
José Ermírio de Moraes Neto – President
Irlau Machado Filho
Edson Vaz Musa – Vice President
Chief Executive Officer (CEO)
Aguinaldo Thomaz de Andrade Rocha
Aristides Pereira Maltez Filho
Carlos Francisco Bandeira Lins
Adriana Seixas Braga
Marketing Superintendent
Horácio Lafer Piva
Alexandre José Sales
José Hermílio Curado
Chief Financial Officer (CFO)
Marcos Fernandes de Oliveira Moraes
Paulo Sérgio Leite Fernandes
Waldemar Benassi
Waldomiro Carvas Junior
Jarbas José Salto Jr.
Operations Superintendent
Lino José Rodrigues Alves
Legal Superintendent
E x e c u t i v e b oa r d
Lourdes Marques
Ricardo Renzo Brentani*
Business Support Superintendent
President
Mari Galvão
José Hermílio Curado
Hospitality Superintendent
Vice President
Mauricio Alves da Silva
Liana Maria Carraro de Moraes
Human Resources Superintendent
Voluntary Network Director
Antonio Evangelista
Fixed Assets Director
Nelson Koichi Shimada
Financial and Administrative Diector
Celso Marques de Oliveira
Company Director
* Position exercised up to the day of his
passing away on the 29/11/2011.
A N T Ô N I O P R U D E N T E F O U N D AT I O N (GRI 2.4)
Telephone (55 11) 2189-5000
Rua Professor Antônio Prudente, 211
Liberdade – São Paulo – SP – Brazil
CEP 01509-010
www.accamargo.org.br
s u s t a i n a b i l i t y r e p o r t 2 011
director Irlau Machado Filho – CEO
supervision Adriana Seixas Braga
production coordination Danielle Zanandré Lago
planning and production Comunique Editorial
editorial director Paulo Alves
editorial production Ana Luiza Guímaro
text Suzel Tunes
research and reporting Suzel Tunes and Moura Leite Netto
tr anslation into english Dominique Makins Bennett, Daniel Claster
layout project and designNegrito Produção Editorial
Ricardo Assis
Tainá Nunes Costa
Sebastian Ribeiro
photosLalo de Almeida, Jorge Rosenberg, Mário Bock
and images from the Hospital’s archive
printingEskenazi